



NOTICE – Items in this issue will be listed online weekly and printed monthly.

A-MARK PRECIOUS METALS, INC

Earnings, 9 mos. to Mar 31(Consol. – \$000):

	2018	2017
Total Revenues	5,839,491	5,662,859
Cost & expenses	5,841,590	5,655,388
Operating income	(1,311)	9,196
Interest income	10,516	9,101
Interest expense	9,734	7,388
Other income (expense), net	811	270
Foreign currency	6	12
Net before taxes	(500)	9,466
Income taxes	(209)	3,482
Net income	(291)	5,984
Earnings common share		
Primary	\$(0.05)	\$0.83
Fully Diluted	\$(0.05)	\$0.82
Common Shares:		
Full Diluted	7,031	7,122
Year-end	7,031	7,031

ACADIA HEALTHCARE COMPANY INC.

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total Revenues	742,241,000	679,194,000
Cost & expenses	654,380,000	597,097,000
Operating income	48,088,000	48,484,000
Net before taxes	48,088,000	48,484,000
Income taxes	(2,786,000)	13,711,000
Net income	50,874,000	34,773,000
Earnings common share		
Primary	\$0.58	\$0.40
Fully Diluted	\$0.58	\$0.40
Common Shares:		
Full Diluted	87,294,000	86,908,000
Year-end	87,287,865	86,916,624

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	57,808,000	
Inventories	4,772,000	
Current assets	503,893,000	
Net property & equip.	3,151,529,000	
Total assets	6,584,729,000	
Liabilities:		
Current liabilities	389,641,000	
Long-term debt	3,208,088,000	
Stockholders' equity	2,701,619,000	
Net current assets	114,252,000	

ACADIA PHARMACEUTICALS INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total Revenues	48,868,000	15,286,000
Net Sales	48,868,000	15,286,000
Cost & expenses	103,687,000	104,007,000
Operating income	(54,819,000)	(88,721,000)
Net before taxes	(53,649,000)	(87,758,000)
Income taxes	647,000	85,000
Net income	(54,296,000)	(87,843,000)
Earnings common share		
Primary	\$(0.44)	\$(0.72)
Fully Diluted	\$(0.44)	\$(0.72)
Common Shares:		
Full Diluted	124,727,000	121,651,000
Year-end	124,799,500	121,986,842

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	116,328,000	
Inventories	5,583,000	
Current assets	340,014,000	

Net property & equip.	2,709,000	
Total assets	351,040,000	
Liabilities:		
Current liabilities	46,089,000	
Stockholders' equity	304,169,000	
Net current assets	293,925,000	

ACCELERON PHARMA, INC.

Earnings, 3 mos. to Mar 31(Consol. – \$000):

	2018	2017
Total Revenues	3,232	3,705
Cost & expenses	30,872	29,563
Operating income	(27,640)	(25,858)
Interest income	1,312	502
Other income (expense), net	119	(45)
Net before taxes	(26,209)	(25,401)
Income taxes	10	6
Net income	(26,219)	(25,407)
Balance for common	(26,219)	(25,407)
Earnings common share		
Primary	\$(0.58)	\$(0.66)
Fully Diluted	\$(0.58)	\$(0.66)
Common Shares:		
Full Diluted	45,516	38,404
Year-end	45,723	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	69,736	
Current assets	300,290	
Net property & equip.	7,019	
Total assets	370,034	
Liabilities:		
Current liabilities	12,942	
Stockholders' equity	353,780	
Net current assets	287,348	

ACETO CORP

Earnings, 9 mos. to Mar 31(Consol. – \$000):

	2018	2017
Net Sales	542,482	443,698
Cost & expenses	790,548	420,347
Operating income	(248,066)	23,351
Interest expense	15,443	10,223
Net before taxes	(261,398)	14,358
Income taxes	(51,353)	4,949
Net income	(210,045)	9,409
Earnings common share		
Primary	\$(5.97)	\$0.30
Fully Diluted	\$(5.97)	\$0.30
Common Shares:		
Full Diluted	35,162	31,792
Year-end	30,839	30,105

ACI WORLDWIDE INC

Earnings, 3 mos. to Mar 31(Consol. – \$000):

	2018	2017
Total Revenues	209,310	231,462
Cost & expenses	204,669	205,468
Operating income	(6,704)	3,623
Interest income	2,744	106
Interest expense	9,365	10,160
Other income (expense), net	(55)	649
Net before taxes	(23,380)	(5,782)
Income taxes	(3,952)	(4,174)
Net income	(19,428)	(1,608)
Earnings common share		
Primary	\$(0.17)	\$(0.01)
Fully Diluted	\$(0.17)	\$(0.01)
Common Shares:		

Full Diluted	115,642	116,610
Year-end	116,394	118,039

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	74,281	
Current assets	419,294	
Net property & equip.	80,775	
Total assets	2,015,169	
Liabilities:		
Current liabilities	270,337	
Long-term debt	658,861	
Stockholders' equity	979,022	
Net current assets	148,957	

ACORDA THERAPEUTICS INC

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Total Revenues	106,165,000	119,386,000
Net Sales	103,003,000	112,593,000
Cost & expenses	105,711,000	134,659,000
Operating income	454,000	(15,273,000)
Interest income	326,000	38,000
Net before taxes	(4,722,000)	(19,822,000)
Income taxes	3,477,000	(918,000)
Net income	(8,199,000)	(18,904,000)
Earnings common share		
Primary	\$(0.18)	\$(0.41)
Fully Diluted	\$(0.18)	\$(0.41)
Common Shares:		
Full Diluted	46,529,000	45,808,000
Year-end	46,661,610	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	226,276,000	
Inventories	27,662,000	
Current assets	428,188,000	
Net property & equip.	39,023,000	
Total assets	1,187,073,000	
Liabilities:		
Current liabilities	117,358,000	
Long-term debt	337,128,000	
Stockholders' equity	549,925,000	
Net current assets	310,830,000	

ADTRAN, INC.

Earnings, 3 mos. to Mar 31(Consol. – \$):

	2018	2017
Net Sales	120,806,000	170,279,000
Cost & expenses	147,453,000	163,330,000
Operating income	(26,647,000)	6,949,000
Interest expense	132,000	141,000
Other income (expense), net	11,265,000	134,000
Invest. income	(97,000)	470,000
Net before taxes	(14,745,000)	8,345,000
Income taxes	(3,931,000)	1,694,000
Net income	(10,814,000)	6,651,000
Earnings common share		
Primary	\$(0.22)	\$0.14
Fully Diluted	\$(0.22)	\$0.14
Common Shares:		
Full Diluted	48,292,000	48,939,000
Year-end	47,914,000	48,321,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	82,623,000	
Inventories	120,021,000	
Current assets	344,746,000	
Net property & equip.	83,875,000	

Total assets	642,647,000
Liabilities:	
Current liabilities	102,567,000
Long-term debt	25,600,000
Stockholders' equity	475,736,000
Net current assets	242,179,000

AEGLEA BIOTHERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	9,755	7,313
Operating income	(8,245)	(6,331)
Interest income	143	95
Other income (expense), net	(17)	(11)
Net income	(8,119)	(6,247)
Earnings common share		
Primary	\$(0.49)	\$(0.47)
Fully Diluted	\$(0.49)	\$(0.47)
Common Shares:		
Full Diluted	16,672	13,366
Year-end	16,810	13,452

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	10,760	10,760
Current assets	48,843	48,843
Net property & equip.	810	810
Total assets	49,786	49,786
Liabilities:		
Current liabilities	5,765	5,765
Stockholders' equity	43,920	43,920
Net current assets	43,078	43,078

AERIE PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	40,795	25,429
Operating income	(40,795)	(25,429)
Interest income	810	296
Interest expense	507	597
Other income (expense), net	(207)	(11)
Net before taxes	(25,741)	(25,741)
Income taxes	46	46
Net income	(40,699)	(25,787)
Earnings common share		
Primary	\$(1.05)	\$(0.76)
Fully Diluted	\$(1.05)	\$(0.76)
Common Shares:		
Full Diluted	38,599	33,777
Year-end	39,503	33,635

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	249,501	249,501
Inventories	1,062	1,062
Current assets	341,154	341,154
Net property & equip.	47,810	47,810
Total assets	391,043	391,043
Liabilities:		
Current liabilities	25,136	25,136
Long-term debt	123,922	123,922
Stockholders' equity	236,271	236,271
Net current assets	316,018	316,018

AGILE THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Cost & expenses	7,046,000	7,126,000
Operating income	(7,046,000)	(7,126,000)
Interest income	97,000	47,000
Interest expense	368,000	546,000
Gains or losses	7,000	109,000
Net before taxes	(7,310,000)	(7,310,000)
Income taxes	(477,000)	(477,000)
Net income	(6,833,000)	(7,516,000)
Earnings common share		
Primary	\$(0.20)	\$(0.26)
Fully Diluted	\$(0.20)	\$(0.26)
Common Shares:		
Full Diluted	34,229,162	28,769,361
Year-end	34,248,268	28,776,398

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	28,344,000
Current assets	28,977,000

Net property & equip.	13,927,000
Total assets	42,922,000
Liabilities:	
Current liabilities	12,313,000
Stockholders' equity	30,609,000
Net current assets	16,664,000

AGIOS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	8,762	10,508
Cost & expenses	102,774	77,555
Operating income	(94,012)	(67,047)
Interest income	3,187	881
Net income	(90,825)	(66,166)
Earnings common share		
Primary	\$(1.63)	\$(1.56)
Fully Diluted	\$(1.63)	\$(1.56)
Common Shares:		
Full Diluted	55,695	42,281
Year-end	57,542	42,383

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	364,469	364,469
Current assets	802,993	802,993
Net property & equip.	23,732	23,732
Total assets	1,040,126	1,040,126
Liabilities:		
Current liabilities	74,699	74,699
Stockholders' equity	865,594	865,594
Net current assets	728,294	728,294

AGNC INVESTMENT CORP**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	224,000	116,000
Net income	424,000	76,000
Balance for common	415,000	69,000
Earnings common share		
Primary	\$1.06	\$0.21
Fully Diluted	\$1.06	\$0.21
Common Shares:		
Full Diluted	391,500	331,100
Year-end	391,300	331,000

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	972,000	972,000
Current assets	1,358,000	1,358,000
Total assets	69,221,000	69,221,000
Liabilities:		
Current liabilities	60,515,000	60,515,000
Long-term debt	336,000	336,000
Stockholders' equity	8,338,000	8,338,000
Net current assets	(59,157,000)	(59,157,000)

AIMMUNE THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	50,119	26,341
Operating income	(50,119)	(26,341)
Net before taxes	(49,483)	(49,483)
Income taxes	17	17
Net income	(49,500)	(25,870)
Earnings common share		
Primary	\$(0.92)	\$(0.52)
Fully Diluted	\$(0.92)	\$(0.52)
Common Shares:		
Full Diluted	53,578	50,069
Year-end	58,024	50,204

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	209,324	209,324
Current assets	330,297	330,297
Net property & equip.	21,021	21,021
Total assets	361,845	361,845
Liabilities:		
Current liabilities	30,412	30,412
Stockholders' equity	329,092	329,092
Net current assets	299,885	299,885

AKCEA THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	17,108	6,094
Cost & expenses	47,435	69,470
Operating income	(30,327)	(63,376)
Interest expense		541
Other income (expense), net	(168)	
Gains or losses	868	61
Net income	(29,627)	(63,856)
Earnings common share		
Primary	\$(0.44)	\$(2.21)
Fully Diluted	\$(0.44)	\$(2.21)
Common Shares:		
Full Diluted	66,616	28,885
Year-end	66,804	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	69,907
Current assets	250,563
Net property & equip.	50
Total assets	252,465
Liabilities:	
Current liabilities	98,296
Stockholders' equity	146,300
Net current assets	152,267

AKEBIA THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Cost & expenses	70,428,000	65,837,000
Operating income	(24,498,000)	(44,972,000)
Other income (expense), net	4,000	(6,000)
Net income	(23,418,000)	(44,543,000)
Earnings common share		
Primary	\$(0.48)	\$(1.15)
Fully Diluted	\$(0.48)	\$(1.15)
Common Shares:		
Full Diluted	48,613,565	38,759,221
Year-end	56,857,470	

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	158,171,000
Current assets	436,981,000
Net property & equip.	3,714,000
Total assets	442,713,000
Liabilities:	
Current liabilities	151,419,000
Stockholders' equity	197,097,000
Net current assets	285,562,000

ALDER BIOPHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	85,710	100,670
Operating income	(85,710)	(100,670)
Interest income	1,643	485
Interest expense	2,851	
Equity earnings	222	149
Foreign currency	109	6
Net income	(87,031)	(100,328)
Balance for common	(117,574)	
Earnings common share		
Primary	\$(1.73)	\$(1.99)
Fully Diluted	\$(1.73)	\$(1.99)
Common Shares:		
Full Diluted	67,845	50,396
Year-end	67,849	50,410

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	201,956
Current assets	340,742
Net property & equip.	5,055
Total assets	599,413
Liabilities:	
Current liabilities	25,611
Long-term debt	173,197
Stockholders' equity	302,398
Net current assets	315,131

ALLEGiant TRAVEL COMPANY**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	425,444	380,011
Cost & expenses	317,327	275,733
Deprec., depl. & amort.	28,149	30,549
Operating income	79,968	73,729
Other income (expense), net	240	360
Net before taxes	69,391	66,952
Income taxes	14,198	24,601
Net income	55,193	42,351
Balance for common	54,425	41,657
Earnings common share		
Primary	\$3.43	\$2.54
Fully Diluted	\$3.42	\$2.54
Common Shares:		
Full Diluted	15,898	16,405
Year-end	16,149	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	50,777	
Inventories	18,335	
Current assets	516,805	
Net property & equip.	1,635,821	
Total assets	2,288,965	
Liabilities:		
Current liabilities	560,872	
Long-term debt	984,926	
Stockholders' equity	599,804	
Net current assets	(44,067)	

ALLENA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	7,973	5,542
Operating income	(7,973)	(5,542)
Other income (expense), net	(7)	3
Net income	(7,880)	(5,671)
Earnings common share		
Primary	\$(0.38)	\$(4.24)
Fully Diluted	\$(0.38)	\$(4.24)
Common Shares:		
Full Diluted	20,695	1,342
Year-end	20,696	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	86,382	
Current assets	87,344	
Net property & equip.	128	
Total assets	87,568	
Liabilities:		
Current liabilities	7,246	
Long-term debt	4,537	
Stockholders' equity	75,408	
Net current assets	80,098	

ALNYLAM PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	21,899	18,960
Cost & expenses	169,304	125,471
Operating income	(147,405)	(106,511)
Interest income	5,794	2,128
Other income (expense), net	335	(2,907)
Net before taxes	(141,276)	
Income taxes	(62)	
Net income	(141,214)	(107,290)
Earnings common share		
Primary	\$(1.41)	\$(1.25)
Fully Diluted	\$(1.41)	\$(1.25)
Common Shares:		
Full Diluted	99,979	86,027
Year-end	100,468	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	396,149	
Current assets	1,685,297	
Net property & equip.	201,979	
Total assets	1,923,139	
Liabilities:		
Current liabilities	115,383	
Long-term debt	30,000	
Stockholders' equity	1,754,805	
Net current assets	1,569,914	

AMAG PHARMACEUTICALS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	146,356,000	139,472,000
Cost & expenses	191,244,000	179,496,000
Operating income	(44,888,000)	(40,024,000)
Interest expense	15,977,000	18,300,000
Gains or losses		27,000
Net before taxes	(60,221,000)	(57,266,000)
Income taxes	(5,979,000)	(20,706,000)
Net income	(54,242,000)	(36,560,000)
Earnings common share		
Primary	\$(1.59)	\$(1.06)
Fully Diluted	\$(1.59)	\$(1.06)
Common Shares:		
Full Diluted	34,162,000	34,378,000
Year-end	34,322,193	34,445,394

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	370,557,000	
Inventories	31,598,000	
Current assets	518,445,000	
Net property & equip.	25,921,000	
Total assets	1,834,950,000	
Liabilities:		
Current liabilities	329,419,000	
Long-term debt	718,103,000	
Stockholders' equity	739,995,000	
Net current assets	189,026,000	

AMC NETWORKS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	740,823	720,189
Cost & expenses	486,814	465,025
Operating income	233,655	231,671
Interest income	5,019	3,493
Interest expense	38,205	30,500
Other income (expense), net	16,946	11,049
Net before taxes	217,415	215,713
Income taxes	56,879	73,082
Net income	160,536	142,631
Earnings common share		
Primary	\$2.57	\$2.00
Fully Diluted	\$2.54	\$1.98
Common Shares:		
Full Diluted	61,719	68,764
Year-end	59,856	67,235

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	529,200	
Current assets	1,889,454	
Net property & equip.	185,440	
Total assets	5,113,367	
Liabilities:		
Current liabilities	715,666	
Long-term debt	3,126,371	
Stockholders' equity	230,744	
Net current assets	1,173,788	

AMEDISYS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	359,664,000	335,079,000
Operating income	36,005,000	25,165,000
Interest income	120,000	19,000
Interest expense	1,703,000	1,068,000
Other income (expense), net	2,461,000	1,006,000
Net before taxes	36,883,000	25,122,000
Income taxes	9,563,000	9,923,000
Net income	27,320,000	15,199,000
Earnings common share		
Primary	\$0.80	\$0.45
Fully Diluted	\$0.79	\$0.44
Common Shares:		
Full Diluted	34,592,000	34,073,000
Year-end	34,056,627	33,693,027

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	120,005,000	
Current assets	343,519,000	
Net property & equip.	28,223,000	
Total assets	842,298,000	

Liabilities:

Current liabilities	210,810,000
Long-term debt	75,800,000
Stockholders' equity	548,320,000
Net current assets	132,709,000

AMERICAN PUBLIC EDUCATION INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	74,967	75,688
Cost & expenses	64,283	62,637
Deprec., depl. & amort.	4,522	4,744
Operating income	6,162	8,307
Equity earnings	201	(40)
Net before taxes	6,655	8,318
Income taxes	1,865	3,849
Net income	4,589	4,509
Earnings common share		
Primary	\$0.28	\$0.28
Fully Diluted	\$0.28	\$0.28
Common Shares:		
Full Diluted	16,534	16,321
Year-end	16,399	16,233

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	186,168	
Current assets	201,501	
Net property & equip.	90,247	
Total assets	346,231	
Liabilities:		
Current liabilities	45,321	
Stockholders' equity	293,779	
Net current assets	156,180	

AMPHASTAR PHARMACEUTICALS INC (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	58,393	56,670
Cost & expenses	68,311	55,266
Operating income	(9,918)	1,404
Interest income	124	91
Interest expense	18	191
Other income (expense), net	782	200
Net before taxes	(9,030)	1,504
Income taxes	(1,784)	611
Net income	(7,246)	893
Earnings common share		
Primary	\$(0.16)	\$0.02
Fully Diluted	\$(0.16)	\$0.02
Common Shares:		
Full Diluted	46,514	48,057
Year-end	46,657	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	54,547	
Inventories	62,780	
Current assets	174,046	
Net property & equip.	191,915	
Total assets	449,782	
Liabilities:		
Current liabilities	72,542	
Long-term debt	39,706	
Stockholders' equity	327,104	
Net current assets	101,504	

ANAPTYSBIO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	15,757	9,988
Operating income	(15,757)	(9,988)
Interest income	1,185	122
Interest expense	451	428
Other income (expense), net	(63)	(1,141)
Net income	(15,086)	(11,435)
Earnings common share		
Primary	\$(0.63)	\$(0.75)
Fully Diluted	\$(0.63)	\$(0.75)
Common Shares:		
Full Diluted	23,801	15,295
Year-end	23,817	20,249

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	69,474
Current assets	251,945
Net property & equip.	659
Total assets	314,837
Liabilities:	
Current liabilities	14,343
Long-term debt	5,834
Stockholders' equity	294,527
Net current assets	237,602

ANDERSONS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	638,031	857,586
Operating income	(2,292)	(5,570)
Net before taxes	(2,292)	(5,570)
Income taxes	(310)	(2,535)
Net income	(1,982)	(3,035)
Balance for common	(1,700)	(3,089)
Earnings common share		
Primary	\$(0.06)	\$(0.11)
Fully Diluted	\$(0.06)	\$(0.11)
Common Shares:		
Full Diluted	28,237	28,281
Year-end	28,475	28,356

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	31,497
Inventories	731,629
Current assets	1,137,879
Net property & equip.	393,763
Total assets	2,363,528
Liabilities:	
Current liabilities	923,950
Long-term debt	438,628
Stockholders' equity	800,642
Net current assets	213,929

ANI PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	46,483,000	36,628,000
Cost & expenses	31,751,000	25,297,000
Deprec., depl. & amort.	8,195,000	6,706,000
Operating income	6,537,000	4,625,000
Interest expense	3,634,000	2,932,000
Other income (expense), net	(61,000)	(18,000)
Net before taxes	2,842,000	1,675,000
Income taxes	592,000	523,000
Net income	2,250,000	1,152,000
Earnings common share		
Primary	\$0.19	\$0.10
Fully Diluted	\$0.19	\$0.10
Common Shares:		
Full Diluted	11,706,000	11,653,000
Year-end	11,725,692	11,652,864

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	51,970,000
Inventories	34,294,000
Current assets	143,394,000
Net property & equip.	21,882,000
Total assets	418,019,000
Liabilities:	
Current liabilities	39,650,000
Long-term debt	198,725,000
Stockholders' equity	179,644,000
Net current assets	103,744,000

ANIKA THERAPEUTICS INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	21,264,000	23,386,000
Cost & expenses	29,096,000	15,380,000
Operating income	(7,832,000)	8,006,000
Net before taxes	(7,737,000)	8,064,000
Net income	(6,686,000)	5,493,000
Earnings common share		
Primary	\$(0.46)	\$0.38
Fully Diluted	\$(0.46)	\$0.37
Common Shares:		
Full Diluted	14,679,000	15,043,000
Year-end	14,745,000	14,655,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	141,797,000
Inventories	22,770,000
Current assets	208,187,000
Net property & equip.	55,772,000
Total assets	284,336,000
Liabilities:	
Current liabilities	14,122,000
Stockholders' equity	263,766,000
Net current assets	194,065,000

APPIAN CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	51,696	38,329
Cost & expenses	61,943	41,842
Operating income	(10,247)	(3,513)
Interest expense	13	256
Other income (expense), net	918	499
Net before taxes	(9,342)	(3,270)
Income taxes	211	125
Net income	(9,553)	(3,395)
Balance for common	(9,553)	(3,609)
Earnings common share		
Primary	\$(0.16)	\$(0.10)
Fully Diluted	\$(0.16)	\$(0.10)
Common Shares:		
Full Diluted	60,851	34,275
Year-end	61,210	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	60,876
Current assets	129,735
Net property & equip.	3,359
Total assets	145,798
Liabilities:	
Current liabilities	88,876
Stockholders' equity	38,628
Net current assets	40,859

APPLIED MATERIALS, INC.**Earnings, 6 mos. to (Consol. - \$000):**

	04/29/18	04/30/17
Net Sales	8,771,000	6,824,000
Cost & expenses	6,248,000	5,077,000
Operating income	2,523,000	1,747,000
Net before taxes	2,457,000	1,679,000
Income taxes	1,193,000	152,000
Net income	1,264,000	1,527,000
Earnings common share		
Primary	\$1.21	\$1.42
Fully Diluted	\$1.20	\$1.40
Common Shares:		
Full Diluted	1,056,000	1,088,000
Year-end	1,008,048	1,074,632

APPTIO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	54,070	43,931
Cost & expenses	62,143	51,228
Operating income	(8,073)	(7,297)
Foreign currency	114	(53)
Net before taxes	(7,831)	(7,114)
Income taxes	268	25
Net income	(8,099)	(7,139)
Balance for common	(8,099)	(7,139)
Earnings common share		
Primary	\$(0.19)	\$(0.19)
Fully Diluted	\$(0.19)	\$(0.19)
Common Shares:		
Full Diluted	42,762	38,407
Year-end	43,453	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	190,066
Current assets	321,174
Net property & equip.	9,876
Total assets	405,946
Liabilities:	
Current liabilities	147,103
Long-term debt	106,691
Stockholders' equity	141,876

Net current assets	174,071
--------------------	---------

AQUINOX PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	14,817,000	8,522,000
Interest income	248,000	234,000
Other income (expense), net	(54,000)	(28,000)
Net income	(14,623,000)	(8,316,000)
Earnings common share		
Primary	\$(0.62)	\$(0.36)
Fully Diluted	\$(0.62)	\$(0.36)
Common Shares:		
Full Diluted	23,480,757	23,423,150
Year-end	23,492,161	23,423,150

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	66,610,000
Current assets	94,223,000
Net property & equip.	849,000
Total assets	95,623,000
Liabilities:	
Current liabilities	9,355,000
Long-term debt	28,000
Stockholders' equity	85,825,000
Net current assets	84,868,000

ARATANA THERAPEUTICS, INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	4,043	3,795
Cost & expenses	11,746	15,566
Operating income	(7,833)	(11,835)
Interest income	141	85
Interest expense	853	860
Other income (expense), net	(3)	(2)
Net income	(8,548)	(12,612)
Earnings common share		
Primary	\$(0.19)	\$(0.34)
Fully Diluted	\$(0.19)	\$(0.34)
Common Shares:		
Full Diluted	44,788	36,712
Year-end	45,944	36,974

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	66,427
Inventories	13,952
Current assets	84,578
Net property & equip.	1,047
Total assets	134,672
Liabilities:	
Current liabilities	25,087
Long-term debt	13,882
Stockholders' equity	95,636
Net current assets	59,491

ARCBEST CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	700,001	651,088
Cost & expenses	660,790	635,594
Deprec., depl. & amort.	26,486	25,394
Operating income	12,725	(9,900)
Other income (expense), net	(2,201)	(1,706)
Net before taxes	8,991	(12,647)
Income taxes	(963)	(5,240)
Net income	9,954	(7,407)
Earnings common share		
Primary	\$0.39	\$(0.29)
Fully Diluted	\$0.37	\$(0.29)
Common Shares:		
Full Diluted	26,596	25,684
Year-end	25,642	25,628

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	124,652
Current assets	532,136
Net property & equip.	574,163
Total assets	1,358,083
Liabilities:	
Current liabilities	398,636
Long-term debt	196,425
Stockholders' equity	665,474
Net current assets	133,500

ARDELYX INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	20,005	28,434
Operating income	(17,685)	(28,434)
Other income (expense), net	670	426
Net before taxes	(17,015)	
Income taxes	4	
Net income	(17,019)	(28,008)
Earnings common share		
Primary	\$(0.36)	\$(0.59)
Fully Diluted	\$(0.36)	\$(0.59)
Common Shares:		
Full Diluted	47,559	47,343
Year-end	47,604	47,387

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	67,745	
Current assets	135,320	
Net property & equip.	7,358	
Total assets	142,837	
Liabilities:		
Current liabilities	13,162	
Stockholders' equity	128,976	
Net current assets	122,158	

ARENA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Total Revenues	1,755,000	1,660,000
Cost & expenses	32,724,000	22,864,000
Operating income	(30,969,000)	(21,204,000)
Interest income	774,000	34,000
Interest expense	1,472,000	1,570,000
Other income (expense), net	534,000	189,000
Income contin. oper.	(31,133,000)	(22,551,000)
Net income	(31,963,000)	(22,497,000)
Earnings common share		
Primary	\$(0.80)	\$(0.90)
Fully Diluted	\$(0.80)	\$(0.90)
Common Shares:		
Full Diluted	39,996,000	24,482,000
Year-end	49,234,094	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	516,141,000	
Current assets	649,861,000	
Net property & equip.	29,507,000	
Total assets	685,468,000	
Liabilities:		
Current liabilities	42,527,000	
Long-term debt	56,989,000	
Stockholders' equity	584,135,000	
Net current assets	607,334,000	

ARMO BIOSCIENCES INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	22,115	9,414
Operating income	(22,115)	(9,414)
Interest income	393	18
Net income	(21,722)	(9,396)
Earnings common share		
Primary	\$(0.97)	\$(6.42)
Fully Diluted	\$(0.97)	\$(6.42)
Common Shares:		
Full Diluted	22,370	1,463
Year-end	30,405	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	165,313	
Current assets	171,935	
Net property & equip.	327	
Total assets	175,070	
Liabilities:		
Current liabilities	15,894	
Stockholders' equity	156,862	
Net current assets	156,041	

ARRAY BIOPHARMA INC.**Earnings, 9 mos. to Mar 31**(Consol. – \$):

	2018	2017
Total Revenues	138,331,000	117,074,000
Cost & expenses	221,309,000	192,814,000
Operating income	(82,978,000)	(75,740,000)
Interest income	3,075,000	510,000
Interest expense	8,407,000	9,181,000
Other income (expense), net	(6,657,000)	(3,600,000)
Invest. income	69,000	785,000
Net income	(94,898,000)	(87,226,000)
Earnings common share		
Primary	\$(0.49)	\$(0.54)
Fully Diluted	\$(0.49)	\$(0.54)
Common Shares:		
Full Diluted	194,434,000	160,689,000
Year-end	210,503,949	169,897,032

ARROWHEAD PHARMACEUTICALS INC**Earnings, 6 mos. to Mar 31**(Consol. – \$):

	2018	2017
Total Revenues	4,159,946	13,351,426
Cost & expenses	33,007,353	34,382,957
Operating income	(28,847,407)	(21,031,531)
Other income (expense), net	432,141	2,768,972
Net income	(28,083,189)	(18,128,667)
Earnings common share		
Primary	\$(0.35)	\$(0.25)
Fully Diluted	\$(0.35)	\$(0.25)
Common Shares:		
Full Diluted	79,406,838	73,019,726
Year-end	87,570,398	74,772,103

ASTEC INDUSTRIES, INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Net Sales	325,453	318,401
Cost & expenses	299,526	295,751
Operating income	25,927	22,650
Interest income	214	175
Interest expense	150	265
Other income (expense), net	350	310
Gains or losses	(103)	27
Net before taxes	26,238	22,897
Income taxes	6,022	7,817
Net income	20,216	15,080
Earnings common share		
Primary	\$0.88	\$0.66
Fully Diluted	\$0.87	\$0.65
Common Shares:		
Full Diluted	23,236	23,176
Year-end	23,087	23,060

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	41,940	
Inventories	411,159	
Current assets	632,237	
Net property & equip.	189,287	
Total assets	918,365	
Liabilities:		
Current liabilities	186,442	
Long-term debt	1,357	
Stockholders' equity	707,001	
Net current assets	445,795	

ATARA BIOTHERAPEUTICS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	42,452	26,161
Operating income	(42,452)	(26,161)
Net before taxes		(25,652)
Income taxes		2
Net income	(41,443)	(25,654)
Earnings common share		
Primary	\$(1.05)	\$(0.88)
Fully Diluted	\$(1.05)	\$(0.88)
Common Shares:		
Full Diluted	39,596	29,056
Year-end	43,893	29,109

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	90,495	
Current assets	413,614	
Net property & equip.	58,194	
Total assets	473,108	
Liabilities:		

Current liabilities		21,049
Stockholders' equity		439,184
Net current assets		392,565

ATHENEX INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	37,836	4,581
Cost & expenses	45,709	39,046
Operating income	(7,873)	(34,465)
Other income (expense), net		(4,276)
Net before taxes	(7,646)	(41,117)
Income taxes	(307)	(92)
Net income	(7,339)	(41,025)
Earnings common share		
Primary	\$(0.12)	\$(1.01)
Fully Diluted	\$(0.12)	\$(1.01)
Common Shares:		
Full Diluted	61,655	40,693
Year-end	63,276	48,964

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents		39,217
Inventories		18,571
Current assets		140,090
Net property & equip.		10,368
Total assets		197,533
Liabilities:		
Current liabilities		36,632
Long-term debt		428
Stockholders' equity		155,441
Net current assets		103,458

AUDENTES THERAPEUTICS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	26,410	18,245
Operating income	(26,410)	(18,245)
Interest income	859	147
Other income (expense), net	(20)	(17)
Net income	(25,571)	(18,115)
Earnings common share		
Primary	\$(0.74)	\$(0.83)
Fully Diluted	\$(0.74)	\$(0.83)
Common Shares:		
Full Diluted	34,582	21,755
Year-end	36,698	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents		230,864
Current assets		329,373
Net property & equip.		26,436
Total assets		373,089
Liabilities:		
Current liabilities		16,119
Stockholders' equity		352,442
Net current assets		313,254

AVEXIS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Cost & expenses	222,456,000	29,964,894
Operating income	(222,456,000)	(29,964,894)
Interest income	354,000	245,940
Net income	(222,102,000)	(29,718,954)
Earnings common share		
Primary	\$(6.20)	\$(1.07)
Fully Diluted	\$(6.20)	\$(1.07)
Common Shares:		
Full Diluted	35,842,000	27,733,701
Year-end	36,810,000	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	586,808,000	
Current assets	598,444,000	
Net property & equip.	62,864,000	
Total assets	667,253,000	
Liabilities:		
Current liabilities	72,827,000	
Stockholders' equity	569,326,000	
Net current assets	525,617,000	

AXT INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	24,619	20,616
Cost & expenses	20,488	19,245
Operating income	3,931	1,371
Other income (expense), net	(549)	(885)
Net before taxes	3,524	584
Income taxes	334	159
Net income	3,190	425
Earnings common share		
Primary	\$0.07	\$0.02
Fully Diluted	\$0.07	\$0.02
Common Shares:		
Full Diluted	40,364	35,624
Year-end	39,438	38,581
Consolidated Balance Sheet Items, as of (\$000):		
Assets:	2018	2017
Cash & equivalents	39,189	51,122
Inventories	51,122	133,557
Current assets	133,557	58,763
Net property & equip.	58,763	216,307
Total assets	216,307	
Liabilities:		
Current liabilities	21,239	189,667
Stockholders' equity	189,667	112,318
Net current assets	112,318	

B RILEY FINANCIAL INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	95,778	52,897
Cost & expenses	85,176	42,186
Operating income	10,602	10,711
Interest income	128	132
Interest expense	4,227	791
Other income (expense), net	(672)	
Net before taxes	5,831	10,052
Income taxes	989	(3,849)
Net income	4,842	13,901
Earnings common share		
Primary	\$0.17	\$0.73
Fully Diluted	\$0.17	\$0.71
Common Shares:		
Full Diluted	27,272	19,627
Year-end	26,677	19,307

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:	2018	2017
Cash & equivalents	74,339	1,196,608
Current assets	1,196,608	11,467
Net property & equip.	11,467	1,430,329
Total assets	1,430,329	
Liabilities:		
Current liabilities	92,981	210,960
Long-term debt	210,960	271,543
Stockholders' equity	271,543	1,103,627
Net current assets	1,103,627	

BALCHEM CORP.**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Net Sales	161,410	137,728
Cost & expenses	133,998	115,025
Operating income	27,412	22,703
Other income (expense), net	(361)	(196)
Net before taxes	25,177	20,710
Income taxes	5,831	5,192
Net income	19,346	15,518
Earnings common share		
Primary	\$0.60	\$0.49
Fully Diluted	\$0.60	\$0.48
Common Shares:		
Full Diluted	32,327	32,190
Year-end	32,100	31,867

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:	2018	2017
Cash & equivalents	42,679	66,270
Inventories	66,270	211,808
Current assets	211,808	187,935
Net property & equip.	187,935	967,989
Total assets	967,989	
Liabilities:		
Current liabilities	98,115	175,323
Long-term debt	175,323	639,890
Stockholders' equity	639,890	113,693
Net current assets	113,693	

BANDWIDTH INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	53,012	39,625
Cost & expenses	44,236	34,443
Operating income	8,776	5,182
Other income (expense), net	49	(421)
Net before taxes	8,825	4,761
Income taxes	2,634	1,772
Net income	6,191	2,989
Balance for common	6,191	2,598
Earnings common share		
Primary	\$0.35	\$0.22
Fully Diluted	\$0.30	\$0.20
Common Shares:		
Full Diluted	20,485	12,973
Year-end	17,692	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:	2018	2017
Cash & equivalents	47,265	78,622
Current assets	78,622	15,902
Net property & equip.	15,902	115,764
Total assets	115,764	
Liabilities:		
Current liabilities	24,772	83,175
Stockholders' equity	83,175	53,850
Net current assets	53,850	

BARRETT BUSINESS SERVICES, INC.**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	223,975	209,997
Cost & expenses	237,141	226,157
Operating income	(14,170)	(17,102)
Interest expense	42	83
Other income (expense), net	16	
Gains or losses	2,019	158
Net before taxes	(12,177)	(17,027)
Income taxes	(3,054)	(5,800)
Net income	(9,123)	(11,227)
Earnings common share		
Primary	\$(1.25)	\$(1.55)
Fully Diluted	\$(1.25)	\$(1.55)
Common Shares:		
Full Diluted	7,304	7,249
Year-end	7,307	7,252

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:	2018	2017
Cash & equivalents	24,000	290,218
Current assets	290,218	25,068
Net property & equip.	25,068	690,121
Total assets	690,121	
Liabilities:		
Current liabilities	330,189	4,116
Long-term debt	4,116	75,440
Stockholders' equity	75,440	(39,971)
Net current assets	(39,971)	

BEACON ROOFING SUPPLY INC**Earnings, 6 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Net Sales	2,547,604	1,872,908
Cost & expenses	2,555,906	1,829,007
Operating income	(8,302)	43,901
Net before taxes	(70,440)	18,059
Income taxes	(71,381)	6,985
Net income	941	11,074
Balance for common	(5,059)	11,074
Earnings common share		
Primary	\$(0.07)	\$0.18
Fully Diluted	\$(0.07)	\$0.18
Common Shares:		
Full Diluted	67,922	61,070
Year-end	68,043	60,255

BEASLEY BROADCAST GROUP INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	55,153,627	53,740,551
Cost & expenses	53,211,245	40,694,935
Deprec., depl. & amort.	1,546,734	1,502,837
Operating income	395,648	11,542,779
Other income (expense), net	448,901	356,198
Net before taxes	(2,780,691)	7,071,638

Income taxes	380,501	(414,858)
Net income	(3,161,192)	7,486,496
Earnings common share		
Primary	\$(0.11)	\$0.27
Fully Diluted	\$(0.11)	\$0.27
Common Shares:		
Full Diluted	27,717,394	27,766,662
Year-end	27,503,924	28,838,099

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:	2018	2017
Cash & equivalents	13,169,964	66,629,705
Current assets	66,629,705	58,979,747
Net property & equip.	58,979,747	636,202,501
Total assets	636,202,501	
Liabilities:		
Current liabilities	28,928,559	212,169,482
Long-term debt	212,169,482	267,984,145
Stockholders' equity	267,984,145	37,701,146
Net current assets	37,701,146	

BEL FUSE INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Net Sales	118,251,000	113,668,000
Cost & expenses	117,814,000	111,313,000
Operating income	437,000	2,355,000
Interest expense	1,177,000	1,424,000
Other income (expense), net	(238,000)	(208,000)
Net before taxes	(978,000)	723,000
Income taxes	325,000	(23,000)
Net income	(1,303,000)	746,000
Balance for common	(2,133,000)	(83,000)
Earnings common share		
Primary	\$(0.11)	\$0.05
Fully Diluted	\$(0.11)	\$0.05
Common Shares:		
Full Diluted	2,175,000	2,175,000
Year-end	12,022,014	12,013,914

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:	2018	2017
Cash & equivalents	66,852,000	102,693,000
Inventories	102,693,000	269,979,000
Current assets	269,979,000	43,322,000
Net property & equip.	43,322,000	435,394,000
Total assets	435,394,000	
Liabilities:		
Current liabilities	85,884,000	119,390,000
Long-term debt	119,390,000	164,175,000
Stockholders' equity	164,175,000	184,095,000
Net current assets	184,095,000	

BELLEROPHON THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	8,492	4,783
Operating income	(8,492)	(4,783)
Other income (expense), net	7,050	(14,387)
Net before taxes	(1,343)	
Income taxes	(5,439)	
Net income	4,096	(19,143)
Earnings common share		
Primary	\$0.07	\$(0.60)
Fully Diluted	\$(0.04)	\$(0.60)
Common Shares:		
Full Diluted	72,101	31,934
Year-end	57,369	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:	2018	2017
Cash & equivalents	28,350	34,763
Current assets	34,763	935
Net property & equip.	935	35,888
Total assets	35,888	
Liabilities:		
Current liabilities	8,396	2,217
Stockholders' equity	2,217	26,367
Net current assets	26,367	

BELLICUM PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	154	128
Cost & expenses	22,258	21,577
Operating income	(22,104)	(21,449)
Interest income	267	197
Interest expense	1,003	721
Net income	(22,840)	(21,973)
Earnings common share		
Primary	\$(0.68)	\$(0.80)
Fully Diluted	\$(0.68)	\$(0.80)
Common Shares:		
Full Diluted	33,456	27,296
Year-end	33,611	33,078

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	31,794	31,794
Current assets	84,935	84,935
Net property & equip.	25,152	25,152
Total assets	116,352	116,352
Liabilities:		
Current liabilities	12,597	12,597
Long-term debt	35,287	35,287
Stockholders' equity	66,183	66,183
Net current assets	72,338	72,338

BENEFITFOCUS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	62,363	57,623
Cost & expenses	73,036	70,163
Operating income	(10,673)	(12,540)
Interest income	58	27
Other income (expense), net		(148)
Net before taxes	(13,798)	
Income taxes	4	
Net income	(13,802)	(15,583)
Earnings common share		
Primary	\$(0.44)	\$(0.51)
Fully Diluted	\$(0.44)	\$(0.51)
Common Shares:		
Full Diluted	31,333	30,658
Year-end	31,339	30,786

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	54,785	54,785
Current assets	99,540	99,540
Net property & equip.	71,233	71,233
Total assets	187,755	187,755
Liabilities:		
Current liabilities	91,327	91,327
Long-term debt	94,970	94,970
Stockholders' equity	(17,974)	(17,974)
Net current assets	8,213	8,213

BGC PARTNERS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	956,646,000	783,193,000
Cost & expenses	863,195,000	731,213,000
Operating income	99,252,000	52,774,000
Other income (expense), net	39,743,000	5,257,000
Gains or losses		557,000
Net before taxes	133,194,000	57,794,000
Income taxes	35,763,000	6,678,000
Net income	97,431,000	51,116,000
Balance for common	58,774,000	36,825,000
Earnings common share		
Primary	\$0.19	\$0.13
Fully Diluted	\$0.19	\$0.13
Common Shares:		
Full Diluted	307,728,000	444,826,000
Year-end	314,127,000	283,315,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	692,739,000	692,739,000
Current assets	3,445,724,000	3,445,724,000
Net property & equip.	196,906,000	196,906,000
Total assets	6,777,496,000	6,777,496,000
Liabilities:		
Current liabilities	3,914,846,000	3,914,846,000
Long-term debt	1,375,943,000	1,375,943,000
Stockholders' equity	877,849,000	877,849,000
Net current assets	(469,122,000)	(469,122,000)

BIO-TECHNE CORP**Earnings, 9 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	462,739,000	406,425,000
Cost & expenses	369,476,000	325,887,000
Operating income	93,263,000	80,538,000
Interest income	307,000	211,000
Interest expense	7,135,000	5,430,000
Other income (expense), net	(16,753,000)	(1,206,000)
Net before taxes	69,682,000	74,113,000
Income taxes	(14,767,000)	25,637,000
Net income	84,449,000	48,476,000
Earnings common share		
Primary	\$2.25	\$1.30
Fully Diluted	\$2.22	\$1.29
Common Shares:		
Full Diluted	37,933,000	37,486,000
Year-end	37,545,189	37,333,015

BIO SIG TECHNOLOGIES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	2,634,216	2,895,945
Operating income	(2,637,119)	(2,899,014)
Other income (expense), net		(373,611)
Net income	(2,637,034)	(3,272,625)
Balance for common	(2,942,080)	(3,296,370)
Earnings common share		
Primary	\$(0.09)	\$(0.14)
Fully Diluted	\$(0.09)	\$(0.14)
Common Shares:		
Full Diluted	29,944,445	23,051,872
Year-end	30,497,707	24,405,863

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	1,035,100	1,035,100
Current assets	1,154,211	1,154,211
Net property & equip.	19,457	19,457
Total assets	1,196,145	1,196,145
Liabilities:		
Current liabilities	821,447	821,447
Stockholders' equity	(590,302)	(590,302)
Net current assets	332,764	332,764

BJ'S RESTAURANTS INC**Earnings, 3 mos. to (Consol. - \$):**

	04/03/18	04/04/17
Total Revenues	278,523,000	257,816,000
Cost & expenses	244,696,000	228,118,000
Operating income	16,373,000	12,949,000
Other income (expense), net	(100,000)	785,000
Net before taxes	14,886,000	12,846,000
Income taxes	222,000	3,580,000
Net income	14,664,000	9,266,000
Earnings common share		
Primary	\$0.71	\$0.42
Fully Diluted	\$0.70	\$0.42
Common Shares:		
Full Diluted	21,063,000	22,313,000
Year-end	20,669,000	21,572,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	28,705,000	28,705,000
Inventories	10,160,000	10,160,000
Current assets	64,191,000	64,191,000
Net property & equip.	587,758,000	587,758,000
Total assets	686,997,000	686,997,000
Liabilities:		
Current liabilities	120,494,000	120,494,000
Long-term debt	158,500,000	158,500,000
Stockholders' equity	268,787,000	268,787,000
Net current assets	(56,303,000)	(56,303,000)

BLACKBAUD, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	204,184	185,072
Cost & expenses	185,334	171,108
Operating income	17,581	13,273
Interest expense	3,517	2,377
Other income (expense), net	160	286
Net before taxes	14,224	11,182
Income taxes	(3,527)	(1,960)
Net income	17,751	13,142

Earnings common share

Primary	\$0.38	\$0.28
Fully Diluted	\$0.37	\$0.28
Common Shares:		
Full Diluted	48,009	47,483
Year-end	48,524	48,035

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	25,013	25,013
Current assets	359,563	359,563
Net property & equip.	44,647	44,647
Total assets	1,367,934	1,367,934
Liabilities:		
Current liabilities	504,350	504,350
Long-term debt	458,592	458,592
Stockholders' equity	344,321	344,321
Net current assets	(144,787)	(144,787)

BLOOMIN' BRANDS INC**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	03/26/17
Total Revenues	1,116,465	1,154,711
Cost & expenses	987,974	1,031,287
Operating income	78,371	76,834
Interest expense	10,310	9,141
Other income (expense), net	1	(51)
Net before taxes	68,062	67,642
Income taxes	1,925	18,004
Net income	66,137	49,638
Earnings common share		
Primary	\$0.71	\$0.47
Fully Diluted	\$0.68	\$0.46
Common Shares:		
Full Diluted	95,782	106,413
Year-end	91,416	101,480

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	105,840	105,840
Inventories	50,182	50,182
Current assets	271,291	271,291
Net property & equip.	1,166,960	1,166,960
Total assets	2,454,268	2,454,268
Liabilities:		
Current liabilities	667,380	667,380
Long-term debt	1,116,570	1,116,570
Stockholders' equity	97,657	97,657
Net current assets	(396,089)	(396,089)

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	105,840	105,840
Inventories	50,182	50,182
Current assets	271,291	271,291
Net property & equip.	1,166,960	1,166,960
Total assets	2,454,268	2,454,268
Liabilities:		
Current liabilities	667,380	667,380
Long-term debt	1,116,570	1,116,570
Stockholders' equity	97,657	97,657
Net current assets	(396,089)	(396,089)

BLUCORA, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	205,965,000	182,375,000
Cost & expenses	143,009,000	129,258,000
Operating income	52,734,000	43,889,000
Interest income	40,000	20,000
Other income (expense), net	(884,000)	(2,905,000)
Net before taxes	47,506,000	34,181,000
Income taxes	1,963,000	3,471,000
Net income	45,543,000	30,710,000
Earnings common share		
Primary	\$0.97	\$0.73
Fully Diluted	\$0.93	\$0.67
Common Shares:		
Full Diluted	48,665,000	45,428,000
Year-end	46,828,000	42,635,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	77,107,000	77,107,000
Current assets	116,264,000	116,264,000
Net property & equip.	8,769,000	8,769,000
Total assets	1,010,072,000	1,010,072,000
Liabilities:		
Current liabilities	49,601,000	49,601,000
Long-term debt	299,078,000	299,078,000
Stockholders' equity	593,141,000	593,141,000
Net current assets	66,663,000	66,663,000

BLUE HILLS BANCORP INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	18,849	17,110
Operating income	8,846	9,240
Net before taxes	8,846	9,240
Income taxes	2,263	1,753
Net income	6,583	7,487
Earnings common share		
Primary	\$0.27	\$0.31
Fully Diluted	\$0.27	\$0.31
Common Shares:		
Full Diluted	24,828	24,276
Year-end	26,862	26,858

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	45,072	45,072
Current assets	365,958	365,958
Net property & equip.	20,685	20,685
Total assets	2,669,151	2,669,151
Liabilities:		
Current liabilities	2,142,838	2,142,838
Long-term debt	105,000	105,000
Stockholders' equity	395,444	395,444
Net current assets	(1,776,880)	(1,776,880)

BMC STOCK HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	834,202	757,700
Cost & expenses	797,009	732,832
Operating income	24,030	10,486
Interest expense	5,982	6,088
Other income (expense), net	1,950	319
Net before taxes	19,998	4,717
Income taxes	4,639	973
Net income	15,359	3,744
Earnings common share		
Primary	\$0.23	\$0.06
Fully Diluted	\$0.23	\$0.06
Common Shares:		
Full Diluted	67,664	67,186
Year-end	67,200	66,900

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	9,002	9,002
Inventories	338,767	338,767
Current assets	795,474	795,474
Net property & equip.	295,897	295,897
Total assets	1,543,508	1,543,508
Liabilities:		
Current liabilities	359,455	359,455
Long-term debt	370,117	370,117
Stockholders' equity	763,575	763,575
Net current assets	436,019	436,019

BOINGO WIRELESS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	58,159	44,333
Cost & expenses	59,998	50,000
Operating income	(2,566)	(6,578)
Net before taxes	(2,645)	(6,574)
Income taxes	128	199
Net income	(2,773)	(6,773)
Balance for common	(3,229)	(6,880)
Earnings common share		
Primary	\$(0.08)	\$(0.18)
Fully Diluted	\$(0.08)	\$(0.18)
Common Shares:		
Full Diluted	41,330	38,712
Year-end	41,753	38,951

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	18,552	18,552
Current assets	54,407	54,407
Net property & equip.	264,629	264,629
Total assets	378,547	378,547
Liabilities:		
Current liabilities	138,714	138,714
Long-term debt	6,961	6,961
Stockholders' equity	99,045	99,045
Net current assets	(84,307)	(84,307)

BOTTOMLINE TECHNOLOGIES (DELAWARE) INC**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	287,627	255,911
Cost & expenses	267,817	256,441
Operating income	3,102	(18,911)
Interest income	184	390
Interest expense	9,724	12,591
Other income (expense), net	252	(395)
Net before taxes	(6,186)	(31,507)
Income taxes	(4,031)	(4,029)
Net income	(2,155)	(27,478)
Earnings common share		
Primary	\$(0.06)	\$(0.73)
Fully Diluted	\$(0.06)	\$(0.73)
Common Shares:		
Full Diluted	38,055	37,891
Year-end	38,510	38,135

BRAVO BRIO RESTAURANT GROUP INC**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	03/26/17
Total Revenues	97,359	106,719
Cost & expenses	96,791	100,515
Operating income	(4,354)	1,090
Interest expense	693	511
Net before taxes	(5,047)	579
Income taxes	25	29
Net income	(5,072)	550
Earnings common share		
Primary	\$(0.33)	\$0.04
Fully Diluted	\$(0.33)	\$0.04
Common Shares:		
Full Diluted	15,236	15,138
Year-end	15,295	15,160

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	1,737	1,737
Inventories	2,909	2,909
Current assets	15,753	15,753
Net property & equip.	113,022	113,022
Total assets	133,876	133,876
Liabilities:		
Current liabilities	100,768	100,768
Stockholders' equity	(32,273)	(32,273)
Net current assets	(85,015)	(85,015)

BROOKS AUTOMATION INC**Earnings, 6 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	396,588	329,288
Cost & expenses	351,929	301,325
Operating income	44,659	27,963
Other income (expense), net	(1,912)	1,313
Equity earnings	(3,602)	(4,719)
Net before taxes	38,874	29,377
Income taxes	(41,030)	6,220
Net income	83,506	27,876
Earnings common share		
Primary	\$1.19	\$0.40
Fully Diluted	\$1.18	\$0.40
Common Shares:		
Full Diluted	70,908	70,073
Year-end	70,540	69,644

BRUKER CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	431,700,000	384,900,000
Cost & expenses	393,600,000	347,300,000
Operating income	38,100,000	37,600,000
Other income (expense), net	600,000	600,000
Foreign currency	500,000	(2,300,000)
Net before taxes	35,800,000	31,600,000
Income taxes	8,400,000	9,900,000
Net income	27,400,000	21,700,000
Earnings common share		
Primary	\$0.17	\$0.14
Fully Diluted	\$0.17	\$0.13
Common Shares:		
Full Diluted	157,000,000	160,500,000
Year-end	156,079,898	159,933,578

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	283,900,000	283,900,000
Inventories	518,000,000	518,000,000

Current assets	1,240,500,000
Net property & equip.	270,000,000
Total assets	1,830,500,000
Liabilities:	
Current liabilities	558,700,000
Long-term debt	205,600,000
Stockholders' equity	781,500,000
Net current assets	681,800,000

BUILDERS FIRSTSOURCE INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	1,700,436	1,533,064
Cost & expenses	1,648,292	1,492,787
Operating income	52,144	40,277
Interest expense	26,742	36,157
Net before taxes	25,402	4,120
Income taxes	2,182	298
Net income	23,220	3,822
Earnings common share		
Primary	\$0.20	\$0.03
Fully Diluted	\$0.20	\$0.03
Common Shares:		
Full Diluted	116,696	114,580
Year-end	114,619	112,356

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	10,069	10,069
Inventories	678,790	678,790
Current assets	1,503,115	1,503,115
Net property & equip.	643,721	643,721
Total assets	3,109,689	3,109,689
Liabilities:		
Current liabilities	719,391	719,391
Long-term debt	1,928,410	1,928,410
Stockholders' equity	400,973	400,973
Net current assets	783,724	783,724

CALUMET SPECIALTY PRODUCT PARTNERS LP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	750,500	886,500
Cost & expenses	709,200	847,100
Operating income	41,300	39,400
Interest expense	45,200	43,900
Other income (expense), net	900	200
Gains or losses	(100)	5,700
Net before taxes	(3,100)	1,400
Income taxes	(200)	(100)
Income contin. oper.	(2,900)	1,500
Net income	(4,800)	(6,200)
Earnings common share		
Primary	\$(0.06)	\$(0.08)
Fully Diluted	\$(0.06)	\$(0.08)
Common Shares:		
Full Diluted	78,045	78,260
Year-end	78,475	78,260

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	146,600	146,600
Inventories	325,000	325,000
Current assets	1,120,300	1,120,300
Net property & equip.	1,149,700	1,149,700
Total assets	2,606,100	2,606,100
Liabilities:		
Current liabilities	887,200	887,200
Long-term debt	1,598,800	1,598,800
Net current assets	233,100	233,100

CARBONITE INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	64,026	57,099
Cost & expenses	66,013	63,522
Operating income	(2,926)	(6,873)
Interest income	244	20
Interest expense	2,601	222
Other income (expense), net	12	280
Net before taxes	(5,271)	(6,795)
Income taxes	(17,215)	(14,390)
Net income	(22,486)	(21,165)
Earnings common share		
Primary	\$0.42	\$0.27
Fully Diluted	\$0.40	\$0.27

Common Shares:		
Full Diluted	30,044	28,505
Year-end	28,570	27,488
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2018
Cash & equivalents		71,009
Current assets		110,848
Net property & equip.		38,622
Total assets		456,124
Liabilities:		
Current liabilities		151,585
Long-term debt		203,398
Stockholders' equity		67,444
Net current assets		(40,737)

CARDLYTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	32,713	26,881
Cost & expenses	41,620	33,164
Operating income	(9,817)	(7,048)
Interest expense	1,749	2,644
Other income (expense), net	(8,489)	(2,771)
Net income	(20,055)	(12,463)
Balance for common	(20,212)	(12,707)
Earnings common share		
Primary	\$(1.54)	\$(4.80)
Fully Diluted	\$(1.54)	\$(4.80)
Common Shares:		
Full Diluted	13,093	2,645
Year-end	20,226	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		89,785
Current assets		136,098
Net property & equip.		7,363
Total assets		157,807
Liabilities:		
Current liabilities		80,801
Long-term debt		32,894
Stockholders' equity		40,558
Net current assets		55,297

CARGURUS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	98,701	67,035
Cost & expenses	94,046	60,103
Operating income	3,922	6,384
Other income (expense), net	282	164
Net before taxes	4,204	6,548
Income taxes	553	2,341
Net income	3,651	4,207
Balance for common	3,651	1,725
Earnings common share		
Primary	\$0.03	\$0.04
Fully Diluted	\$0.03	\$0.04
Common Shares:		
Full Diluted	113,341	46,268
Year-end	106,128	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		62,003
Current assets		161,503
Net property & equip.		16,175
Total assets		182,538
Liabilities:		
Current liabilities		41,219
Stockholders' equity		134,795
Net current assets		120,284

CARRIZO OIL & GAS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	225,280,000	151,355,000
Cost & expenses	133,002,000	56,952,000
Deprec., depl. & amort.	64,467,000	54,382,000
Operating income	27,811,000	40,021,000
Net before taxes	27,811,000	
Income taxes	319,000	
Net income	27,492,000	40,021,000
Balance for common	14,743,000	40,021,000
Earnings common share		

Primary	\$0.18	\$0.61
Fully Diluted	\$0.18	\$0.61
Common Shares:		
Full Diluted	82,578,000	65,778,000
Year-end	82,065,561	65,796,342

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		4,885,000
Current assets		119,201,000
Net property & equip.		2,400,985,000
Total assets		2,538,457,000
Liabilities:		
Current liabilities		431,581,000
Long-term debt		1,442,898,000
Stockholders' equity		391,281,000
Net current assets		(312,380,000)

CASELLA WASTE SYSTEMS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	147,455,000	133,802,000
Cost & expenses	130,634,000	113,389,000
Deprec., depl. & amort.	15,983,000	13,849,000
Operating income	838,000	6,564,000
Interest income	29,000	69,000
Other income (expense), net	89,000	(391,000)
Net before taxes	(5,498,000)	(208,000)
Income taxes	(1,588,000)	16,000
Net income	(3,910,000)	(224,000)
Earnings common share		
Primary	\$(0.09)	\$(0.01)
Fully Diluted	\$(0.09)	\$(0.01)
Common Shares:		
Full Diluted	42,370,000	41,584,000
Year-end	42,688,000	41,880,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		2,392,000
Inventories		6,492,000
Current assets		84,917,000
Net property & equip.		366,817,000
Total assets		631,375,000
Liabilities:		
Current liabilities		84,609,000
Long-term debt		494,934,000
Stockholders' equity		(38,817,000)
Net current assets		308,000

CASS INFORMATION SYSTEMS INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	26,751	24,699
Operating income	9,801	7,972
Net before taxes	9,801	7,972
Income taxes	1,709	1,665
Net income	8,092	6,307
Earnings common share		
Primary	\$0.66	\$0.51
Fully Diluted	\$0.65	\$0.51
Common Shares:		
Full Diluted	12,422	12,432
Year-end	12,288	12,316

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		199,582
Current assets		199,582
Net property & equip.		22,012
Total assets		1,650,802
Liabilities:		
Current liabilities		1,386,698
Stockholders' equity		222,422
Net current assets		(1,187,116)

CENTRAL GARDEN & PET CO**Earnings, 6 mos. to (Consol. - \$000):**

	03/31/18	03/25/17
Net Sales	1,055,105	989,422
Cost & expenses	966,798	905,624
Operating income	88,307	83,798
Interest income	880	46
Interest expense	17,980	13,703
Other income (expense), net	(1,584)	(1,932)
Net before taxes	69,623	68,209

Income taxes	(2,593)	25,171
Net income	72,216	43,038
Earnings common share		
Primary	\$1.41	\$0.85
Fully Diluted	\$1.36	\$0.82
Common Shares:		
Full Diluted	52,693	51,911
Year-end	51,969	51,560

CENTURY ALUMINUM CO.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	454,500	365,786
Cost & expenses	451,000	360,610
Operating income	3,500	5,176
Other income (expense), net	(1,100)	384
Gains or losses	700	(16,137)
Equity earnings	(600)	(471)
Net before taxes	(1,900)	(15,918)
Income taxes	(1,000)	(308)
Net income	(300)	(15,139)
Earnings common share		
Primary	\$(0.17)	\$(0.17)
Fully Diluted	\$(0.17)	\$(0.17)
Common Shares:		
Full Diluted	87,600	87,254
Year-end	87,576	87,262

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		130,800
Inventories		330,700
Current assets		568,600
Net property & equip.		955,100
Total assets		1,580,800
Liabilities:		
Current liabilities		197,200
Long-term debt		248,300
Stockholders' equity		830,400
Net current assets		371,400

CERUS CORP.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	30,374	26,527
Operating income	(13,355)	(18,093)
Interest expense	915	531
Other income (expense), net	331	106
Foreign currency	108	(45)
Net before taxes	(13,831)	(18,563)
Income taxes	54	35
Net income	(13,885)	(18,598)
Earnings common share		
Primary	\$(0.11)	\$(0.18)
Fully Diluted	\$(0.11)	\$(0.18)
Common Shares:		
Full Diluted	124,814	103,564
Year-end	130,544	103,938

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		14,877
Inventories		13,165
Current assets		133,776
Net property & equip.		1,969
Total assets		144,421
Liabilities:		
Current liabilities		23,656
Long-term debt		28,387
Stockholders' equity		85,598
Net current assets		110,120

CEVA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	17,569	21,287
Cost & expenses	20,118	16,632
Operating income	(2,908)	4,346
Net before taxes	(1,981)	4,917
Income taxes	201	810
Net income	(2,182)	4,107
Earnings common share		
Primary	\$(0.10)	\$0.19
Fully Diluted	\$(0.10)	\$0.19
Common Shares:		
Full Diluted	22,148	22,187

Year-end	22,221	21,531
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		
Cash & equivalents	51,651	2018
Current assets	164,326	
Net property & equip.	6,805	
Total assets	286,542	
Liabilities:		
Current liabilities	23,543	
Stockholders' equity	252,815	
Net current assets	140,783	

CHEESECAKE FACTORY INC. (THE)**Earnings, 3 mos. to (Consol. - \$):**

	04/03/18	04/04/17
Total Revenues	590,691,000	563,426,000
Cost & expenses	535,138,000	496,667,000
Operating income	31,551,000	43,563,000
Net before taxes	30,045,000	42,307,000
Income taxes	4,016,000	7,264,000
Net income	26,029,000	35,043,000
Earnings common share		
Primary	\$0.57	\$0.74
Fully Diluted	\$0.56	\$0.71
Common Shares:		
Full Diluted	46,574,000	49,210,000
Year-end	45,695,637	47,911,748

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	24,801,000	2018
Inventories	40,959,000	
Current assets	163,868,000	
Net property & equip.	935,279,000	
Total assets	1,287,343,000	
Liabilities:		
Current liabilities	344,306,000	
Long-term debt	30,000,000	
Stockholders' equity	594,193,000	
Net current assets	(180,438,000)	

CHEMOCENTRYX, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	9,546	8,230
Cost & expenses	19,402	14,543
Operating income	(9,856)	(6,313)
Interest income	613	317
Interest expense	174	
Net income	(9,417)	(5,996)
Earnings common share		
Primary	\$(0.19)	\$(0.12)
Fully Diluted	\$(0.19)	\$(0.12)
Common Shares:		
Full Diluted	48,853	48,115
Year-end	49,071	48,169

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	30,550	2018
Current assets	149,798	
Net property & equip.	1,131	
Total assets	181,764	
Liabilities:		
Current liabilities	76,641	
Long-term debt	4,700	
Stockholders' equity	25,532	
Net current assets	73,157	

CHUY'S HOLDINGS INC**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	03/26/17
Total Revenues	93,850	86,904
Cost & expenses	85,462	76,282
Deprec., depl. & amort.	4,713	4,161
Operating income	3,675	6,461
Interest expense	16	16
Net before taxes	3,659	6,445
Income taxes	476	1,895
Net income	3,183	4,550
Earnings common share		
Primary	\$0.19	\$0.27
Fully Diluted	\$0.19	\$0.27
Common Shares:		
Full Diluted	17,069	17,002
Year-end	16,925	16,895

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	8,436	2018
Inventories	1,435	
Current assets	21,462	
Net property & equip.	204,628	
Total assets	274,253	
Liabilities:		
Current liabilities	24,579	
Stockholders' equity	190,610	
Net current assets	(3,117)	

CISCO SYSTEMS INC**Earnings, 9 mos. to (Consol. - \$000):**

	04/28/18	04/29/17
Net Sales	36,486,000	35,872,000
Cost & expenses	27,335,000	26,732,000
Operating income	8,963,000	8,939,000
Other income (expense), net	(86,000)	(27,000)
Gains or losses	134,000	(144,000)
Net before taxes	9,447,000	9,107,000
Income taxes	13,140,000	1,922,000
Net income	(3,693,000)	7,185,000
Earnings common share		
Primary	\$(0.76)	\$1.43
Fully Diluted	\$(0.76)	\$1.42
Common Shares:		
Full Diluted	4,892,000	5,056,000
Year-end	4,734,000	4,998,000

CLARUS CORP (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	53,267	41,556
Cost & expenses	52,773	41,832
Operating income	494	(276)
Other income (expense), net	121	14
Net before taxes	361	(1,245)
Income taxes	(42)	210
Net income	403	(1,455)
Earnings common share		
Primary	\$0.01	\$(0.05)
Fully Diluted	\$0.01	\$(0.05)
Common Shares:		
Full Diluted	30,157	30,015
Year-end	30,041	30,013

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2,196	2018
Inventories	53,122	
Current assets	96,010	
Net property & equip.	24,383	
Total assets	203,234	
Liabilities:		
Current liabilities	20,046	
Long-term debt	14,812	
Stockholders' equity	164,598	
Net current assets	75,964	

CLEARSIDE BIOMEDICAL INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	5	5
Cost & expenses	16,453	10,261
Operating income	(16,453)	(10,256)
Other income (expense), net	(154)	(117)
Net income	(16,607)	(10,373)
Earnings common share		
Primary	\$(0.62)	\$(0.41)
Fully Diluted	\$(0.62)	\$(0.41)
Common Shares:		
Full Diluted	26,818	25,250
Year-end	31,947	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	84,834	2018
Current assets	103,229	
Net property & equip.	838	
Total assets	104,462	
Liabilities:		
Current liabilities	13,843	
Long-term debt	4,107	
Stockholders' equity	85,931	
Net current assets	89,386	

COCA-COLA BOTTLING CO. CONSOLIDATED**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	04/02/17
Net Sales	1,072,064	865,702
Cost & expenses	1,091,061	850,752
Operating income	(18,997)	14,950
Interest expense	12,046	9,470
Other income (expense), net	4,510	(13,588)
Net before taxes	(26,533)	(8,108)
Income taxes	(12,971)	(3,691)
Net income	(13,562)	(4,417)
Earnings common share		
Primary	\$(1.52)	\$(1.08)
Fully Diluted	\$(1.52)	\$(1.08)
Common Shares:		
Full Diluted	11,539	11,497
Year-end	9,354	9,334

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	8,479	2018
Inventories	207,163	
Current assets	828,901	
Net property & equip.	1,022,325	
Total assets	3,090,443	
Liabilities:		
Current liabilities	574,956	
Long-term debt	1,244,260	
Stockholders' equity	354,754	
Net current assets	253,945	

COHERENT INC**Earnings, 6 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Net Sales	958,683	768,906
Cost & expenses	743,143	646,300
Operating income	209,984	113,289
Other income (expense), net	386	(461)
Gains or losses	2,575	1,695
Net before taxes	191,974	108,206
Income taxes	84,769	35,320
Income contin. oper.	107,205	72,886
Net income	107,203	72,253
Earnings common share		
Primary	\$4.34	\$2.96
Fully Diluted	\$4.29	\$2.93
Common Shares:		
Full Diluted	25,018	24,700
Year-end	24,834	24,578

COHERUS BIOSCIENCES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	42,032	72,578
Operating income	(42,032)	(72,417)
Other income (expense), net	138	(29)
Net income	(44,302)	(74,822)
Earnings common share		
Primary	\$(0.74)	\$(1.54)
Fully Diluted	\$(0.74)	\$(1.54)
Common Shares:		
Full Diluted	60,122	48,712
Year-end	61,163	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	82,021	2018
Current assets	112,241	
Net property & equip.	11,859	
Total assets	128,462	
Liabilities:		
Current liabilities	27,624	
Long-term debt	101,966	
Stockholders' equity	(1,794)	
Net current assets	84,617	

COHU, INC.**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	03/25/17
Net Sales	95,150	81,097
Cost & expenses	85,137	73,077
Operating income	10,013	8,020
Net before taxes	10,249	8,121
Income taxes	2,127	1,358
Net income	8,122	6,763
Earnings common share		
Primary	\$0.28	\$0.25

Fully Diluted	\$0.28	\$0.24
Common Shares:		
Full Diluted	29,531	28,252
Year-end	28,796	27,278
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2018
Cash & equivalents	115,136	
Inventories	62,676	
Current assets	297,506	
Net property & equip.	35,122	
Total assets	422,718	
Liabilities:		
Current liabilities	78,151	
Long-term debt	4,547	
Stockholders' equity	298,352	
Net current assets	219,355	

COLLECTORS UNIVERSE INC**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	51,328	52,206
Cost & expenses	44,581	40,212
Operating income	6,747	11,994
Net before taxes	6,854	11,935
Income taxes	1,678	4,467
Net income	5,265	7,465
Earnings common share		
Primary	\$0.61	\$0.88
Fully Diluted	\$0.59	\$0.87
Common Shares:		
Full Diluted	8,855	8,569
Year-end	9,016	8,921

COMMERCEHUB INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	26,263	24,568
Cost & expenses	25,081	20,301
Operating income	1,182	4,267
Interest income	25	
Interest expense	132	227
Net before taxes	1,075	4,040
Income taxes	886	1,581
Net income	189	2,459
Earnings common share		
Primary	\$0.06	\$0.06
Fully Diluted	\$0.06	\$0.06
Common Shares:		
Full Diluted	45,762	44,670
Year-end	43,672	43,147

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	33,438	
Current assets	48,065	
Net property & equip.	6,575	
Total assets	90,839	
Liabilities:		
Current liabilities	20,352	
Stockholders' equity	58,801	
Net current assets	27,713	

COMMERCEHUB INC

Merger Completed On May 21, 2018, Great Dane Parent, LLC ("Parent"), a company by affiliates of GTCR LLC ("GTCR") and Sycamore Partners Management L.P. ("Sycamore"), wholly-owned subsidiary, Great Dane Merger Sub, Inc. ("Merger Sub"), merged with and into Co., with Co. continuing as the surviving corporation and became a wholly-owned subsidiary of Parent. As the result of the merger, each outstanding share of Co.'s Series A, Series B and Series C common stock (collectively, "Co.'s common stock") was automatically converted into the right to receive \$22.75 in cash, without interest and less any applicable withholding taxes. Each share of Co.'s common stock held by Co. as treasury stock or owned by Merger Sub or Parent immediately prior to the Effective Time was cancelled without the right to receive any payment with respect thereto. No stockholder demanded appraisal of shares of Co.'s common stock in accordance with Section 262 of the General Corporation Law of the State of Delaware.

COMPUTER PROGRAMS & SYSTEMS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	70,882,000	64,075,000
Cost & expenses	60,632,000	58,240,000
Operating income	7,648,000	3,234,000

Interest expense	1,978,000	1,807,000
Other income (expense), net	198,000	70,000
Net before taxes	5,868,000	1,497,000
Income taxes	1,901,000	1,251,000
Net income	3,967,000	246,000
Balance for common	3,846,000	244,000
Earnings common share		
Primary	\$0.29	\$0.02
Fully Diluted	\$0.29	\$0.02
Common Shares:		
Full Diluted	13,475,000	13,374,000
Year-end	14,086,000	13,536,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	1,727,000	
Inventories	1,358,000	
Current assets	65,166,000	
Net property & equip.	11,223,000	
Total assets	325,385,000	
Liabilities:		
Current liabilities	40,567,000	
Long-term debt	136,231,000	
Stockholders' equity	142,568,000	
Net current assets	24,599,000	

COMPUTER TASK GROUP, INC.**Earnings, 3 mos. to (Consol. - \$000):**

	03/30/18	03/31/17
Total Revenues	82,713	77,006
Cost & expenses	82,130	75,606
Operating income	583	1,400
Net before taxes	529	1,277
Income taxes	115	526
Net income	414	751
Earnings common share		
Primary	\$0.03	\$0.05
Fully Diluted	\$0.03	\$0.05
Common Shares:		
Full Diluted	15,298	15,430
Year-end	15,550	15,564

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	11,163	
Current assets	93,471	
Net property & equip.	5,808	
Total assets	145,144	
Liabilities:		
Current liabilities	44,171	
Long-term debt	9,020	
Stockholders' equity	80,177	
Net current assets	49,300	

CONATUS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	9,737,000	6,998,076
Cost & expenses	14,794,000	10,688,736
Operating income	(5,057,000)	(3,690,660)
Interest expense	185,000	97,327
Other income (expense), net	(9,000)	(5,599)
Net income	(5,018,000)	(3,622,745)
Earnings common share		
Primary	\$(0.17)	\$(0.14)
Fully Diluted	\$(0.17)	\$(0.14)
Common Shares:		
Full Diluted	30,048,000	26,162,958
Year-end	30,063,000	26,169,896

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	16,615,000	
Current assets	73,829,000	
Net property & equip.	157,000	
Total assets	76,646,000	
Liabilities:		
Current liabilities	30,607,000	
Long-term debt	13,343,000	
Stockholders' equity	23,352,000	
Net current assets	43,222,000	

CONNECTONE BANCORP INC (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	70,882,000	64,075,000
Cost & expenses	60,632,000	58,240,000
Operating income	7,648,000	3,234,000

Cost & expenses	47,018	27,099
Operating income	4,695	16,794
Net before taxes	4,695	16,794
Income taxes	444	4,914
Net income	4,251	11,880
Balance for common	4,239	11,853
Earnings common share		
Primary	\$0.13	\$0.37
Fully Diluted	\$0.13	\$0.37
Common Shares:		
Full Diluted	32,296	32,193
Year-end	32,175	32,004

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	142,787	
Current assets	158,807	
Net property & equip.	21,039	
Total assets	5,158,368	
Liabilities:		
Current liabilities	3,749,587	
Long-term debt	823,342	
Stockholders' equity	564,266	
Net current assets	(3,590,780)	

CONSOLIDATED COMMUNICATIONS HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	356,039	169,935
Cost & expenses	239,265	108,661
Deprec., depl. & amort.	107,899	42,195
Operating income	8,875	19,079
Other income (expense), net	606	(565)
Gains or losses	7,789	5,278
Net before taxes	(15,446)	(5,879)
Income taxes	(4,248)	(2,174)
Net income	(11,198)	(3,705)
Balance for common	(11,298)	(3,685)
Earnings common share		
Primary	\$(0.16)	\$(0.07)
Fully Diluted	\$(0.16)	\$(0.07)
Common Shares:		
Full Diluted	70,598	50,410
Year-end	71,253	50,734

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	11,140	
Current assets	228,853	
Net property & equip.	2,019,399	
Total assets	3,708,864	
Liabilities:		
Current liabilities	273,591	
Long-term debt	2,317,398	
Stockholders' equity	544,103	
Net current assets	(44,738)	

CONTROL4 CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	59,149	50,208
Cost & expenses	58,178	52,067
Operating income	971	(1,859)
Interest income	236	38
Other income (expense), net	(357)	(144)
Net before taxes	850	(1,965)
Income taxes	(116)	(2,786)
Net income	966	821
Earnings common share		
Primary	\$0.04	\$0.03
Fully Diluted	\$0.04	\$0.03
Common Shares:		
Full Diluted	27,526	25,657
Year-end	26,008	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	19,989	
Inventories	39,314	
Current assets	141,297	
Net property & equip.	7,104	
Total assets	203,147	
Liabilities:		
Current liabilities	34,838	
Stockholders' equity	164,326	
Net current assets	106,459	

COPART INC

Earnings, 9 mos. to Apr 30 (Consol. - \$):	2018	2017
Total Revenues	1,356,472,000	1,069,385,000
Cost & expenses	906,964,000	718,893,000
Operating income	449,508,000	350,492,000
Interest income	676,000	1,084,000
Interest expense	15,769,000	17,972,000
Other income (expense), net	(4,633,000)	117,000
Net before taxes	429,782,000	333,721,000
Income taxes	121,516,000	9,829,000
Net income	308,266,000	323,892,000
Earnings common share		
Primary	\$1.33	\$1.42
Fully Diluted	\$1.28	\$1.37
Common Shares:		
Full Diluted	241,030,000	236,808,000
Year-end	232,255,380	230,331,255

CORE MARK HOLDING CO INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Net Sales	3,805,900	3,504,200
Cost & expenses	3,801,800	3,500,200
Operating income	1,600	2,200
Interest income	100	100
Foreign currency	400	600
Net before taxes	(1,800)	900
Income taxes	(500)	(1,200)
Net income	(1,300)	2,100
Earnings common share		
Primary	\$(0.03)	\$0.05
Fully Diluted	\$(0.03)	\$0.05
Common Shares:		
Full Diluted	46,200	46,400
Year-end	46,152	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	51,500	
Inventories	620,300	
Current assets	1,270,200	
Net property & equip.	243,400	
Total assets	1,669,500	
Liabilities:		
Current liabilities	609,200	
Long-term debt	444,000	
Stockholders' equity	545,100	
Net current assets	661,000	

CORIUM INTERNATIONAL INC

Earnings, 6 mos. to Mar 31 (Consol. - \$000):	2018	2017
Total Revenues	19,375	14,313
Cost & expenses	43,807	31,403
Operating income	(24,790)	(17,445)
Interest income	285	72
Interest expense	4,533	4,091
Other income (expense), net	(2,258)	
Net before taxes	(31,296)	(21,464)
Income taxes	2	2
Net income	(31,298)	(21,466)
Earnings common share		
Primary	\$(0.87)	\$(0.88)
Fully Diluted	\$(0.87)	\$(0.88)
Common Shares:		
Full Diluted	36,110	24,448
Year-end	36,139	29,232

CORNERSTONE ONDEMAND, INC.

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Total Revenues	133,113	111,582
Cost & expenses	141,959	124,730
Operating income	(8,846)	(13,148)
Interest income	1,819	613
Interest expense	8,700	3,302
Other income (expense), net	44	197
Net before taxes	(15,683)	(15,640)
Income taxes	533	571
Net income	(16,216)	(16,211)
Earnings common share		
Primary	\$(0.28)	\$(0.29)
Fully Diluted	\$(0.28)	\$(0.29)
Common Shares:		

Full Diluted	57,425	56,642
Year-end	57,525	56,730

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	413,345	
Current assets	785,190	
Net property & equip.	24,582	
Total assets	934,733	
Liabilities:		
Current liabilities	602,293	
Long-term debt	286,256	
Stockholders' equity	32,361	
Net current assets	182,897	

CORVUS PHARMACEUTICALS INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Cost & expenses	14,644	16,217
Operating income	(14,644)	(16,217)
Interest income	343	181
Net income	(14,301)	(16,036)
Earnings common share		
Primary	\$(0.63)	\$(0.79)
Fully Diluted	\$(0.63)	\$(0.79)
Common Shares:		
Full Diluted	22,581	20,349
Year-end	29,183	20,935

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	102,565	
Current assets	145,166	
Net property & equip.	2,459	
Total assets	148,689	
Liabilities:		
Current liabilities	10,604	
Stockholders' equity	137,228	
Net current assets	134,562	

CRA INTERNATIONAL INC

Earnings, 3 mos. to (Consol. - \$000):	03/31/18	04/01/17
Total Revenues	99,476	88,171
Cost & expenses	91,041	81,297
Deprec., depl. & amort.	2,231	1,963
Operating income	6,204	4,911
Other income (expense), net	(241)	(191)
Net before taxes	5,926	4,608
Net income	4,886	2,830
Earnings common share		
Primary	\$0.59	\$0.34
Fully Diluted	\$0.57	\$0.33
Common Shares:		
Full Diluted	8,580	8,621
Year-end	8,221	8,517

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	10,852	
Current assets	148,449	
Net property & equip.	46,917	
Total assets	343,054	
Liabilities:		
Current liabilities	104,272	
Stockholders' equity	203,954	
Net current assets	44,177	

CROCS INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Total Revenues	283,148	267,907
Cost & expenses	257,226	252,325
Operating income	25,922	15,582
Interest income	279	150
Interest expense	113	184
Other income (expense), net	53	124
Foreign currency	1,071	276
Net before taxes	27,212	15,948
Income taxes	10,758	4,938
Net income	16,454	11,010
Balance for common	10,429	6,028
Earnings common share		
Primary	\$0.15	\$0.08
Fully Diluted	\$0.15	\$0.08
Common Shares:		

Full Diluted	71,668	74,561
Year-end	68,300	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	101,953	
Inventories	148,187	
Current assets	463,769	
Net property & equip.	30,746	
Total assets	572,883	
Liabilities:		
Current liabilities	188,622	
Stockholders' equity	183,484	
Net current assets	275,147	

CROSS COUNTRY HEALTHCARE INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Cost & expenses	203,131	202,127
Operating income	4,248	3,255
Interest expense	1,266	1,219
Other income (expense), net	101	(4,969)
Gains or losses	1,581	
Net before taxes	3,083	(1,352)
Income taxes	1,163	366
Net income	1,920	(1,718)
Balance for common	1,642	(2,010)
Earnings common share		
Primary	\$0.05	\$(0.06)
Fully Diluted	\$0.05	\$(0.08)
Common Shares:		
Full Diluted	36,087	36,480
Year-end	36,400	36,434

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	32,621	
Current assets	203,469	
Net property & equip.	13,967	
Total assets	459,794	
Liabilities:		
Current liabilities	87,636	
Long-term debt	92,314	
Stockholders' equity	235,500	
Net current assets	115,833	

CSG SYSTEMS INTERNATIONAL INC.

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Total Revenues	201,704	192,470
Cost & expenses	172,023	162,142
Operating income	25,767	27,013
Interest expense	4,266	4,306
Other income (expense), net	(2,108)	(1,163)
Net before taxes	20,204	22,350
Income taxes	6,190	2,113
Net income	14,014	20,237
Earnings common share		
Primary	\$0.43	\$0.63
Fully Diluted	\$0.42	\$0.62
Common Shares:		
Full Diluted	33,102	32,594
Year-end	33,674	33,825

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	222,098	
Current assets	515,224	
Net property & equip.	59,553	
Total assets	928,438	
Liabilities:		
Current liabilities	184,701	
Long-term debt	354,759	
Stockholders' equity	358,075	
Net current assets	330,523	

CURIS INC

Earnings, 3 mos. to Mar 31 (Consol. - \$000):	2018	2017
Total Revenues	2,468	2,131
Cost & expenses	12,215	17,084
Operating income	(9,908)	(15,053)
Other income (expense), net		(103)
Net income	(10,747)	(15,742)
Earnings common share		
Primary	\$(0.35)	\$(0.55)

Fully Diluted	\$(0.35)	\$(0.55)
Common Shares:		
Full Diluted	33,054	28,402
Year-end	33,126	28,735
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2018
Cash & equivalents		24,736
Current assets		51,853
Net property & equip.		390
Total assets		61,381
Liabilities:		
Current liabilities		14,391
Long-term debt		32,460
Stockholders' equity		14,467
Net current assets		37,462

CYBEROPTICS CORP.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	14,120	11,920
Cost & expenses	14,421	12,442
Operating income	(318)	(539)
Net before taxes	(256)	(627)
Income taxes	(83)	(413)
Net income	(173)	(214)
Earnings common share		
Primary	\$(0.02)	\$(0.03)
Fully Diluted	\$(0.02)	\$(0.03)
Common Shares:		
Full Diluted	6,986	6,912
Year-end	7,006	6,943

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		6,848
Inventories		14,673
Current assets		41,645
Net property & equip.		2,292
Total assets		61,788
Liabilities:		
Current liabilities		8,896
Stockholders' equity		52,521
Net current assets		32,749

DATATRAK INTERNATIONAL INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	1,754,313	1,952,531
Cost & expenses	1,717,115	2,065,298
Deprec., depl. & amort.	149,024	160,885
Operating income	(111,826)	(273,652)
Interest income	896	230
Interest expense	395	41,984
Gains or losses	1,600	
Net income	(109,725)	(315,406)
Earnings common share		
Primary	\$(0.05)	\$(0.18)
Fully Diluted	\$(0.05)	\$(0.18)
Common Shares:		
Full Diluted	2,281,489	1,784,319
Year-end	2,290,116	1,804,675

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		2,517,320
Current assets		3,371,214
Net property & equip.		1,496,133
Total assets		5,396,722
Liabilities:		
Current liabilities		4,262,838
Long-term debt		5,000
Stockholders' equity		96,187
Net current assets		(891,624)

DAWSON GEOPHYSICAL CO (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	49,880,000	42,366,000
Cost & expenses	42,842,000	44,329,000
Operating income	(1,640,000)	(12,139,000)
Other income (expense), net	(49,000)	106,000
Net before taxes	(1,740,000)	(11,975,000)
Income taxes	(31,000)	(2,823,000)
Net income	(1,709,000)	(9,152,000)
Earnings common share		

Primary	\$(0.07)	\$(0.40)
Fully Diluted	\$(0.07)	\$(0.40)
Common Shares:		
Full Diluted	22,879,805	22,742,516
Year-end	22,893,941	22,762,182
Consolidated Balance Sheet Items, as of (\$):		
Assets:		2018
Cash & equivalents		17,608,000
Current assets		85,852,000
Net property & equip.		82,056,000
Total assets		170,079,000
Liabilities:		
Current liabilities		25,175,000
Long-term debt		4,446,000
Stockholders' equity		139,492,000
Net current assets		60,677,000

DEL FRISCO'S RESTAURANT GROUP INC**Earnings, 3 mos. to (Consol. - \$000):**

	03/27/18	03/21/17
Total Revenues	89,303	83,890
Cost & expenses	83,360	74,666
Operating income	761	4,408
Other income (expense), net	1	(2)
Net before taxes	459	4,396
Income taxes	59	1,086
Net income	400	3,310
Earnings common share		
Primary	\$0.02	\$0.14
Fully Diluted	\$0.02	\$0.14
Common Shares:		
Full Diluted	20,603	23,277
Year-end	20,343	21,826

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		2,979
Inventories		18,115
Current assets		36,634
Net property & equip.		182,695
Total assets		333,354
Liabilities:		
Current liabilities		45,863
Long-term debt		30,545
Stockholders' equity		190,764
Net current assets		(9,229)

DEPOMED INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	128,404,000	90,447,000
Cost & expenses	51,622,000	71,377,000
Operating income	51,338,000	(6,665,000)
Net before taxes	33,499,000	(26,539,000)
Income taxes	(325,000)	202,000
Net income	33,824,000	(26,741,000)
Earnings common share		
Primary	\$0.53	\$(0.43)
Fully Diluted	\$0.48	\$(0.43)
Common Shares:		
Full Diluted	81,877,097	62,128,862
Year-end	63,587,401	62,341,162

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		101,693,000
Inventories		5,368,000
Current assets		193,304,000
Net property & equip.		11,658,000
Total assets		1,002,071,000
Liabilities:		
Current liabilities		257,128,000
Long-term debt		524,647,000
Stockholders' equity		206,090,000
Net current assets		(63,824,000)

DIAMONDBACK ENERGY, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	480,195,000	235,230,000
Cost & expenses	97,333,000	59,891,000
Operating income	267,646,000	116,410,000
Other income (expense), net	2,736,000	1,145,000
Gains or losses	(31,446,000)	37,701,000
Net before taxes	225,235,000	143,031,000

Income taxes	47,081,000	1,957,000
Net income	178,154,000	141,074,000
Earnings common share		
Primary	\$1.65	\$1.46
Fully Diluted	\$1.65	\$1.46
Common Shares:		
Full Diluted	98,769,000	93,364,000
Year-end	98,610,608	98,127,709

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		72,487,000
Inventories		8,963,000
Current assets		324,467,000
Net property & equip.		7,751,172,000
Total assets		8,224,888,000
Liabilities:		
Current liabilities		607,668,000
Long-term debt		1,701,912,000
Stockholders' equity		5,417,083,000
Net current assets		(283,201,000)

DIGIRAD CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	25,465,000	25,840,000
Cost & expenses	26,717,000	26,917,000
Operating income	(1,609,000)	(1,451,000)
Other income (expense), net	(17,000)	
Net before taxes	(1,843,000)	(1,644,000)
Income taxes	(455,000)	607,000
Income contin. oper.	(1,388,000)	(2,251,000)
Net income	4,106,000	(2,076,000)
Earnings common share		
Primary	\$0.20	\$(0.10)
Fully Diluted	\$0.20	\$(0.10)

Common Shares:

Full Diluted	20,092,000	19,933,000
Year-end	20,118,336	

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		1,033,000
Inventories		5,755,000
Current assets		22,186,000
Net property & equip.		27,176,000
Total assets		59,962,000
Liabilities:		
Current liabilities		13,690,000
Long-term debt		13,001,000
Stockholders' equity		30,931,000
Net current assets		8,496,000

DIXIE GROUP INC.**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Net Sales	98,858	97,541
Cost & expenses	100,297	96,842
Operating income	(1,515)	623
Other income (expense), net	(2)	1
Net before taxes	(3,050)	(738)
Income taxes	(166)	(163)
Income contin. oper.	(2,884)	(575)
Net income	(2,907)	(604)
Earnings common share		
Primary	\$(0.18)	\$(0.04)
Fully Diluted	\$(0.18)	\$(0.04)
Common Shares:		
Full Diluted	15,715	15,673
Year-end	16,419	16,126

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		21
Inventories		116,988
Current assets		170,672
Net property & equip.		91,522
Total assets		287,351
Liabilities:		
Current liabilities		63,421
Long-term debt		125,592
Stockholders' equity		77,552
Net current assets		107,251

DOVA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	13,677	5,231
Operating income	(13,677)	(5,231)
Net income	(13,770)	(5,424)
Earnings common share		
Primary	\$(0.52)	\$(0.31)
Fully Diluted	\$(0.52)	\$(0.31)
Common Shares:		
Full Diluted	26,589	17,332
Year-end	28,191	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		126,897
Current assets		128,562
Net property & equip.		188
Total assets		128,750
Liabilities:		
Current liabilities		3,648
Stockholders' equity		125,102
Net current assets		124,914

DUNKIN' BRANDS GROUP INC**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	301,342	296,358
Cost & expenses	201,103	199,174
Operating income	89,831	86,773
Gains or losses	(327)	187
Net before taxes	58,669	62,410
Income taxes	18,117	8,517
Net income	50,152	44,293
Earnings common share		
Primary	\$0.58	\$0.48
Fully Diluted	\$0.57	\$0.48
Common Shares:		
Full Diluted	87,877	93,120
Year-end	82,721	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		338,461
Current assets		615,842
Net property & equip.		180,959
Total assets		3,244,108
Liabilities:		
Current liabilities		409,290
Long-term debt		3,036,248
Stockholders' equity		(860,281)
Net current assets		206,552

DXP ENTERPRISES, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	285,936	238,527
Cost & expenses	274,787	230,291
Operating income	11,149	8,236
Other income (expense), net	22	228
Net before taxes	6,130	4,811
Income taxes	1,636	1,817
Net income	4,494	2,994
Balance for common	4,528	3,110
Earnings common share		
Primary	\$0.25	\$0.18
Fully Diluted	\$0.24	\$0.17
Common Shares:		
Full Diluted	18,741	18,249
Year-end	17,354	17,418

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		13,045
Inventories		103,194
Current assets		326,798
Net property & equip.		52,257
Total assets		654,873
Liabilities:		
Current liabilities		134,023
Long-term debt		238,217
Stockholders' equity		273,694
Net current assets		192,775

EASTERN CO.**Earnings, 3 mos. to (Consol. - \$):**

	03/31/18	04/01/17
Net Sales	59,444,997	36,043,295
Cost & expenses	55,273,110	33,867,624
Operating income	4,171,887	2,175,671
Interest expense	296,330	21,024
Other income (expense), net	218,731	80,183
Net before taxes	4,094,288	2,234,830
Income taxes	994,093	717,689
Net income	3,100,195	1,517,141
Earnings common share		
Primary	\$0.49	\$0.24
Fully Diluted	\$0.49	\$0.24
Common Shares:		
Full Diluted	6,291,726	6,256,496
Year-end	6,265,000	6,258,233

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		16,361,816
Inventories		48,976,948
Current assets		99,258,736
Net property & equip.		28,868,362
Total assets		175,765,778
Liabilities:		
Current liabilities		27,612,415
Long-term debt		28,287,500
Stockholders' equity		90,424,960
Net current assets		71,646,321

EBIX INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	108,230	79,103
Cost & expenses	71,527	50,558
Operating income	33,896	25,690
Interest income	121	774
Interest expense	4,847	2,468
Other income (expense), net	53	
Foreign currency	(641)	3,496
Net before taxes	28,582	27,492
Income taxes	2,126	869
Net income	26,456	26,623
Earnings common share		
Primary	\$0.83	\$0.83
Fully Diluted	\$0.83	\$0.83
Common Shares:		
Full Diluted	31,659	31,973
Year-end	31,459	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		111,898
Current assets		290,867
Net property & equip.		40,647
Total assets		1,162,444
Liabilities:		
Current liabilities		158,675
Long-term debt		409,472
Stockholders' equity		498,032
Net current assets		132,192

ECHOSTAR CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	501,792	433,151
Cost & expenses	298,228	266,417
Operating income	58,010	51,651
Other income (expense), net	(805)	4,182
Invest. income	(36,663)	12,035
Net before taxes	(26,574)	30,763
Income taxes	(5,403)	(12)
Income contin. oper.		30,775
Income discount. oper.		6,577
Net income	(21,171)	37,352
Balance for common	(21,551)	38,924
Earnings common share		
Primary	\$(0.22)	\$0.41
Fully Diluted	\$(0.22)	\$0.41
Common Shares:		
Full Diluted	95,888	95,893
Year-end	96,087	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		2,239,591
Inventories		85,995

Current assets	3,682,276
Net property & equip.	3,461,004
Total assets	8,761,744
Liabilities:	
Current liabilities	409,777
Long-term debt	3,585,972
Stockholders' equity	4,190,527
Net current assets	3,272,499

EDITAS MEDICINE INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	35,486	31,309
Operating income	(31,559)	(30,627)
Other income (expense), net	182	140
Net income	(30,939)	(31,097)
Balance for common	(30,939)	(31,097)
Earnings common share		
Primary	\$(0.67)	\$(0.85)
Fully Diluted	\$(0.67)	\$(0.85)
Common Shares:		
Full Diluted	45,992	36,485
Year-end	46,712	40,712

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		358,821
Current assets		362,812
Net property & equip.		39,551
Total assets		403,982
Liabilities:		
Current liabilities		30,994
Long-term debt		33,190
Stockholders' equity		247,515
Net current assets		331,818

EHEALTH INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	43,070	41,556
Cost & expenses	49,339	45,409
Operating income	(6,720)	(4,113)
Other income (expense), net	184	277
Net before taxes	(6,536)	(3,836)
Income taxes	(1,691)	(4,916)
Net income	(4,845)	1,080
Balance for common	(4,845)	1,080
Earnings common share		
Primary	\$(0.26)	\$0.06
Fully Diluted	\$(0.26)	\$0.06
Common Shares:		
Full Diluted	18,873	18,561
Year-end	18,993	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		34,742
Current assets		140,186
Net property & equip.		4,616
Total assets		380,538
Liabilities:		
Current liabilities		31,727
Stockholders' equity		290,103
Net current assets		108,459

ELDORADO RESORTS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	440,192	202,393
Cost & expenses	354,464	172,761
Operating income	54,194	14,028
Interest expense	31,251	12,670
Net before taxes	22,943	1,358
Income taxes	2,088	413
Net income	20,855	945
Earnings common share		
Primary	\$0.27	\$0.02
Fully Diluted	\$0.27	\$0.02
Common Shares:		
Full Diluted	78,080	48,081
Year-end	77,241	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		183,138
Inventories		15,210

Current assets	475,309
Net property & equip.	1,396,286
Total assets	3,552,220
Liabilities:	
Current liabilities	217,290
Long-term debt	2,190,110
Stockholders' equity	958,631
Net current assets	258,019

ELECTRONICS FOR IMAGING, INC.

Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Total Revenues	239,866	228,691
Cost & expenses	229,793	209,770
Operating income	(2,065)	8,143
Interest expense	4,954	4,660
Net before taxes	(5,730)	3,770
Income taxes	(2,135)	(1,017)
Net income	(3,595)	4,787
Earnings common share		
Primary	\$(0.08)	\$0.10
Fully Diluted	\$(0.08)	\$0.10
Common Shares:		
Full Diluted	45,030	47,208
Year-end	44,805	49,596

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	163,077	123,824
Inventories	742,959	99,333
Current assets	1,464,890	291,838
Liabilities:		
Current liabilities	291,838	336,621
Long-term debt	781,642	451,121
Stockholders' equity		
Net current assets		

EMPIRE RESORTS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Total Revenues	33,522	14,769
Cost & expenses	46,705	20,789
Operating income	(18,891)	(6,356)
Interest income	376	454
Net income	(20,911)	(11,451)
Balance for common	(20,943)	(11,483)
Earnings common share		
Primary	\$(0.64)	\$(0.37)
Fully Diluted	\$(0.64)	\$(0.37)
Common Shares:		
Full Diluted	32,538	31,003
Year-end	32,735	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	29,632	1,437
Inventories	39,458	652,280
Current assets	818,552	93,299
Liabilities:		
Current liabilities	463,047	254,301
Long-term debt	53,841	
Stockholders' equity		
Net current assets		

ENANTA PHARMACEUTICALS INC

Earnings, 6 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Total Revenues	82,158	19,376
Cost & expenses	50,922	35,928
Operating income	31,236	(16,552)
Other income (expense), net	30	(28)
Net before taxes	33,262	(15,479)
Income taxes	9,014	(5,107)
Net income	24,248	(10,372)
Earnings common share		
Primary	\$1.27	\$(0.54)
Fully Diluted	\$1.20	\$(0.54)
Common Shares:		
Full Diluted	20,256	19,042
Year-end	19,120	19,054

ENDOCYTE INC

Earnings, 3 mos. to Mar 31(Consol. - \$):		
	2018	2017
Total Revenues	15,855	12,500
Cost & expenses	9,032,611	11,739,734
Operating income	(9,016,756)	(11,727,234)
Other income (expense), net	1,213	3,198
Net income	(8,602,646)	(11,488,585)
Earnings common share		
Primary	\$(0.16)	\$(0.27)
Fully Diluted	\$(0.16)	\$(0.27)
Common Shares:		
Full Diluted	55,000,743	42,434,709
Year-end	69,427,773	42,470,874

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	89,831,744	174,556,437
Current assets	1,942,852	176,678,230
Liabilities:		
Current liabilities	4,613,077	171,701,887
Stockholders' equity	169,943,360	
Net current assets		

ENDURANCE INTERNATIONAL GROUP HOLDINGS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Total Revenues	291,356	295,137
Cost & expenses	259,954	281,543
Operating income	31,402	13,594
Interest expense	36,050	39,516
Equity earnings	27	
Net before taxes	(4,444)	(25,804)
Income taxes	2,617	5,774
Net income	(7,088)	(31,578)
Earnings common share		
Primary	\$(0.05)	\$(0.26)
Fully Diluted	\$(0.05)	\$(0.26)
Common Shares:		
Full Diluted	140,362	134,935
Year-end	140,191	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	86,678	235,032
Current assets	87,653	2,677,808
Liabilities:		
Current liabilities	554,311	1,841,146
Long-term debt	144,189	(319,279)
Stockholders' equity		
Net current assets		

ENERGY RECOVERY INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Cost & expenses	12,231	11,734
Operating income	(1,331)	353
Other income (expense), net	(53)	(53)
Net before taxes	(1,083)	470
Income taxes	(357)	48
Net income	(726)	422
Earnings common share		
Primary	\$(0.01)	\$0.01
Fully Diluted	\$(0.01)	\$0.01
Common Shares:		
Full Diluted	53,987	56,056
Year-end	54,027	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	32,153	7,328
Inventories	118,041	15,253
Current assets	155,857	25,603
Liabilities:		
Current liabilities	13	91,474
Long-term debt	92,438	
Stockholders' equity		
Net current assets		

ENPHASE ENERGY INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

Total Revenues	69,972	54,751
Cost & expenses	72,447	76,846
Operating income	(2,475)	(22,095)
Interest expense	2,292	2,139
Other income (expense), net	(126)	1,060
Net before taxes	(4,893)	(23,174)
Income taxes	235	131
Net income	(5,128)	(23,305)
Earnings common share		
Primary	\$(0.06)	\$(0.30)
Fully Diluted	\$(0.06)	\$(0.30)
Common Shares:		
Full Diluted	91,422	76,651
Year-end	96,765	84,276

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	53,255	18,541
Inventories	147,853	24,926
Current assets	212,118	103,685
Liabilities:		
Current liabilities	36,459	(31,151)
Long-term debt	44,168	
Stockholders' equity		
Net current assets		

EPIZYME INC.

Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Cost & expenses	34,982	32,964
Operating income	(34,982)	(32,964)
Interest income	899	438
Other income (expense), net	18	4
Net income	(34,065)	(32,522)
Earnings common share		
Primary	\$(0.49)	\$(0.56)
Fully Diluted	\$(0.49)	\$(0.56)
Common Shares:		
Full Diluted	69,386	58,219
Year-end	69,486	58,350

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	130,289	256,862
Current assets	2,275	260,201
Liabilities:		
Current liabilities	24,633	231,132
Stockholders' equity	232,229	
Net current assets		

EURONET WORLDWIDE INC.

Earnings, 3 mos. to Mar 31(Consol. - \$000):		
	2018	2017
Total Revenues	550,515	473,380
Cost & expenses	479,041	410,457
Deprec., depl. & amort.	26,002	21,637
Operating income	45,472	41,286
Interest income	296	1,170
Interest expense	7,606	7,148
Other income (expense), net	(117)	
Gains or losses	31	17
Foreign currency	1,935	1,715
Net before taxes	40,011	37,040
Income taxes	13,667	8,971
Net income	26,344	28,069
Earnings common share		
Primary	\$0.51	\$0.54
Fully Diluted	\$0.49	\$0.51
Common Shares:		
Full Diluted	53,953	54,922
Year-end	59,021	52,428

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	885,646	1,869,942
Current assets	280,606	3,157,375
Liabilities:		
Current liabilities	1,318,322	583,086
Long-term debt		

Stockholders' equity	1,128,087
Net current assets	551,620

EVOLUS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	6,045	3,866
Operating income	(6,045)	(3,977)
Interest expense	107	1
Net before taxes	(6,152)	(3,978)
Income taxes	10	20
Net income	(6,162)	(3,998)
Earnings common share		
Primary	\$(0.30)	\$(0.24)
Fully Diluted	\$(0.30)	\$(0.24)
Common Shares:		
Full Diluted	20,226	16,527
Year-end	23,640	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	49,570	
Current assets	50,111	
Total assets	127,395	
Liabilities:		
Current liabilities	3,629	
Long-term debt	16,149	
Stockholders' equity	51,982	
Net current assets	46,482	

EXPONENT INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	96,457	84,122
Cost & expenses	74,859	69,488
Operating income	21,598	14,634
Other income (expense), net	322	2,542
Net before taxes	22,450	17,410
Income taxes	2,110	834
Net income	20,340	16,576
Earnings common share		
Primary	\$0.77	\$0.63
Fully Diluted	\$0.75	\$0.61
Common Shares:		
Full Diluted	27,006	26,981
Year-end	26,004	25,871

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	103,152	
Current assets	305,461	
Net property & equip.	40,420	
Total assets	440,459	
Liabilities:		
Current liabilities	69,644	
Stockholders' equity	306,625	
Net current assets	235,817	

FIESTA RESTAURANT GROUP, INC**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	04/02/17
Total Revenues	169,484	175,607
Net Sales	168,833	174,977
Cost & expenses	153,607	189,539
Operating income	6,878	(23,118)
Interest expense	1,069	584
Net before taxes	5,809	(23,702)
Income taxes	1,625	(8,642)
Net income	4,184	(15,060)
Balance for common	4,144	(15,060)
Earnings common share		
Primary	\$0.15	\$(0.56)
Fully Diluted	\$0.15	\$(0.56)
Common Shares:		
Full Diluted	26,880	26,774
Year-end	26,906	26,787

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	3,791	
Inventories	2,688	
Current assets	37,114	
Net property & equip.	235,038	
Total assets	419,084	
Liabilities:		
Current liabilities	48,391	

Long-term debt	81,718
Stockholders' equity	236,297
Net current assets	(11,277)

FINANCIAL ENGINES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	127,826	114,243
Cost & expenses	96,710	92,995
Operating income	26,682	17,085
Other income (expense), net	(59)	(128)
Net before taxes	27,459	17,024
Income taxes	17,544	12,639
Net income	10,000	4,385
Earnings common share		
Primary	\$0.28	\$0.20
Fully Diluted	\$0.27	\$0.20
Common Shares:		
Full Diluted	64,506	64,503
Year-end	63,492	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	172,248	
Current assets	371,135	
Net property & equip.	25,663	
Total assets	930,730	
Liabilities:		
Current liabilities	51,937	
Stockholders' equity	868,081	
Net current assets	319,198	

FIVE PRIME THERAPEUTICS, INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	54,030	44,246
Operating income	(21,544)	(34,111)
Other income (expense), net	(5)	
Net income	(20,390)	(33,443)
Earnings common share		
Primary	\$(0.63)	\$(1.21)
Fully Diluted	\$(0.63)	\$(1.21)
Common Shares:		
Full Diluted	32,314	27,657
Year-end	34,335	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	65,941	
Current assets	403,043	
Net property & equip.	30,290	
Total assets	436,714	
Liabilities:		
Current liabilities	41,166	
Stockholders' equity	362,216	
Net current assets	361,877	

FLUIDIGM CORP (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	25,248	25,533
Cost & expenses	37,881	43,069
Operating income	(12,633)	(17,536)
Interest expense	1,889	1,455
Other income (expense), net	92	9
Net before taxes	(14,430)	(18,982)
Income taxes	(1,183)	(1,780)
Net income	(13,247)	(17,202)
Earnings common share		
Primary	\$(0.34)	\$(0.59)
Fully Diluted	\$(0.34)	\$(0.59)
Common Shares:		
Full Diluted	38,856	29,239
Year-end	38,908	29,292

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	41,972	
Inventories	15,253	
Current assets	81,001	
Net property & equip.	11,433	
Total assets	269,702	
Liabilities:		
Current liabilities	33,704	
Long-term debt	164,156	
Stockholders' equity	48,574	
Net current assets	47,297	

FORESCOUT TECHNOLOGIES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	59,697	42,176
Cost & expenses	87,184	67,730
Operating income	(27,487)	(25,554)
Interest expense	243	345
Other income (expense), net	662	(536)
Net before taxes	(27,068)	(26,435)
Income taxes	1,128	635
Net income	(28,196)	(27,070)
Earnings common share		
Primary	\$(0.74)	\$(4.57)
Fully Diluted	\$(0.74)	\$(4.57)
Common Shares:		
Full Diluted	38,313	5,924
Year-end	39,214	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	82,356	
Inventories	136	
Current assets	299,855	
Net property & equip.	23,918	
Total assets	353,623	
Liabilities:		
Current liabilities	143,128	
Long-term debt	13,754	
Stockholders' equity	117,052	
Net current assets	156,727	

FORMFACTOR INC**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	118,290	128,829
Cost & expenses	114,656	121,770
Operating income	3,634	7,059
Interest income	257	67
Interest expense	967	1,174
Other income (expense), net	(512)	(400)
Net before taxes	2,412	5,552
Income taxes	287	367
Net income	2,125	5,185
Earnings common share		
Primary	\$0.03	\$0.07
Fully Diluted	\$0.03	\$0.07
Common Shares:		
Full Diluted	74,342	72,922
Year-end	73,014	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	93,699	
Inventories	73,780	
Current assets	311,795	
Net property & equip.	47,851	
Total assets	646,188	
Liabilities:		
Current liabilities	96,630	
Long-term debt	67,315	
Stockholders' equity	471,010	
Net current assets	215,165	

FORRESTER RESEARCH INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	77,749	77,194
Cost & expenses	77,855	72,188
Operating income	(2,288)	3,136
Other income (expense), net	(118)	9
Gains or losses	(25)	(203)
Net before taxes	(2,431)	2,942
Income taxes	(698)	(88)
Net income	(1,733)	3,030
Earnings common share		
Primary	\$(0.10)	\$0.17
Fully Diluted	\$(0.10)	\$0.16
Common Shares:		
Full Diluted	18,036	18,536
Year-end	18,017	17,883

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	82,073	
Current assets	231,848	
Net property & equip.	24,487	

Total assets	340,736
Liabilities:	
Current liabilities	191,038
Stockholders' equity	141,295
Net current assets	40,810

FORTINET INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	399,000	340,600
Cost & expenses	366,600	335,200
Operating income	32,400	5,400
Interest income	4,500	2,400
Other income (expense), net	(200)	300
Net before taxes	36,700	8,100
Income taxes	(4,900)	(2,600)
Net income	41,600	10,700
Earnings common share		
Primary	\$0.25	\$0.06
Fully Diluted	\$0.24	\$0.06
Common Shares:		
Full Diluted	171,800	178,300
Year-end	168,000	175,443

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	835,600
Inventories	80,000
Current assets	1,735,800
Net property & equip.	245,100
Total assets	2,400,700
Liabilities:	
Current liabilities	1,029,700
Stockholders' equity	693,500
Net current assets	706,100

FOSSIL GROUP INC**Earnings, 3 mos. to (Consol. – \$):**

	03/31/18	04/01/17
Net Sales	569,156,000	581,790,000
Cost & expenses	597,437,000	627,053,000
Operating income	(28,281,000)	(45,263,000)
Other income (expense), net	(1,888,000)	5,638,000
Net before taxes	(40,860,000)	(48,009,000)
Income taxes	6,645,000	(1,220,000)
Net income	(47,505,000)	(46,789,000)
Earnings common share		
Primary	\$(0.99)	\$(1.00)
Fully Diluted	\$(0.99)	\$(1.00)
Common Shares:		
Full Diluted	48,712,000	48,313,000
Year-end	48,900,000	48,460,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	229,863,000
Inventories	530,706,000
Current assets	1,156,424,000
Net property & equip.	208,477,000
Total assets	1,515,671,000
Liabilities:	
Current liabilities	523,897,000
Long-term debt	335,536,000
Stockholders' equity	521,448,000
Net current assets	632,527,000

FRANKLIN ELECTRIC CO., INC.**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Net Sales	295,630	220,252
Cost & expenses	272,930	201,747
Operating income	22,700	18,505
Interest expense	2,428	3,514
Other income (expense), net	(204)	672
Foreign currency	(551)	475
Net before taxes	19,517	16,138
Income taxes	(1,698)	204
Net income	21,215	15,934
Earnings common share		
Primary	\$0.45	\$0.33
Fully Diluted	\$0.45	\$0.33
Common Shares:		
Full Diluted	47,100	47,000
Year-end	46,522	46,443

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	67,370
Inventories	343,316
Current assets	641,851
Net property & equip.	217,368
Total assets	1,240,664
Liabilities:	
Current liabilities	288,717
Long-term debt	125,100
Stockholders' equity	720,360
Net current assets	353,134

FRESHPET INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Net Sales	43,169,601	33,677,572
Cost & expenses	46,579,527	36,418,043
Operating income	(3,409,926)	(2,740,471)
Other income (expense), net	(22,977)	57,677
Net before taxes	(3,501,905)	(2,858,771)
Income taxes	19,032	20,754
Net income	(3,520,937)	(2,879,525)
Balance for common	(3,520,937)	(2,879,525)
Earnings common share		
Primary	\$(0.10)	\$(0.09)
Fully Diluted	\$(0.10)	\$(0.09)
Common Shares:		
Full Diluted	35,137,502	33,563,133
Year-end	35,139,244	34,040,832

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	3,039,341
Inventories	9,874,896
Current assets	26,662,305
Net property & equip.	101,663,419
Total assets	135,226,296
Liabilities:	
Current liabilities	20,200,845
Stockholders' equity	114,727,716
Net current assets	6,461,460

FTD COMPANIES INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	318,170	316,493
Cost & expenses	321,085	294,833
Operating income	(4,417)	17,840
Interest income	121	115
Interest expense	2,607	2,388
Other income (expense), net	(24)	(25)
Net before taxes	(6,927)	15,542
Income taxes	(331)	6,519
Net income	(6,596)	9,023
Balance for common	(6,596)	8,817
Earnings common share		
Primary	\$(0.24)	\$0.32
Fully Diluted	\$(0.24)	\$0.32
Common Shares:		
Full Diluted	27,713	27,435
Year-end	27,759	27,434

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	25,576
Inventories	27,912
Current assets	98,615
Net property & equip.	38,578
Total assets	619,733
Liabilities:	
Current liabilities	366,174
Stockholders' equity	214,322
Net current assets	(267,559)

GAIA INC (NEW)**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	9,615,000	5,784,000
Cost & expenses	17,493,000	12,637,000
Operating income	(7,878,000)	(6,853,000)
Net before taxes	(7,861,000)	(6,809,000)
Income taxes	(1,826,000)	(629,000)
Net income	(6,035,000)	(6,180,000)
Earnings common share		
Primary	\$(0.39)	\$(0.41)
Fully Diluted	\$(0.39)	\$(0.41)

Common Shares:

Full Diluted	15,364,000	15,153,000
Year-end	17,883,546	15,153,235

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	50,671,000
Current assets	55,361,000
Net property & equip.	39,949,000
Total assets	118,637,000
Liabilities:	
Current liabilities	10,735,000
Stockholders' equity	107,738,000
Net current assets	44,626,000

GENTEX CORP.**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Net Sales	465,420,105	453,535,250
Cost & expenses	336,904,772	319,108,130
Operating income	128,515,333	134,427,120
Other income (expense), net	1,206,993	(1,034,743)
Gains or losses	2,037,605	1,472,527
Net before taxes	131,759,931	134,864,904
Income taxes	20,511,188	37,308,163
Net income	111,248,743	97,556,741
Earnings common share		
Primary	\$0.40	\$0.34
Fully Diluted	\$0.40	\$0.33
Common Shares:		
Full Diluted	277,509,428	291,479,838
Year-end	273,854,076	287,270,285

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	524,323,560
Inventories	207,232,952
Current assets	1,141,694,188
Net property & equip.	496,274,467
Total assets	2,254,352,468
Liabilities:	
Current liabilities	228,169,606
Stockholders' equity	1,969,977,496
Net current assets	913,524,582

GEOSPACE TECHNOLOGIES CORP**Earnings, 6 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	33,891	35,843
Cost & expenses	48,718	58,214
Operating income	(14,827)	(22,371)
Interest income	542	268
Interest expense	191	16
Other income (expense), net	(54)	(33)
Foreign currency	(349)	(281)
Net before taxes	(14,879)	(22,433)
Income taxes	(670)	775
Net income	(14,209)	(23,208)
Earnings common share		
Primary	\$(1.07)	\$(1.77)
Fully Diluted	\$(1.07)	\$(1.77)
Common Shares:		
Full Diluted	13,233	13,120
Year-end	13,579	13,441

GIGGLES N' HUGS INC**Earnings, 3 mos. to (Consol. – \$):**

	04/01/18	04/02/17
Net Sales	613,363	661,703
Cost & expenses	777,903	1,439,525
Operating income	(226,175)	(841,891)
Other income (expense), net	(1,000)	134,975
Net income	(241,565)	(756,186)
Earnings common share		
Primary	\$(0.01)	\$(0.01)
Fully Diluted	\$(0.01)	\$(0.01)
Common Shares:		
Full Diluted	146,988,918	96,515,942
Year-end	147,332,251	134,222,251

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	134,609
Inventories	27,078
Current assets	174,461
Net property & equip.	678,554

Total assets	855,635
Liabilities:	
Current liabilities	2,056,492
Stockholders' equity	(2,107,462)
Net current assets	(1,882,031)

GLADSTONE LAND CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	9,245,000	5,750,000
Cost & expenses	4,270,000	1,674,000
Operating income	2,786,000	2,604,000
Interest expense	2,832,000	2,157,000
Other income (expense), net	(272,000)	(274,000)
Net income	(318,000)	173,000

Earnings common share

Primary	\$(0.02)	\$0.01
Fully Diluted	\$(0.02)	\$0.01

Common Shares:

Full Diluted	13,957,732	10,395,736
Year-end	15,216,199	11,850,624

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	2,679,000
Current assets	2,679,000
Total assets	472,916,000
Liabilities:	
Current liabilities	9,525,000
Long-term debt	292,950,000
Stockholders' equity	124,055,000
Net current assets	(6,846,000)

GLOBAL BLOOD THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	42,695	23,721
Operating income	(42,695)	(23,721)
Interest income	1,173	441
Net income	(41,556)	(23,332)

Earnings common share

Primary	\$(0.87)	\$(0.60)
Fully Diluted	\$(0.87)	\$(0.60)

Common Shares:

Full Diluted	47,770	39,126
Year-end	51,637	43,009

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	455,637
Current assets	553,850
Net property & equip.	17,414
Total assets	573,376
Liabilities:	
Current liabilities	23,960
Stockholders' equity	537,764
Net current assets	529,890

GOGO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	231,825	165,406
Cost & expenses	198,077	149,669
Operating income	(2,171)	(14,698)
Other income (expense), net	505	(38)
Net before taxes	(31,144)	(41,134)
Income taxes	(3,725)	233
Net income	(27,419)	(41,367)

Earnings common share

Primary	\$(0.34)	\$(0.52)
Fully Diluted	\$(0.34)	\$(0.52)

Common Shares:

Full Diluted	79,696	79,139
Year-end	87,007	86,412

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	299,672
Inventories	168,782
Current assets	628,830
Net property & equip.	530,687
Total assets	1,300,142
Liabilities:	
Current liabilities	272,837
Long-term debt	1,006,442
Stockholders' equity	(191,336)
Net current assets	355,993

GOPRO INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	202,346	218,614
Cost & expenses	277,085	306,829
Operating income	(74,739)	(88,215)
Interest expense	4,567	814
Other income (expense), net	177	161
Net before taxes	(79,129)	(88,868)
Income taxes	(2,782)	22,282
Net income	(76,347)	(111,150)

Earnings common share

Primary	\$(0.55)	\$(0.78)
Fully Diluted	\$(0.55)	\$(0.78)

Common Shares:

Full Diluted	137,857	142,899
Year-end	138,673	142,239

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	144,833
Inventories	132,619
Current assets	391,586
Net property & equip.	62,791
Total assets	648,874
Liabilities:	
Current liabilities	249,714
Long-term debt	132,189
Stockholders' equity	216,077
Net current assets	141,872

GREEN PLAINS INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	1,045,287,000	887,684,000
Cost & expenses	1,022,738,000	844,209,000
Deprec., depl. & amort.	26,474,000	26,083,000
Operating income	(3,925,000)	17,392,000
Other income (expense), net	(66,000)	10,000
Net before taxes	(25,482,000)	(730,000)
Income taxes	(6,027,000)	(2,381,000)
Net income	(19,455,000)	1,651,000

Earnings common share

Primary	\$(0.60)	\$(0.09)
Fully Diluted	\$(0.60)	\$(0.09)

Common Shares:

Full Diluted	40,164,000	38,420,000
Year-end	41,375,970	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	240,964,000
Inventories	659,026,000
Current assets	1,146,070,000
Net property & equip.	1,157,825,000
Total assets	2,659,869,000
Liabilities:	
Current liabilities	779,481,000
Long-term debt	767,784,000
Stockholders' equity	929,320,000
Net current assets	366,589,000

GREEN PLAINS PARTNERS LP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	25,885	27,229
Cost & expenses	9,811	9,743
Operating income	14,893	16,232
Interest expense	20	20
Other income (expense), net	1,571	1,228
Equity earnings	13	
Net before taxes	13,417	15,024
Income taxes	32	47
Net income	13,372	14,977

Earnings common share

Primary	\$0.41	\$0.46
Fully Diluted	\$0.41	\$0.46

Common Shares:

Full Diluted	15,922	15,910
Year-end	31,812	31,800

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	588
Current assets	25,022

Net property & equip.	48,339
Total assets	96,890
Liabilities:	
Current liabilities	20,371
Long-term debt	136,988
Net current assets	4,651

GULF ISLAND FABRICATION, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	57,290	37,993
Cost & expenses	62,070	47,209
Operating income	(4,780)	(9,216)
Interest expense	469	59
Other income (expense), net	12	9
Net before taxes	(5,237)	(9,266)
Net income	(5,296)	(6,454)

Balance for common:

(5,296)	(6,420)
---------	---------

Earnings common share

Primary	\$(0.35)	\$(0.44)
Fully Diluted	\$(0.35)	\$(0.44)

Common Shares:

Full Diluted	14,964	14,758
Year-end	15,043	14,850

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	6,492
Inventories	5,053
Current assets	178,110
Net property & equip.	86,006
Total assets	269,122
Liabilities:	
Current liabilities	41,040
Long-term debt	10,000
Stockholders' equity	214,086
Net current assets	137,070

GULFPORT ENERGY CORP.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	325,392,000	333,004,000
Cost & expenses	104,056,000	85,330,000
Deprec., depl. & amort.	111,018,000	65,991,000
Operating income	110,318,000	181,683,000
Interest income	37,000	842,000
Other income (expense), net	13,631,000	(4,591,000)
Net before taxes	90,021,000	
Income taxes	(69,000)	
Net income	90,090,000	154,455,000

Earnings common share

Primary	\$0.50	\$0.91
Fully Diluted	\$0.50	\$0.91

Common Shares:

Full Diluted	180,802,301	170,488,519
Year-end	173,523,487	182,835,801

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	118,613,000
Current assets	376,540,000
Net property & equip.	5,295,698,000
Total assets	6,028,392,000
Liabilities:	
Current liabilities	615,867,000
Long-term debt	2,239,023,000
Stockholders' equity	3,088,889,000
Net current assets	(239,327,000)

GULFPORT ENERGY CORP.

Interest Sale Completed On May 1, 2018, EQT Corp. ("EQT"), the ultimate parent company of EQT GP Holdings, LP ("EQGP") and its wholly-owned subsidiary, EQT Midstream Partners, LP ("EQM"), through EQM's wholly-owned subsidiary, EQM Gathering Holdings, LLC, acquired the 25% equity interest in Strike Force Midstream LLC from Co. for \$175,000,000 in an all cash transaction.

H&E EQUIPMENT SERVICES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	260,482	226,828
Cost & expenses	233,156	205,503
Operating income	27,326	21,325
Interest expense	14,653	13,232
Other income (expense), net	395	437
Net before taxes	13,068	8,530

Income taxes	3,590	3,140	Fully Diluted	\$(1.99)	\$(0.02)	Current liabilities	69,094
Net income	9,478	5,390	Common Shares:			Long-term debt	240,000
Earnings common share			Full Diluted	12,417	12,391	Stockholders' equity	615,143
Primary	\$0.27	\$0.15	Year-end	12,520	12,491	Net current assets	216,917
Fully Diluted	\$0.26	\$0.15					
Common Shares:			HEALTH INSURANCE INNOVATIONS INC			HOMESTREET INC	
Full Diluted	35,879	35,621	Earnings, 3 mos. to Mar 31(Consol. – \$000):			Earnings, 3 mos. to Mar 31(Consol. – \$000):	
Year-end	35,656	35,575	2018	2017	2018	2017	
Consolidated Balance Sheet Items, as of (\$000):			Total Revenues	67,750	55,868	Cost & expenses	114,327
Assets:	2018	2017	Cost & expenses	58,802	47,875	Operating income	7,772
Cash & equivalents	38,084		Operating income	7,783	7,055	Net before taxes	7,772
Inventories	148,701		Other income (expense), net	(28)	(3)	Income taxes	1,906
Current assets	347,217		Net before taxes	7,781	7,053	Net income	5,866
Net property & equip.	103,121		Income taxes	1,796	(1,469)	Earnings common share	
Total assets	1,517,298		Net income	5,985	8,522	Primary	\$0.22
Liabilities:			Earnings common share			Fully Diluted	\$0.22
Current liabilities	164,489		Primary	\$0.36	\$0.66	Common Shares:	
Long-term debt	945,630		Fully Diluted	\$0.33	\$0.58	Full Diluted	27,159
Stockholders' equity	217,745		Common Shares:			Year-end	26,972
Net current assets	182,728		Full Diluted	12,658	10,051		26,863
			Year-end	16,376			
HAIN CELESTIAL GROUP INC			Consolidated Balance Sheet Items, as of (\$000):			Consolidated Balance Sheet Items, as of (\$000):	
Earnings, 9 mos. to Mar 31(Consol. – \$000):			Assets:	2018	2017	Assets:	2018
2018	2017		Cash & equivalents	41,926		Cash & equivalents	66,289
Net Sales	1,838,171	1,740,614	Current assets	96,984		Current assets	108,212
Cost & expenses	1,734,852	1,625,478	Net property & equip.	5,578		Net property & equip.	104,508
Operating income	89,460	102,249	Total assets	164,912		Total assets	6,924,056
Other income (expense), net	5,447	(246)	Liabilities:			Liabilities:	
Equity earnings	(104)	(45)	Current liabilities	34,234		Current liabilities	5,246,115
Net before taxes	75,364	86,512	Stockholders' equity	91,139		Long-term debt	976,978
Income taxes	(11,516)	19,512	Net current assets	62,750		Stockholders' equity	700,963
Income contin. oper.	86,984	67,045				Net current assets	(5,137,903)
Income discont. oper.	(7,349)	72					
Net income	79,635	67,117	HEALTHSTREAM INC			HORIZON BANCORP INC	
Earnings common share			Earnings, 3 mos. to Mar 31(Consol. – \$):			Earnings, 3 mos. to Mar 31(Consol. – \$000):	
Primary	\$0.77	\$0.65	2018	2017	2018	2017	
Fully Diluted	\$0.76	\$0.64	Total Revenues	54,858,000	51,967,000	Cost & expenses	32,419
Common Shares:			Cost & expenses	45,055,000	43,700,000	Operating income	15,325
Full Diluted	104,473	104,232	Operating income	3,730,000	2,365,000	Net before taxes	15,325
Year-end	103,925		Other income (expense), net	313,000	130,000	Income taxes	2,521
			Net before taxes	4,043,000	2,495,000	Net income	12,804
HARMONIC, INC.			Income taxes	414,000	786,000	Earnings common share	
Earnings, 3 mos. to (Consol. – \$000):			Income contin. oper.	3,629,000	1,709,000	Primary	\$0.50
03/30/18	03/31/17		Income discont. oper.	20,217,000	(424,000)	Fully Diluted	\$0.50
Total Revenues	90,127	82,943	Net income	23,846,000	1,285,000	Common Shares:	
Cost & expenses	98,650	103,327	Earnings common share			Full Diluted	25,646
Operating income	(9,327)	(21,158)	Primary	\$0.74	\$0.04	Year-end	25,555
Other income (expense), net	(532)	(511)	Fully Diluted	\$0.74	\$0.04		22,176
Net before taxes	(12,616)	(24,259)	Common Shares:			Consolidated Balance Sheet Items, as of (\$000):	
Income taxes	1,078	(232)	Full Diluted	32,132,000	32,104,000	Assets:	2018
Net income	(13,694)	(24,027)	Year-end	32,302,000		Cash & equivalents	63,591
Earnings common share			Consolidated Balance Sheet Items, as of (\$):			Current assets	75,635
Primary	\$(0.16)	\$(0.30)	Assets:	2018		Net property & equip.	75,408
Fully Diluted	\$(0.16)	\$(0.30)	Cash & equivalents	156,028,000		Total assets	3,969,750
Common Shares:			Current assets	258,499,000		Liabilities:	
Full Diluted	83,912	79,810	Net property & equip.	8,297,000		Current liabilities	2,934,892
Year-end	85,194		Total assets	457,183,000		Long-term debt	557,999
Consolidated Balance Sheet Items, as of (\$000):			Liabilities:			Stockholders' equity	460,416
Assets:	2018	2017	Current liabilities	139,631,000		Net current assets	(2,859,257)
Cash & equivalents	52,045		Stockholders' equity	309,044,000			
Inventories	25,074		Net current assets	118,868,000			
Current assets	181,846		HMS HOLDINGS CORP			HORTONWORKS INC	
Net property & equip.	27,703		Earnings, 3 mos. to Mar 31(Consol. – \$000):			Earnings, 3 mos. to Mar 31(Consol. – \$000):	
Total assets	516,234		2018	2017	2018	2017	
Liabilities:			Cost & expenses	121,371	103,504	Total Revenues	79,061
Current liabilities	142,436		Operating income	11,922	3,943	Cost & expenses	119,889
Long-term debt	125,625		Interest expense	2,648	2,286	Operating income	(40,828)
Stockholders' equity	225,973		Net before taxes	9,394	1,812	Other income (expense), net	(911)
Net current assets	39,410		Income taxes	3,003	370	Net before taxes	(41,739)
			Net income	6,391	1,442	Income taxes	316
HAYNES INTERNATIONAL, INC.			Earnings common share			Net income	(42,055)
Earnings, 6 mos. to Mar 31(Consol. – \$000):			Primary	\$0.08	\$0.02	Earnings common share	
2018	2017		Fully Diluted	\$0.07	\$0.02	Primary	\$(0.55)
Total Revenues	199,899	196,467	Common Shares:			Fully Diluted	\$(0.55)
Cost & expenses	206,344	198,979	Full Diluted	85,682	85,580	Common Shares:	
Operating income	(6,445)	(2,512)	Year-end	83,213	83,885	Full Diluted	76,135
Interest income	35	101	Consolidated Balance Sheet Items, as of (\$000):			Year-end	78,411
Interest expense	459	405	Assets:	2018		Consolidated Balance Sheet Items, as of (\$000):	
Net before taxes	(6,869)	(2,816)	Cash & equivalents	83,898		Assets:	2018
Income taxes	17,725	(254)	Current assets	286,011		Cash & equivalents	64,756
Net income	(24,594)	(2,562)	Net property & equip.	96,037		Current assets	202,442
Balance for common	(24,655)	(2,614)	Total assets	959,736		Net property & equip.	15,150
Earnings common share			Liabilities:			Total assets	285,203
Primary	\$(1.99)	\$(0.02)	Current liabilities	139,631,000		Liabilities:	
			Stockholders' equity	309,044,000		Current liabilities	206,830
			Net current assets	118,868,000		Stockholders' equity	6,134
						Net current assets	(4,388)

HOSPITALITY PROPERTIES TRUST

Earnings, 3 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	528,633	488,602
Cost & expenses	326,716	315,069
Operating income	102,300	80,082
Interest income	292	257
Interest expense	47,540	43,566
Other income (expense), net	626	626
Gains or losses	24,955	
Equity earnings	(44)	(128)
Net before taxes	80,633	37,399
Income taxes	471	356
Net income	80,206	37,171
Balance for common	80,206	25,843
Earnings common share		
Primary	\$0.49	\$0.16
Fully Diluted	\$0.49	\$0.16
Common Shares:		
Full Diluted	164,219	164,149
Year-end	164,346	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2017
	16,832	16,832
Current assets	76,365	76,365
Total assets	7,120,874	7,120,874
Liabilities:		
Current liabilities	293,357	293,357
Long-term debt	4,077,543	4,077,543
Stockholders' equity	2,749,974	2,749,974
Net current assets	(216,992)	(216,992)

IAC/INTERACTIVECORP

Earnings, 3 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	995,075	760,833
Cost & expenses	865,915	694,724
Operating income	89,950	37,060
Other income (expense), net	(4,619)	(7,714)
Net before taxes	58,826	4,554
Income taxes	(29,013)	(23,909)
Net income	87,839	28,463
Earnings common share		
Primary	\$0.86	\$0.34
Fully Diluted	\$0.71	\$0.29
Common Shares:		
Full Diluted	89,069	82,504
Year-end	83,390	88,972

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2017
	1,657,537	1,657,537
Current assets	2,222,932	2,222,932
Net property & equip.	301,865	301,865
Total assets	6,030,974	6,030,974
Liabilities:		
Current liabilities	829,493	829,493
Long-term debt	1,980,579	1,980,579
Stockholders' equity	2,494,527	2,494,527
Net current assets	1,393,439	1,393,439

IES HOLDINGS INC

Earnings, 6 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	403,977	395,840
Cost & expenses	396,846	387,228
Operating income	7,131	8,612
Interest expense	914	874
Other income (expense), net	141	48
Net before taxes	6,358	7,786
Income taxes	33,584	3,311
Net income	(27,226)	4,475
Earnings common share		
Primary	\$(1.29)	\$0.21
Fully Diluted	\$(1.29)	\$0.20
Common Shares:		
Full Diluted	21,190	21,561
Year-end	21,259	21,472

II-VI INC

Earnings, 9 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	837,719	698,329
Cost & expenses	749,732	613,399
Operating income	87,987	84,930

Net before taxes	87,987	84,930
Income taxes	27,152	22,303
Net income	60,835	62,627
Earnings common share		
Primary	\$0.97	\$1.00
Fully Diluted	\$0.93	\$0.97
Common Shares:		
Full Diluted	65,124	64,333
Year-end	62,467	63,068

IMMERSION CORP

Earnings, 3 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	85,416	9,224
Cost & expenses	15,311	22,076
Operating income	70,105	(12,852)
Net before taxes	70,336	(12,713)
Income taxes	453	152
Net income	69,883	(12,865)
Earnings common share		
Primary	\$2.35	\$(0.44)
Fully Diluted	\$2.29	\$(0.44)
Common Shares:		
Full Diluted	30,566	29,024
Year-end	30,357	29,164

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2017
	119,128	119,128
Current assets	147,253	147,253
Net property & equip.	2,903	2,903
Total assets	155,335	155,335
Liabilities:		
Current liabilities	15,024	15,024
Stockholders' equity	105,272	105,272
Net current assets	132,229	132,229

IMMUNOGEN, INC.

Earnings, 3 mos. to Mar 31(Consol. – \$):		
	2018	2017
Total Revenues	19,815,000	28,499,000
Cost & expenses	56,557,000	41,393,000
Operating income	(36,742,000)	(12,894,000)
Other income (expense), net	537,000	134,000
Gains or losses	662,000	115,000
Net income	(38,613,000)	(17,345,000)
Earnings common share		
Primary	\$(0.30)	\$(0.20)
Fully Diluted	\$(0.30)	\$(0.20)
Common Shares:		
Full Diluted	130,619,000	87,160,000
Year-end	133,024,000	89,348,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		
Cash & equivalents	2018	2017
	218,383,000	218,383,000
Inventories	368,000	368,000
Current assets	247,434,000	247,434,000
Net property & equip.	12,850,000	12,850,000
Total assets	264,965,000	264,965,000
Liabilities:		
Current liabilities	66,227,000	66,227,000
Long-term debt	2,053,000	2,053,000
Stockholders' equity	(36,311,000)	(36,311,000)
Net current assets	181,207,000	181,207,000

IMMUNOMEDICS, INC.

Earnings, 9 mos. to Mar 31(Consol. – \$):		
	2018	2017
Total Revenues	1,770,000	2,449,415
Cost & expenses	90,422,165	54,875,855
Operating income	(88,652,165)	(52,426,440)
Interest expense	13,821,273	4,109,866
Other income (expense), net	(56,483,597)	(43,563,168)
Foreign currency	181,659	(117,476)
Net income	(156,847,565)	(99,997,414)
Earnings common share		
Primary	\$(1.08)	\$(0.97)
Fully Diluted	\$(1.08)	\$(0.97)
Common Shares:		
Full Diluted	145,119,409	102,756,818
Year-end	167,221,161	109,569,895

IMPERVA INC

Earnings, 3 mos. to Mar 31(Consol. – \$000):		
---	--	--

Total Revenues	2018	2017
	84,244	72,308
Cost & expenses	95,349	83,729
Operating income	(11,237)	(11,738)
Other income (expense), net	977	(92)
Gains or losses		35,871
Net before taxes	(10,260)	24,041
Income taxes	(479)	958
Net income	(9,781)	23,083

Earnings common share		
Primary	\$(0.28)	\$0.70
Fully Diluted	\$(0.28)	\$0.68
Common Shares:		
Full Diluted	34,457	33,771
Year-end	34,734	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2017
	214,274	214,274
Inventories	162	162
Current assets	459,023	459,023
Net property & equip.	23,693	23,693
Total assets	549,106	549,106
Liabilities:		
Current liabilities	162,784	162,784
Stockholders' equity	338,261	338,261
Net current assets	296,239	296,239

IMPINJ INC

Earnings, 3 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	25,068	31,727
Cost & expenses	39,320	33,725
Operating income	(14,252)	(1,998)
Interest expense	229	374
Other income (expense), net	90	269
Net before taxes	(14,391)	(2,103)
Income taxes	51	57
Net income	(14,442)	(2,160)

Earnings common share		
Primary	\$(0.68)	\$(0.11)
Fully Diluted	\$(0.68)	\$(0.11)
Common Shares:		
Full Diluted	21,125	20,344
Year-end	21,332	20,615

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2017
	28,000	28,000
Inventories	54,706	54,706
Current assets	131,448	131,448
Net property & equip.	17,507	17,507
Total assets	153,044	153,044
Liabilities:		
Current liabilities	16,432	16,432
Long-term debt	20,466	20,466
Stockholders' equity	108,560	108,560
Net current assets	115,016	115,016

INDUSTRIAL LOGISTICS PROPERTIES TRUST

Earnings, 3 mos. to Mar 31(Consol. – \$000):		
	2018	2017
Total Revenues	40,605	39,440
Cost & expenses	10,704	11,707
Deprec., depl. & amort.	6,873	6,811
Operating income	23,028	20,922
Interest income	13	
Interest expense	3,802	555
Net before taxes	19,239	20,367
Income taxes	7	11
Net income	19,232	20,356

Earnings common share		
Primary	\$0.31	\$0.45
Fully Diluted	\$0.31	\$0.45
Common Shares:		
Full Diluted	61,445	45,000
Year-end	65,005	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		
Cash & equivalents	2018	2017
	19,847	19,847
Current assets	19,847	19,847
Total assets	1,433,235	1,433,235
Liabilities:		
Current liabilities	29,177	29,177
Long-term debt	351,369	351,369

Stockholders' equity	1,032,828
Net current assets	(9,330)

INFINITY PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	9,517,000	10,476,000
Operating income	(9,517,000)	(10,476,000)
Interest expense	93,000	302,000
Other income (expense), net	159,000	303,000
Net income	(9,451,000)	(10,475,000)

Earnings common share

Primary	\$(0.18)	\$(0.21)
Fully Diluted	\$(0.18)	\$(0.21)

Common Shares:

Full Diluted	51,883,570	50,423,353
Year-end	53,697,697	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	30,575,000
Current assets	49,062,000
Net property & equip.	156,000
Total assets	49,966,000
Liabilities:	
Current liabilities	4,542,000
Stockholders' equity	45,397,000
Net current assets	44,520,000

INNOPHOS HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	205,440	165,944
Cost & expenses	187,144	149,553
Operating income	18,296	16,391
Other income (expense), net	15	14
Foreign currency	196	57
Net before taxes	15,603	15,109
Income taxes	4,688	4,186
Net income	10,915	10,923
Balance for common	10,893	10,873

Earnings common share

Primary	\$0.56	\$0.56
Fully Diluted	\$0.55	\$0.55

Common Shares:

Full Diluted	19,711	19,695
Year-end	19,536	19,475

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	40,722
Inventories	154,474
Current assets	326,543
Net property & equip.	220,567
Total assets	809,755
Liabilities:	
Current liabilities	101,279
Long-term debt	345,004
Stockholders' equity	336,213
Net current assets	225,264

INNOSPEC INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	360,700	294,300
Cost & expenses	331,800	269,000
Operating income	28,900	25,300
Other income (expense), net	2,500	100
Net before taxes	29,700	23,200
Income taxes	7,500	6,000
Net income	22,200	17,200
Balance for common	22,200	17,200

Earnings common share

Primary	\$0.91	\$0.71
Fully Diluted	\$0.90	\$0.70

Common Shares:

Full Diluted	24,574	24,527
Year-end	24,403	24,131

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	78,100
Inventories	247,700
Current assets	622,700
Net property & equip.	196,800
Total assets	1,472,900

Liabilities:

Current liabilities	292,600
Long-term debt	200,500
Stockholders' equity	824,400
Net current assets	330,100

INNOVIVA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	52,380	40,492
Cost & expenses	11,685	11,149
Operating income	40,695	29,343
Other income (expense), net	(3,099)	47
Net income	30,330	16,845

Earnings common share

Primary	\$0.29	\$0.16
Fully Diluted	\$0.27	\$0.15

Common Shares:

Full Diluted	113,566	120,336
Year-end	101,325	109,198

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	27,138
Current assets	113,245
Net property & equip.	197
Total assets	276,745
Liabilities:	
Current liabilities	4,066
Long-term debt	484,591
Stockholders' equity	(213,558)
Net current assets	109,179

INOVALON HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	92,755	108,306
Cost & expenses	97,210	89,505
Deprec., depl. & amort.	16,380	12,485
Operating income	(20,835)	6,316
Interest income	1,395	1,338
Interest expense	1,882	1,413
Gains or losses	(1,120)	
Net before taxes	(22,442)	6,241
Income taxes	(5,608)	2,599
Net income	(16,834)	3,642
Balance for common	(16,272)	3,569

Earnings common share

Primary	\$(0.12)	\$0.02
Fully Diluted	\$(0.12)	\$0.02

Common Shares:

Full Diluted	139,378	145,165
Year-end	144,555	146,532

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	410,000
Current assets	554,686
Net property & equip.	139,989
Total assets	975,556
Liabilities:	
Current liabilities	123,788
Long-term debt	195,134
Stockholders' equity	631,761
Net current assets	430,898

INSEGO CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	46,733,000	55,389,000
Cost & expenses	48,353,000	65,495,000
Operating income	(2,584,000)	(11,010,000)
Other income (expense), net	64,000	(643,000)
Net before taxes	(7,620,000)	(15,809,000)
Income taxes	440,000	305,000
Net income	(8,060,000)	(16,114,000)

Earnings common share

Primary	\$(0.13)	\$(0.28)
Fully Diluted	\$(0.13)	\$(0.28)

Common Shares:

Full Diluted	60,721,518	57,480,210
Year-end	59,221,551	55,955,138

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	410,000
Current assets	554,686
Net property & equip.	139,989
Total assets	975,556
Liabilities:	
Current liabilities	123,788
Long-term debt	195,134
Stockholders' equity	631,761
Net current assets	430,898

Assets:

Cash & equivalents	16,112,000
Inventories	15,025,000
Current assets	55,620,000
Net property & equip.	6,856,000
Total assets	148,796,000

Liabilities:

Current liabilities	59,544,000
Long-term debt	131,271,000
Stockholders' equity	(49,176,000)
Net current assets	(3,924,000)

INSIGNIA SYSTEMS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	7,419,000	4,767,000
Cost & expenses	7,187,000	6,505,000
Operating income	232,000	(1,738,000)
Other income (expense), net	5,000	3,000
Net before taxes	237,000	(1,735,000)
Income taxes	73,000	(544,000)
Net income	164,000	(1,191,000)

Earnings common share

Primary	\$0.01	\$(0.10)
Fully Diluted	\$0.01	\$(0.10)

Common Shares:

Full Diluted	11,819,000	11,661,000
Year-end	11,963,000	11,661,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	7,259,000
Inventories	485,000
Current assets	17,315,000
Net property & equip.	2,733,000
Total assets	21,329,000
Liabilities:	
Current liabilities	5,171,000
Stockholders' equity	15,121,000
Net current assets	12,144,000

INTERCEPT PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	35,963,000	21,048,000
Cost & expenses	111,419,000	105,011,000
Operating income	(75,456,000)	(83,963,000)
Other income (expense), net	1,375,000	1,240,000
Net income	(81,590,000)	(89,930,000)

Earnings common share

Primary	\$(3.22)	\$(3.61)
Fully Diluted	\$(3.22)	\$(3.61)

Common Shares:

Full Diluted	25,309,000	24,931,000
Year-end	25,331,808	25,012,174

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	48,871,000
Current assets	363,845,000
Net property & equip.	14,074,000
Total assets	393,818,000
Liabilities:	
Current liabilities	79,446,000
Long-term debt	359,449,000
Stockholders' equity	(52,275,000)
Net current assets	284,399,000

INTERNAP CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	74,201,000	72,133,000
Cost & expenses	52,245,000	53,896,000
Operating income	879,000	492,000
Equity earnings		(30,000)
Foreign currency	215,000	(97,000)
Net before taxes	(13,933,000)	(7,742,000)
Income taxes	100,000	518,000
Net income	(14,033,000)	(8,230,000)

Earnings common share

Primary	\$(0.70)	\$(0.50)
Fully Diluted	\$(0.70)	\$(0.50)

Common Shares:

Full Diluted	20,052,000	16,087,000
Year-end	21,131,000	20,539,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	16,159,000
Current assets	49,504,000
Net property & equip.	461,314,000
Total assets	731,920,000
Liabilities:	
Current liabilities	76,350,000
Long-term debt	640,315,000
Stockholders' equity	5,716,000
Net current assets	(26,846,000)

INTERNATIONAL ISOTOPES INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	2,651,421	2,516,621
Operating income	149,605	(682,413)
Interest income	1,307	421
Interest expense	106,034	133,316
Other income (expense), net	53,362	23,090
Net income	98,240	(792,218)

Earnings common share

Common Shares:

Full Diluted	526,418,051	405,649,164
Year-end	409,922,096	406,705,724

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	356,432
Inventories	2,426,956
Current assets	4,444,838
Net property & equip.	1,924,406
Total assets	12,832,647
Liabilities:	
Current liabilities	5,922,932
Long-term debt	453,041
Stockholders' equity	(914,703)
Net current assets	(1,478,094)

INTUIT INC**Earnings, 9 mos. to Apr 30(Consol. - \$000):**

	2018	2017
Total Revenues	4,976,000	4,335,000
Cost & expenses	3,394,000	2,928,000
Operating income	1,578,000	1,405,000
Gains or losses	4,000	6,000
Net before taxes	1,577,000	1,377,000
Income taxes	415,000	430,000
Net income	1,162,000	947,000

Earnings common share

Primary	\$4.54	\$3.68
Fully Diluted	\$4.47	\$3.63
Common Shares:		
Full Diluted	260,000	261,000
Year-end	256,574	256,254

INVIVO THERAPEUTICS HOLDINGS CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	4,832,000	6,669,000
Operating income	(4,832,000)	(6,669,000)
Other income (expense), net	30,000	241,000
Net income	(4,784,000)	(6,391,000)

Earnings common share

Primary	\$(3.34)	\$(4.98)
Fully Diluted	\$(3.34)	\$(4.98)
Common Shares:		
Full Diluted	1,432,963	1,283,206
Year-end	1,562,284	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	11,614,000
Current assets	13,143,000
Net property & equip.	72,000
Total assets	13,291,000
Liabilities:	
Current liabilities	4,105,000
Long-term debt	283,000
Stockholders' equity	8,323,000
Net current assets	9,038,000

INVUITY INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

Total Revenues	9,505	9,023
Cost & expenses	19,917	19,380
Operating income	(10,412)	(10,357)
Interest income	56	57
Interest expense	775	487
Other income (expense), net	(66)	(2,430)
Net income	(11,197)	(13,217)

Earnings common share

Primary	\$(0.62)	\$(0.78)
Fully Diluted	\$(0.62)	\$(0.78)

Common Shares:

Full Diluted	18,125	16,958
Year-end	24,024	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	29,539
Inventories	8,729
Current assets	48,853
Net property & equip.	6,989
Total assets	56,812
Liabilities:	
Current liabilities	14,468
Long-term debt	29,182
Stockholders' equity	10,562
Net current assets	34,385

IONIS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	144,419	115,800
Cost & expenses	147,720	96,315
Operating income	(3,301)	19,485
Other income (expense), net	(168)	(1,438)
Gains or losses	3,610	2,280
Net before taxes	(10,797)	
Income taxes	15	
Net income	(10,812)	8,964

Earnings common share

Primary	\$(0.01)	\$0.07
Fully Diluted	\$(0.01)	\$0.07
Common Shares:		
Full Diluted	125,330	124,972
Year-end	125,449	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	227,505
Inventories	9,060
Current assets	1,143,283
Net property & equip.	123,188
Total assets	1,299,560
Liabilities:	
Current liabilities	212,643
Long-term debt	614,370
Stockholders' equity	301,391
Net current assets	930,640

IOVANCE BIOTHERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	26,877,000	20,882,000
Operating income	(26,877,000)	(20,882,000)
Net income	(26,515,000)	(20,684,000)

Earnings common share

Primary	\$(0.31)	\$(0.33)
Fully Diluted	\$(0.31)	\$(0.33)
Common Shares:		
Full Diluted	84,350,000	62,286,000
Year-end	89,615,417	62,350,149

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	297,082,000
Current assets	302,726,000
Net property & equip.	2,247,000
Total assets	307,248,000
Liabilities:	
Current liabilities	14,690,000
Stockholders' equity	292,558,000
Net current assets	288,036,000

IRIDEX CORP.**Earnings, 3 mos. to (Consol. - \$000):**

Total Revenues	9,509	10,483
Cost & expenses	13,126	12,341
Operating income	(3,617)	(1,858)
Other income (expense), net	18	(2)
Net before taxes	(3,599)	(1,860)
Income taxes	4	6
Net income	(3,603)	(1,866)

Earnings common share

Primary	\$(0.31)	\$(0.16)
Fully Diluted	\$(0.31)	\$(0.16)

Common Shares:

Full Diluted	11,628	11,518
Year-end	11,637	11,543

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	18,522
Inventories	9,306
Current assets	34,909
Net property & equip.	1,488
Total assets	37,212
Liabilities:	
Current liabilities	9,255
Stockholders' equity	27,255
Net current assets	25,654

IROBOT CORP**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	217,068	168,467
Cost & expenses	191,390	146,829
Operating income	25,405	21,638
Other income (expense), net	519	3
Net before taxes	25,924	21,641
Income taxes	5,523	5,282
Net income	20,401	16,359

Earnings common share

Primary	\$0.73	\$0.60
Fully Diluted	\$0.71	\$0.58
Common Shares:		
Full Diluted	28,923	28,295
Year-end	28,073	27,410

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	144,501
Inventories	112,111
Current assets	390,688
Net property & equip.	47,223
Total assets	649,437
Liabilities:	
Current liabilities	131,497
Stockholders' equity	496,628
Net current assets	259,191

IRONWOOD PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	69,155	52,166
Cost & expenses	101,547	91,451
Operating income	(35,868)	(39,705)
Interest expense	9,273	8,983
Other income (expense), net	1,316	(4,208)
Net income	(43,144)	(52,501)

Earnings common share

Primary	\$(0.29)	\$(0.36)
Fully Diluted	\$(0.29)	\$(0.36)
Common Shares:		
Full Diluted	151,013	147,786
Year-end	151,604	148,489

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	144,788
Inventories	1,705
Current assets	275,727
Net property & equip.	16,844
Total assets	571,095
Liabilities:	
Current liabilities	62,336
Long-term debt	388,373
Stockholders' equity	(18,052)
Net current assets	213,391

J2 GLOBAL INC (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	280,623,000	254,669,000
Cost & expenses	234,465,000	206,694,000
Operating income	46,158,000	47,975,000
Other income (expense), net	(4,519,000)	(323,000)
Net before taxes	25,888,000	35,242,000
Income taxes	7,017,000	9,422,000
Net income	18,871,000	25,820,000
Balance for common	18,654,000	25,511,000
Earnings common share		
Primary	\$0.39	\$0.54
Fully Diluted	\$0.38	\$0.52
Common Shares:		
Full Diluted	48,706,717	48,766,031
Year-end	47,893,150	

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	331,367,000
Current assets	537,768,000
Net property & equip.	85,852,000
Total assets	2,452,218,000
Liabilities:	
Current liabilities	241,944,000
Long-term debt	1,004,796,000
Stockholders' equity	1,031,168,000
Net current assets	295,824,000

JACK HENRY & ASSOCIATES, INC.**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,119,374	1,047,349
Cost & expenses	835,532	778,594
Operating income	283,842	268,755
Interest expense	1,173	604
Net before taxes	283,093	268,360
Income taxes	(8,287)	87,258
Net income	291,380	181,102
Earnings common share		
Primary	\$3.77	\$2.32
Fully Diluted	\$3.76	\$2.31
Common Shares:		
Full Diluted	77,586	78,319
Year-end	77,287	77,644

JACK IN THE BOX, INC.**Earnings, 6 mos. to (Consol. - \$000):**

	04/15/18	04/16/17
Total Revenues	504,235	619,065
Cost & expenses	351,496	455,131
Deprec., depl. & amort.	33,112	37,385
Operating income	119,627	126,549
Net before taxes	96,434	107,103
Income taxes	58,564	41,164
Income contin. oper.	37,870	65,939
Net income	59,795	69,023
Earnings common share		
Primary	\$2.04	\$2.18
Fully Diluted	\$2.01	\$2.16
Common Shares:		
Full Diluted	29,705	31,883
Year-end	28,423	

JOINT CORP (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	7,097,915	5,507,147
Cost & expenses	7,149,563	6,634,471
Deprec., depl. & amort.	387,417	577,987
Operating income	(439,065)	(1,705,311)
Other income (expense), net	(11,194)	(19,465)
Net before taxes	(450,259)	(1,724,776)
Income taxes	(63,355)	40,609
Net income	(386,904)	(1,765,385)
Earnings common share		
Primary	\$(0.03)	\$(0.14)
Fully Diluted	\$(0.03)	\$(0.14)
Common Shares:		
Full Diluted	13,587,837	13,042,595
Year-end	13,593,754	

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	4,033,730
Current assets	6,647,346
Net property & equip.	3,719,459

Total assets	18,243,252
Liabilities:	
Current liabilities	5,668,091
Long-term debt	1,000,000
Stockholders' equity	1,058,500
Net current assets	979,255

KELLY SERVICES, INC.**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	04/02/17
Cost & expenses	1,357,900	1,273,300
Operating income	12,000	16,400
Gains or losses	23,700	
Foreign currency	(1,100)	(1,200)
Net before taxes	34,000	14,800
Income taxes	6,400	2,700
Net income	29,100	12,200
Balance for common	28,700	12,000
Earnings common share		
Primary	\$0.74	\$0.31
Fully Diluted	\$0.74	\$0.31
Common Shares:		
Full Diluted	38,900	38,700
Year-end	38,800	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	36,600
Current assets	1,397,700
Net property & equip.	84,300
Total assets	2,436,600
Liabilities:	
Current liabilities	934,200
Stockholders' equity	1,191,300
Net current assets	463,500

KEYW HOLDING CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	125,742	68,256
Cost & expenses	120,798	67,873
Operating income	1,003	(1,267)
Other income (expense), net	5	(8)
Income taxes	(693)	
Net income	(3,127)	(3,884)
Earnings common share		
Primary	\$(0.06)	\$(0.08)
Fully Diluted	\$(0.06)	\$(0.08)
Common Shares:		
Full Diluted	49,866	46,562
Year-end	49,867	49,498

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	3,100
Inventories	20,186
Current assets	134,860
Net property & equip.	41,662
Total assets	687,640
Liabilities:	
Current liabilities	86,463
Long-term debt	263,849
Stockholders' equity	308,101
Net current assets	48,397

KLX INC**Earnings, 3 mos. to Apr 30(Consol. - \$000):**

	2018	2017
Total Revenues	499,100	411,300
Cost & expenses	437,900	362,700
Operating income	61,200	48,600
Net before taxes	42,300	29,600
Income taxes	10,600	11,200
Net income	31,700	18,400
Earnings common share		
Primary	\$0.63	\$0.36
Fully Diluted	\$0.62	\$0.36
Common Shares:		
Full Diluted	50,900	51,800
Year-end	50,800	51,700

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	298,400
Inventories	1,408,300
Current assets	2,109,400

Net property & equip.	298,600
Total assets	3,857,100
Liabilities:	
Current liabilities	330,400
Long-term debt	1,185,200
Stockholders' equity	2,293,600
Net current assets	1,779,000

KOPIN CORP.**Earnings, 3 mos. to (Consol. - \$):**

	03/31/18	04/01/17
Total Revenues	5,653,620	4,378,127
Cost & expenses	15,445,254	13,040,911
Operating income	(9,791,634)	(8,662,784)
Other income (expense), net	1,101,255	534,411
Gains or losses	2,849,816	
Foreign currency	208,608	(1,191,283)
Net before taxes		(9,085,879)
Income taxes		(1,146,000)
Net income	(5,472,104)	(7,939,879)
Earnings common share		
Primary	\$(0.08)	\$(0.12)
Fully Diluted	\$(0.08)	\$(0.12)
Common Shares:		
Full Diluted	73,078,344	64,538,686
Year-end	73,078,783	64,538,686

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	24,167,900
Inventories	3,773,305
Current assets	71,009,531
Net property & equip.	5,304,135
Total assets	86,872,600
Liabilities:	
Current liabilities	8,744,896
Long-term debt	1,484,713
Stockholders' equity	76,751,925
Net current assets	62,264,635

KRAFT HEINZ CO (THE)**Earnings, 3 mos. to (Consol. - \$Millions):**

	03/31/18	04/01/17
Net Sales	6,304	6,324
Cost & expenses	4,823	4,891
Operating income	1,481	1,433
Interest expense	317	313
Other income (expense), net	90	130
Net before taxes	1,254	1,250
Income taxes	261	359
Net income	993	891
Balance for common	993	893
Earnings common share		
Primary	\$0.81	\$0.73
Fully Diluted	\$0.81	\$0.73
Common Shares:		
Full Diluted	1,228	1,229
Year-end	1,219	

Consolidated Balance Sheet Items, as of (\$Millions):

	2018
Assets:	
Cash & equivalents	1,794
Inventories	3,144
Current assets	7,437
Net property & equip.	7,267
Total assets	120,787
Liabilities:	
Current liabilities	10,329
Long-term debt	28,561
Stockholders' equity	66,248
Net current assets	(2,892)

KURA ONCOLOGY INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	14,991	7,653
Operating income	(195)	(195)
Interest income	450	128
Other income (expense), net	195	195
Net income	(14,604)	(7,533)
Earnings common share		
Primary	\$(0.46)	\$(0.39)
Fully Diluted	\$(0.46)	\$(0.39)
Common Shares:		
Full Diluted	31,829	19,464
Year-end	32,856	19,668

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	26,518	
Current assets	140,361	
Net property & equip.	5	
Total assets	141,458	
Liabilities:		
Current liabilities	11,351	
Long-term debt	4,861	
Stockholders' equity	124,800	
Net current assets	129,010	

KVH INDUSTRIES, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	40,101,000	40,211,000
Cost & expenses	43,281,000	44,681,000
Operating income	(3,180,000)	(4,470,000)
Other income (expense), net	(274,000)	(68,000)
Net before taxes	(3,715,000)	(4,725,000)
Income taxes	178,000	160,000
Net income	(3,893,000)	(4,885,000)
Earnings common share		
Primary	\$(0.23)	\$(0.30)
Fully Diluted	\$(0.23)	\$(0.30)
Common Shares:		
Full Diluted	16,742,000	16,261,000
Year-end	17,521,644	17,041,570

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	37,768,000	
Inventories	23,327,000	
Current assets	100,701,000	
Net property & equip.	48,145,000	
Total assets	211,352,000	
Liabilities:		
Current liabilities	49,373,000	
Long-term debt	41,701,000	
Stockholders' equity	106,834,000	
Net current assets	51,328,000	

LATTICE SEMICONDUCTOR CORP**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	98,623	104,587
Cost & expenses	93,782	96,775
Operating income	(795)	(702)
Other income (expense), net	554	(487)
Net before taxes	(5,355)	(6,757)
Net income	(5,952)	(7,275)
Earnings common share		
Primary	\$(0.05)	\$(0.06)
Fully Diluted	\$(0.05)	\$(0.06)
Common Shares:		
Full Diluted	124,076	121,800
Year-end	124,311	121,999

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	99,392	
Inventories	77,917	
Current assets	280,571	
Net property & equip.	37,674	
Total assets	644,833	
Liabilities:		
Current liabilities	66,062	
Long-term debt	298,995	
Stockholders' equity	245,672	
Net current assets	214,509	

LEMAITRE VASCULAR INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	25,994	24,139
Cost & expenses	21,132	19,946
Operating income	4,862	4,193
Interest income	95	20
Foreign currency	(41)	26
Net before taxes	4,916	4,239
Income taxes	1,063	1,020
Net income	3,853	3,219
Earnings common share		
Primary	\$0.20	\$0.17
Fully Diluted	\$0.19	\$0.16
Common Shares:		

Full Diluted 20,181

Year-end 19,300

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	22,781	
Inventories	21,833	
Current assets	84,008	
Net property & equip.	12,170	
Total assets	129,410	
Liabilities:		
Current liabilities	12,642	
Stockholders' equity	113,470	
Net current assets	71,366	

LEXARIA BIOSCIENCE CORP

Wrts. Exercise Terms On May 23, 2018, Co. announced that it has received US\$24,500 from the exercise of warrants previously granted. Co. has received for exercise a total of 175,000 warrants with an exercise price of US\$0.14, previously granted. The warrant exercises are by a third party who is neither an officer nor a director of Co. No commissions or placement fees have been paid related to the funds received from these warrants exercised. Proceeds will be used for general corporate purposes.

LGI HOMES, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	279,024,000	162,911,000
Cost & expenses	248,154,000	146,784,000
Operating income	30,870,000	16,127,000
Other income (expense), net	357,000	715,000
Net before taxes	31,227,000	16,842,000
Income taxes	3,925,000	5,062,000
Net income	27,302,000	11,780,000
Earnings common share		
Primary	\$1.23	\$0.55
Fully Diluted	\$1.10	\$0.52
Common Shares:		
Full Diluted	24,772,027	22,787,652
Year-end	22,615,146	21,599,861

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	52,024,000	
Inventories	1,040,351,000	
Current assets	1,114,035,000	
Net property & equip.	1,647,000	
Total assets	1,170,854,000	
Liabilities:		
Current liabilities	55,835,000	
Long-term debt	571,718,000	
Stockholders' equity	518,910,000	
Net current assets	1,058,200,000	

LIBERTY MEDIA CORP (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,517,000	1,395,000
Cost & expenses	1,074,000	972,000
Operating income	227,000	259,000
Interest expense	150,000	140,000
Other income (expense), net	(2,000)	13,000
Gains or losses	153,000	(12,000)
Net before taxes	228,000	120,000
Income taxes	15,000	76,000
Net income	213,000	44,000
Earnings common share		
Common Shares:		
Year-end	617,371	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	1,042,000	
Current assets	1,919,000	
Net property & equip.	2,603,000	
Total assets	42,540,000	
Liabilities:		
Current liabilities	3,587,000	
Long-term debt	14,077,000	
Stockholders' equity	16,977,000	
Net current assets	(1,668,000)	

LIFEPOINT HEALTH INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

Total Revenues	1,602,800	1,630,200
Cost & expenses	1,524,000	1,446,100
Deprec., depl. & amort.	81,600	88,100
Operating income	(2,800)	96,000
Net before taxes	(2,800)	96,000
Income taxes	2,500	32,000
Net income	(5,300)	64,000
Earnings common share		
Primary	\$(0.22)	\$1.50
Fully Diluted	\$(0.22)	\$1.46
Common Shares:		
Full Diluted	39,000	41,200
Year-end	38,896	40,366

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	140,100	
Inventories	151,500	
Current assets	1,319,300	
Net property & equip.	3,001,200	
Total assets	6,256,900	
Liabilities:		
Current liabilities	751,000	
Long-term debt	2,894,800	
Stockholders' equity	2,210,400	
Net current assets	568,300	

LIGAND PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	56,157,000	29,267,000
Cost & expenses	15,838,000	16,336,000
Operating income	37,041,000	10,216,000
Other income (expense), net	20,876,000	(1,082,000)
Net before taxes	55,312,000	6,193,000
Income taxes	10,033,000	1,114,000
Net income	45,279,000	5,079,000
Earnings common share		
Primary	\$2.13	\$0.24
Fully Diluted	\$1.83	\$0.22
Common Shares:		
Full Diluted	24,800,000	23,019,000
Year-end	21,301,980	20,996,049

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	51,024,000	
Inventories	10,531,000	
Current assets	349,051,000	
Net property & equip.	4,119,000	
Total assets	754,668,000	
Liabilities:		
Current liabilities	246,979,000	
Stockholders' equity	481,100,000	
Net current assets	102,072,000	

LINCOLN ELECTRIC HOLDINGS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	757,696	580,897
Cost & expenses	672,508	501,490
Operating income	85,188	79,407
Interest expense	4,441	5,337
Other income (expense), net	3,451	3,830
Net before taxes	84,198	77,900
Income taxes	23,378	22,052
Net income	60,820	55,848
Earnings common share		
Primary	\$0.93	\$0.85
Fully Diluted	\$0.92	\$0.84
Common Shares:		
Full Diluted	66,443	66,583
Year-end	65,559	65,796

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	369,056	
Inventories	381,530	
Current assets	1,445,845	
Net property & equip.	482,805	
Total assets	2,488,500	
Liabilities:		
Current liabilities	550,200	
Long-term debt	700,869	
Stockholders' equity	979,801	
Net current assets	895,645	

LIVEPERSON INC

Earnings, 3 mos. to Mar 31 (Consol. – \$000):		
	2018	2017
Total Revenues	58,241	50,919
Cost & expenses	61,638	55,371
Operating income	(3,821)	(4,924)
Other income (expense), net	129	320
Net before taxes	(3,692)	(4,604)
Income taxes	(489)	1,072
Net income	(3,203)	(5,676)
Earnings common share		
Primary	\$(0.06)	\$(0.10)
Fully Diluted	\$(0.06)	\$(0.10)
Common Shares:		
Full Diluted	57,310	55,975
Year-end	60,538	58,421

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	57,480	57,480
Current assets	116,787	116,787
Net property & equip.	36,328	36,328
Total assets	249,060	249,060
Liabilities:		
Current liabilities	96,187	96,187
Stockholders' equity	146,117	146,117
Net current assets	20,600	20,600

LOXO ONCOLOGY, INC

Earnings, 3 mos. to Mar 31 (Consol. – \$000):		
	2018	2017
Cost & expenses	44,184	24,942
Operating income	(5,755)	(24,942)
Interest income	2,197	414
Net income	(3,558)	(24,528)
Earnings common share		
Primary	\$(0.12)	\$(0.96)
Fully Diluted	\$(0.12)	\$(0.96)
Common Shares:		
Full Diluted	30,025	25,668
Year-end	30,055	30,055

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	103,780	103,780
Current assets	720,649	720,649
Net property & equip.	1,578	1,578
Total assets	748,609	748,609
Liabilities:		
Current liabilities	204,499	204,499
Stockholders' equity	384,421	384,421
Net current assets	516,150	516,150

LSI INDUSTRIES INC.

Earnings, 9 mos. to Mar 31 (Consol. – \$000):		
	2018	2017
Net Sales	258,614	247,973
Cost & expenses	278,138	244,863
Operating income	(19,524)	3,110
Interest income	24	80
Interest expense	1,244	209
Net before taxes	(20,744)	2,981
Income taxes	(3,867)	677
Net income	(16,877)	2,304
Earnings common share		
Primary	\$(0.65)	\$0.09
Fully Diluted	\$(0.65)	\$0.09
Common Shares:		
Full Diluted	25,835	25,909
Year-end	25,624	25,375

LUMINEX CORP

Earnings, 3 mos. to Mar 31 (Consol. – \$000):		
	2018	2017
Total Revenues	82,662	77,779
Cost & expenses	65,230	61,411
Operating income	15,266	14,012
Other income (expense), net	449	(6)
Net before taxes	15,715	14,006
Income taxes	2,318	4,775
Net income	13,397	9,231
Balance for common	13,192	9,058
Earnings common share		
Primary	\$0.30	\$0.21
Fully Diluted	\$0.30	\$0.21
Common Shares:		

Full Diluted	43,633	42,989
Year-end	43,667	43,092
Consolidated Balance Sheet Items, as of (\$000):		
Assets:	2018	2017
Cash & equivalents	128,655	128,655
Inventories	52,248	52,248
Current assets	234,878	234,878
Net property & equip.	58,589	58,589
Total assets	500,513	500,513
Liabilities:		
Current liabilities	35,130	35,130
Stockholders' equity	457,006	457,006
Net current assets	199,748	199,748

MACROGENICS, INC

Earnings, 3 mos. to Mar 31 (Consol. – \$):		
	2018	2017
Total Revenues	4,695,000	2,055,000
Cost & expenses	54,905,000	40,263,000
Operating income	(50,210,000)	(38,208,000)
Other income (expense), net	674,000	553,000
Net income	(49,536,000)	(37,655,000)
Earnings common share		
Primary	\$(1.34)	\$(1.08)
Fully Diluted	\$(1.34)	\$(1.08)
Common Shares:		
Full Diluted	36,936,560	34,958,228
Year-end	37,024,623	34,980,433

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	200,448,000	200,448,000
Current assets	271,039,000	271,039,000
Net property & equip.	53,443,000	53,443,000
Total assets	326,078,000	326,078,000
Liabilities:		
Current liabilities	49,956,000	49,956,000
Stockholders' equity	247,276,000	247,276,000
Net current assets	221,083,000	221,083,000

MAMMOTH ENERGY SERVICES INC

Earnings, 3 mos. to Mar 31 (Consol. – \$):		
	2018	2017
Total Revenues	494,249,000	74,966,000
Cost & expenses	364,612,000	65,235,000
Operating income	102,729,000	(7,506,000)
Other income (expense), net	(28,000)	(184,000)
Net before taxes	101,464,000	(8,087,000)
Income taxes	45,918,000	(3,106,000)
Net income	55,546,000	(4,981,000)
Earnings common share		
Primary	\$1.24	\$(0.13)
Fully Diluted	\$1.24	\$(0.13)
Common Shares:		
Full Diluted	44,884,000	37,500,000
Year-end	44,714,296	44,714,296

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	10,447,000	10,447,000
Inventories	12,189,000	12,189,000
Current assets	326,029,000	326,029,000
Net property & equip.	365,757,000	365,757,000
Total assets	901,085,000	901,085,000
Liabilities:		
Current liabilities	258,928,000	258,928,000
Long-term debt	39,000,000	39,000,000
Stockholders' equity	564,137,000	564,137,000
Net current assets	67,101,000	67,101,000

MANNATECH INC

Earnings, 3 mos. to Mar 31 (Consol. – \$):		
	2018	2017
Net Sales	41,383,000	40,641,000
Cost & expenses	41,760,000	42,173,000
Deprec., depl. & amort.	511,000	502,000
Operating income	(888,000)	(2,034,000)
Other income (expense), net	288,000	41,000
Net before taxes	(571,000)	(1,964,000)
Income taxes	(307,000)	(717,000)
Net income	(264,000)	(1,247,000)
Earnings common share		
Primary	\$(0.10)	\$(0.46)
Fully Diluted	\$(0.10)	\$(0.46)
Common Shares:		

Full Diluted	2,719,000	2,701,000
Year-end	2,719,271	2,719,271
Consolidated Balance Sheet Items, as of (\$):		
Assets:	2018	2017
Cash & equivalents	37,936,000	37,936,000
Inventories	9,048,000	9,048,000
Current assets	56,642,000	56,642,000
Net property & equip.	3,199,000	3,199,000
Total assets	79,008,000	79,008,000
Liabilities:		
Current liabilities	34,626,000	34,626,000
Long-term debt	127,000	127,000
Stockholders' equity	40,252,000	40,252,000
Net current assets	22,016,000	22,016,000

MANTECH INTERNATIONAL CORP

Earnings, 3 mos. to Mar 31 (Consol. – \$000):		
	2018	2017
Total Revenues	473,236	418,374
Cost & expenses	446,815	393,984
Operating income	26,421	24,390
Other income (expense), net	4	39
Equity earnings	(40)	31
Net before taxes	25,706	24,159
Income taxes	5,679	9,100
Net income	20,067	15,028
Earnings common share		
Primary	\$0.51	\$0.39
Fully Diluted	\$0.51	\$0.39
Common Shares:		
Full Diluted	26,525	25,778
Year-end	39,522	38,794

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	10,382	10,382
Inventories	92	92
Current assets	424,014	424,014
Net property & equip.	50,288	50,288
Total assets	1,801,606	1,801,606
Liabilities:		
Current liabilities	233,833	233,833
Long-term debt	65,500	65,500
Stockholders' equity	1,358,099	1,358,099
Net current assets	190,181	190,181

MASIMO CORP.

Earnings, 3 mos. to Mar 31 (Consol. – \$000):		
	03/31/18	04/01/17
Total Revenues	212,953	196,643
Cost & expenses	159,068	144,492
Operating income	53,885	52,151
Other income (expense), net	1,647	874
Net before taxes	55,532	53,025
Income taxes	9,902	1,492
Net income	45,630	51,533
Earnings common share		
Primary	\$0.88	\$1.02
Fully Diluted	\$0.82	\$0.93
Common Shares:		
Full Diluted	55,496	55,529
Year-end	51,784	51,784
Consolidated Balance Sheet Items, as of (\$000):		
Assets:	2018	2017
Cash & equivalents	369,498	369,498
Inventories	91,062	91,062
Current assets	596,316	596,316
Net property & equip.	164,236	164,236
Total assets	949,559	949,559
Liabilities:		
Current liabilities	130,930	130,930
Stockholders' equity	766,511	766,511
Net current assets	465,386	465,386

MATCH GROUP INC

Earnings, 3 mos. to Mar 31 (Consol. – \$000):		
	2018	2017
Total Revenues	407,367	298,764
Cost & expenses	286,745	231,901
Operating income	112,233	58,871
Other income (expense), net	(7,221)	(5,978)
Net before taxes	87,206	33,943
Income taxes	(12,472)	9,388
Net income	99,678	20,064

Earnings common share		
Primary	\$0.36	\$0.08
Fully Diluted	\$0.33	\$0.07
Common Shares:		
Full Diluted	298,140	291,902
Year-end	276,583	256,642

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	287,510	
Current assets	479,720	
Net property & equip.	58,604	
Total assets	2,201,563	
Liabilities:		
Current liabilities	353,035	
Long-term debt	1,253,442	
Stockholders' equity	538,305	
Net current assets	126,685	

MATRIX SERVICE CO.**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	791,833	904,345
Operating income	6,633	1,328
Interest income	234	111
Interest expense	2,080	1,573
Other income (expense), net	384	3
Net before taxes	5,171	(131)
Income taxes	1,968	(1,223)
Net income	3,203	1,092
Earnings common share		
Primary	\$0.12	\$0.03
Fully Diluted	\$0.12	\$0.03
Common Shares:		
Full Diluted	27,054	26,838
Year-end	27,888	26,594

MATTERSIGHT CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	13,714	10,959
Cost & expenses	14,278	13,505
Operating income	(1,991)	(4,091)
Other income (expense), net	111	107
Net before taxes	(2,146)	(4,953)
Income taxes	(15)	(1)
Net income	(2,131)	(4,952)
Balance for common	(2,277)	(5,098)
Earnings common share		
Primary	\$(0.07)	\$(0.19)
Fully Diluted	\$(0.07)	\$(0.19)
Common Shares:		
Full Diluted	31,747	27,423
Year-end	33,220	32,460

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	8,681	
Current assets	23,705	
Net property & equip.	7,499	
Total assets	40,975	
Liabilities:		
Current liabilities	19,553	
Long-term debt	13,896	
Stockholders' equity	(8,510)	
Net current assets	4,152	

MEDICINES CO (THE)**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	7,771,000	17,465,000
Cost & expenses	72,054,000	76,879,000
Operating income	(64,283,000)	(59,414,000)
Interest expense	12,077,000	12,422,000
Other income (expense), net	2,597,000	868,000
Gains or losses	(29,989,000)	
Net before taxes	(103,752,000)	(70,968,000)
Income taxes	(18,916,000)	28,000
Income contin. oper.	(84,836,000)	(70,996,000)
Income discont. oper.	113,985,000	(31,674,000)
Net income	29,149,000	102,670,000
Earnings common share		
Primary	\$0.39	\$(1.44)
Fully Diluted	\$0.39	\$(1.44)
Common Shares:		
Full Diluted	73,802,000	71,073,000

Year-end 73,548,643

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	215,962,000	
Inventories	4,757,000	
Current assets	283,071,000	
Net property & equip.	16,533,000	
Total assets	861,174,000	
Liabilities:		
Current liabilities	110,453,000	
Long-term debt	655,943,000	
Stockholders' equity	67,656,000	
Net current assets	172,618,000	

MEDIDATA SOLUTIONS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	149,198	127,644
Cost & expenses	135,872	114,765
Operating income	13,326	12,879
Interest income	2,088	1,171
Interest expense	5,575	4,327
Other income (expense), net	(96)	
Net before taxes	9,743	9,723
Income taxes	(582)	(257)
Net income	10,325	9,980
Earnings common share		
Primary	\$0.18	\$0.18
Fully Diluted	\$0.17	\$0.17
Common Shares:		
Full Diluted	60,098	58,083
Year-end	59,189	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	226,588	
Current assets	707,528	
Net property & equip.	92,905	
Total assets	1,075,981	
Liabilities:		
Current liabilities	434,478	
Long-term debt	93,052	
Stockholders' equity	522,203	
Net current assets	273,050	

MELINTA THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	14,841,000	4,872,000
Cost & expenses	58,439,000	27,728,000
Operating income	(43,598,000)	(22,856,000)
Interest income	210,000	211,000
Interest expense	10,196,000	243,000
Other income (expense), net	24,152,000	
Net income	(29,432,000)	(22,888,000)
Balance for common	(29,432,000)	
Earnings common share		
Primary	\$(0.95)	\$(2.20)
Fully Diluted	\$(0.95)	\$(2.20)
Common Shares:		
Full Diluted	30,917,700	10,480,782
Year-end	31,353,254	10,489,642

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	91,479,000	
Inventories	28,220,000	
Current assets	149,911,000	
Net property & equip.	2,276,000	
Total assets	448,749,000	
Liabilities:		
Current liabilities	101,093,000	
Long-term debt	106,090,000	
Stockholders' equity	199,833,000	
Net current assets	48,818,000	

MERCURY SYSTEMS INC**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2017	2016
Total Revenues	292,980	184,724
Cost & expenses	254,363	163,300
Operating income	24,395	16,319
Interest income	187	89
Interest expense	5,613	10
Other income (expense), net	792	298

Net before taxes	19,761	16,696
Income taxes	3,690	4,443
Net income	16,071	12,253

Earnings common share

Primary	\$0.40	\$0.37
Fully Diluted	\$0.39	\$0.36
Common Shares:		
Full Diluted	41,530	33,830
Year-end	46,159	

MERIDIAN BIOSCIENCE INC.**Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	108,734,000	100,934,000
Cost & expenses	92,995,000	76,663,000
Operating income	15,739,000	24,271,000
Interest income	162,000	51,000
Other income (expense), net	(245,000)	358,000
Net before taxes	14,882,000	23,849,000
Income taxes	3,292,000	8,258,000
Net income	11,590,000	15,591,000
Earnings common share		
Primary	\$0.27	\$0.37
Fully Diluted	\$0.27	\$0.37
Common Shares:		
Full Diluted	42,693,000	42,539,000
Year-end	42,344,042	42,202,397

MERRIMACK PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	17,376	27,239
Operating income	(17,376)	(27,239)
Interest income	275	14
Interest expense		1,979
Other income (expense), net	(681)	(2)
Income contin. oper.		(29,206)
Net income	(17,782)	(30,153)
Earnings common share		
Primary	\$(1.33)	\$(2.27)
Fully Diluted	\$(1.33)	\$(2.27)
Common Shares:		
Full Diluted	13,343	13,059
Year-end	13,343	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	34,268	
Current assets	77,110	
Net property & equip.	5,358	
Total assets	97,495	
Liabilities:		
Current liabilities	17,534	
Stockholders' equity	79,254	
Net current assets	59,576	

MGE ENERGY INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	157,632	156,823
Cost & expenses	117,821	112,028
Operating income	26,188	31,836
Interest expense	4,739	4,894
Other income (expense), net	4,919	3,525
Net before taxes	26,368	30,467
Income taxes	6,367	11,167
Net income	20,001	19,300
Earnings common share		
Primary	\$0.58	\$0.56
Fully Diluted	\$0.58	\$0.56
Common Shares:		
Full Diluted	34,668	34,668
Year-end	34,668	34,668

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	101,157	
Inventories	36,718	
Current assets	248,740	
Net property & equip.	1,366,214	
Total assets	1,843,578	
Liabilities:		
Current liabilities	106,230	
Long-term debt	397,133	
Stockholders' equity	787,007	
Net current assets	142,510	

MIDDLEBY CORP

Acquisition Development On May 18, 2018, Co. announced that it has entered into a definitive agreement to acquire the Taylor Company from UTC Climate, Controls & Security, a world leader in beverage solutions, soft serve and ice cream dispensing equipment, frozen drink machines, and automated double-sided grills, a unit of United Technologies Corp. for \$1,000,000,000. Co. will finance the all-cash acquisition under its existing revolving credit facility. The transaction has been structured to provide Co. with a tax step-up with a net present value of approximately \$150,000,000. The transaction completion is subject to customary closing conditions, including regulatory approvals, with an expected closing early in the third quarter of 2018.

MIDDLEBY CORP**Earnings, 3 mos. to (Consol. – \$000):**

	03/31/18	04/01/17
Net Sales	584,800	530,297
Cost & expenses	497,808	437,556
Operating income	86,992	92,741
Other income (expense), net	8,532	6,471
Net before taxes	86,701	93,407
Income taxes	21,281	22,705
Net income	65,420	70,702
Earnings common share		
Primary	\$1.18	\$1.24
Fully Diluted	\$1.18	\$1.24
Common Shares:		
Full Diluted	55,573	57,103
Year-end	55,710	57,532

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	103,290	103,290
Inventories	459,151	459,151
Current assets	959,655	959,655
Net property & equip.	296,473	296,473
Total assets	3,426,894	3,426,894
Liabilities:		
Current liabilities	455,611	455,611
Long-term debt	1,043,885	1,043,885
Stockholders' equity	1,440,658	1,440,658
Net current assets	504,044	504,044

MISONIX, INC.**Earnings, 9 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	28,043,700	19,379,768
Cost & expenses	29,150,173	23,929,971
Operating income	(1,106,473)	(4,550,203)
Other income (expense), net	509,964	2,830,775
Net before taxes	(587,378)	(1,719,372)
Income taxes	5,243,422	(275,000)
Income contin. oper.	(1,444,372)	(1,444,372)
Income discount. oper.	161,861	161,861
Net income	(5,830,800)	(1,282,511)
Earnings common share		
Primary	\$(0.65)	\$(0.16)
Fully Diluted	\$(0.65)	\$(0.16)
Common Shares:		
Full Diluted	8,999,938	8,263,343
Year-end	9,402,466	9,023,354

MKS INSTRUMENTS INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	554,275,000	437,153,000
Cost & expenses	411,446,000	341,072,000
Operating income	131,639,000	83,580,000
Interest income	1,105,000	516,000
Interest expense	5,430,000	8,832,000
Other income (expense), net	(572,000)	2,021,000
Net before taxes	126,742,000	77,285,000
Income taxes	21,621,000	12,225,000
Net income	105,121,000	65,060,000
Earnings common share		
Primary	\$1.93	\$1.21
Fully Diluted	\$1.90	\$1.18
Common Shares:		
Full Diluted	55,286,000	54,958,000
Year-end	54,492,103	53,886,862

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	340,888,000	340,888,000
Inventories	365,709,000	365,709,000

Current assets	1,308,022,000	1,308,022,000
Net property & equip.	172,802,000	172,802,000
Total assets	2,481,456,000	2,481,456,000
Liabilities:		
Current liabilities	291,025,000	291,025,000
Long-term debt	341,290,000	341,290,000
Stockholders' equity	1,698,340,000	1,698,340,000
Net current assets	1,016,997,000	1,016,997,000

MOBILEIRON INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	43,689	42,109
Cost & expenses	60,215	55,457
Operating income	(16,526)	(13,348)
Other income (expense), net	503	174
Net before taxes	(16,023)	(13,174)
Income taxes	347	199
Net income	(16,370)	(13,373)
Earnings common share		
Primary	\$(0.17)	\$(0.15)
Fully Diluted	\$(0.17)	\$(0.15)
Common Shares:		
Full Diluted	98,645	90,439
Year-end	100,608	100,608

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	96,311	96,311
Current assets	150,215	150,215
Net property & equip.	8,205	8,205
Total assets	175,654	175,654
Liabilities:		
Current liabilities	92,124	92,124
Stockholders' equity	58,380	58,380
Net current assets	58,091	58,091

MOMENTA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	4,852,000	26,614,000
Cost & expenses	53,854,000	59,206,000
Operating income	(49,002,000)	(32,592,000)
Other income (expense), net	1,371,000	833,000
Net income	(47,631,000)	(31,759,000)
Earnings common share		
Primary	\$(0.63)	\$(0.46)
Fully Diluted	\$(0.63)	\$(0.46)
Common Shares:		
Full Diluted	75,454,000	69,711,000
Year-end	77,100,000	72,833,000

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	88,226,000	88,226,000
Current assets	338,301,000	338,301,000
Net property & equip.	31,506,000	31,506,000
Total assets	416,944,000	416,944,000
Liabilities:		
Current liabilities	34,512,000	34,512,000
Stockholders' equity	334,417,000	334,417,000
Net current assets	303,789,000	303,789,000

MONARCH CASINO & RESORT, INC.**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	56,268,000	53,414,000
Cost & expenses	44,019,000	41,782,000
Operating income	8,557,000	7,726,000
Interest expense	80,000	272,000
Net before taxes	8,477,000	7,454,000
Income taxes	1,736,000	2,582,000
Net income	6,741,000	4,872,000
Earnings common share		
Primary	\$0.38	\$0.28
Fully Diluted	\$0.36	\$0.27
Common Shares:		
Full Diluted	18,710,000	18,021,000
Year-end	17,792,384	17,504,633

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	29,368,000	29,368,000
Inventories	3,244,000	3,244,000
Current assets	42,971,000	42,971,000
Net property & equip.	265,518,000	265,518,000

Total assets	343,405,000	343,405,000
Liabilities:		
Current liabilities	47,732,000	47,732,000
Long-term debt	26,200,000	26,200,000
Stockholders' equity	269,473,000	269,473,000
Net current assets	(4,761,000)	(4,761,000)

MONEYGRAM INTERNATIONAL INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	380,000	386,100
Cost & expenses	356,200	344,400
Operating income	5,700	23,400
Other income (expense), net	28,500	(1,300)
Net before taxes	21,900	11,300
Income taxes	14,800	2,500
Net income	7,100	8,800
Earnings common share		
Primary	\$0.11	\$0.14
Fully Diluted	\$0.11	\$0.13
Common Shares:		
Full Diluted	66,200	66,100
Year-end	55,528	53,967

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	199,700	199,700
Current assets	199,700	199,700
Net property & equip.	206,300	206,300
Total assets	4,509,200	4,509,200
Liabilities:		
Current liabilities	3,741,300	3,741,300
Long-term debt	906,300	906,300
Stockholders' equity	(232,700)	(232,700)
Net current assets	(3,541,600)	(3,541,600)

MONOLITHIC POWER SYSTEMS INC**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	129,150,000	100,362,000
Cost & expenses	107,113,000	86,792,000
Operating income	22,037,000	13,570,000
Interest income	1,460,000	1,264,000
Other income (expense), net	(435,000)	(507,000)
Gains or losses	(186,000)	733,000
Foreign currency	(399,000)	(109,000)
Net before taxes	22,477,000	14,951,000
Income taxes	621,000	474,000
Net income	21,856,000	14,477,000
Earnings common share		
Primary	\$0.52	\$0.35
Fully Diluted	\$0.49	\$0.33
Common Shares:		
Full Diluted	44,282,000	43,268,000
Year-end	42,145,000	41,239,000

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	76,016,000	76,016,000
Inventories	111,897,000	111,897,000
Current assets	484,104,000	484,104,000
Net property & equip.	153,770,000	153,770,000
Total assets	697,767,000	697,767,000
Liabilities:		
Current liabilities	73,301,000	73,301,000
Stockholders' equity	558,306,000	558,306,000
Net current assets	410,803,000	410,803,000

MONROE CAPITAL CORP**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Cost & expenses	6,485	5,972
Net income	8,465	6,034
Earnings common share		
Primary	\$0.42	\$0.36
Fully Diluted	\$0.42	\$0.36
Common Shares:		
Full Diluted	20,240	16,594
Year-end	20,240	16,712

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	3,070	3,070
Current assets	15,943	15,943
Total assets	512,704	512,704
Liabilities:		

Current liabilities	5,783
Long-term debt	233,916
Stockholders' equity	273,005
Net current assets	10,160

MTS SYSTEMS CORP**Earnings, 6 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Total Revenues	385,485	392,703
Cost & expenses	352,378	367,001
Operating income	33,107	25,702
Interest expense	13,512	14,698
Other income (expense), net	51	(163)
Net before taxes	19,646	10,841
Income taxes	(21,943)	1,937
Net income	41,589	8,904
Earnings common share		
Primary	\$2.17	\$0.47
Fully Diluted	\$2.16	\$0.47
Common Shares:		
Full Diluted	19,258	19,095
Year-end	17,792	16,724

MYOKARDIA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	5,331	2,410
Cost & expenses	23,931	17,393
Operating income	(18,600)	(14,983)
Net income	(17,820)	(14,762)
Balance for common	(17,820)	(14,762)
Earnings common share		
Primary	\$(0.50)	\$(0.47)
Fully Diluted	\$(0.50)	\$(0.47)
Common Shares:		
Full Diluted	35,827	31,089
Year-end	35,923	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	183,865
Current assets	226,007
Net property & equip.	4,030
Total assets	266,172
Liabilities:	
Current liabilities	48,848
Stockholders' equity	217,173
Net current assets	177,159

NATERA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	62,340	49,382
Cost & expenses	92,857	83,932
Operating income	(30,517)	(34,550)
Other income (expense), net	137	1,300
Net before taxes	(32,769)	(33,433)
Income taxes	104	47
Net income	(32,873)	(33,480)
Earnings common share		
Primary	\$(0.61)	\$(0.63)
Fully Diluted	\$(0.61)	\$(0.65)
Common Shares:		
Full Diluted	54,132	53,043
Year-end	54,251	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	33,674
Inventories	11,911
Current assets	187,523
Net property & equip.	26,878
Total assets	218,655
Liabilities:	
Current liabilities	104,383
Long-term debt	82,686
Stockholders' equity	(3,876)
Net current assets	83,140

NATIONAL CINEMEDIA INC**Earnings, 3 mos. to (Consol. - \$000):**

	03/29/18	03/30/17
Total Revenues	80,200	71,900
Cost & expenses	59,700	57,200
Deprec., depl. & amort.	9,500	9,600
Operating income	11,000	5,100

Interest income	200	400
Other income (expense), net	100	100
Net before taxes	(2,500)	(7,600)
Income taxes	1,000	(1,800)
Net income	(3,500)	(5,800)

Earnings common share

Primary	\$(0.03)	\$(0.02)
Fully Diluted	\$(0.03)	\$(0.02)
Common Shares:		
Full Diluted	76,640	60,309
Year-end	76,904	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	46,000
Current assets	192,600
Net property & equip.	31,500
Total assets	1,157,700
Liabilities:	
Current liabilities	79,400
Long-term debt	944,800
Stockholders' equity	(374,100)
Net current assets	113,200

NATIONAL GENERAL HOLDINGS CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,045,035	1,060,267
Cost & expenses	72,222	41,587
Operating income	72,222	41,587
Net before taxes	16,202	10,789
Income taxes	56,020	30,798
Net income	60,333	29,048
Balance for common		
Earnings common share		
Primary	\$0.57	\$0.27
Fully Diluted	\$0.55	\$0.27
Common Shares:		
Full Diluted	108,951	109,167
Year-end	106,888	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	378,053
Current assets	4,036,080
Net property & equip.	316,392
Total assets	8,669,146
Liabilities:	
Current liabilities	848,618
Long-term debt	713,893
Stockholders' equity	1,957,089
Net current assets	3,187,462

NATIONAL RESEARCH CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	31,017,000	30,276,000
Cost & expenses	20,776,000	19,186,000
Operating income	8,958,000	9,984,000
Other income (expense), net	(28,000)	9,000
Net before taxes	8,967,000	9,980,000
Income taxes	1,661,000	3,459,000
Net income	7,306,000	6,521,000
Earnings common share		
Primary	\$0.17	\$0.15
Fully Diluted	\$0.17	\$0.15
Common Shares:		
Full Diluted	21,837,000	21,245,000
Year-end	24,528,942	24,460,033

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	35,478,000
Current assets	52,278,000
Net property & equip.	12,456,000
Total assets	130,976,000
Liabilities:	
Current liabilities	29,484,000
Stockholders' equity	95,364,000
Net current assets	22,794,000

NATUS MEDICAL INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	128,609	124,660
Cost & expenses	126,531	119,183
Operating income	(2,728)	1,403

Interest income	10	332
Interest expense	1,960	980
Other income (expense), net	(475)	37
Foreign currency	604	(428)
Net before taxes	(4,549)	364
Income taxes	(1,401)	16
Net income	(3,148)	348

Earnings common share

Primary	\$(0.10)	\$0.01
Fully Diluted	\$(0.10)	\$0.01
Common Shares:		
Full Diluted	32,760	33,040
Year-end	33,272	33,079

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	64,471
Inventories	74,543
Current assets	290,933
Net property & equip.	22,618
Total assets	682,918
Liabilities:	
Current liabilities	95,069
Long-term debt	129,331
Stockholders' equity	416,830
Net current assets	195,864

NEOS THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	23,247	20,719
Cost & expenses	(12,518)	(15,088)
Operating income	2,220	2,211
Interest expense	302	78
Other income (expense), net		
Net income	(14,436)	(17,221)
Earnings common share		
Primary	\$(0.50)	\$(0.88)
Fully Diluted	\$(0.50)	\$(0.88)
Common Shares:		
Full Diluted	28,997	19,625
Year-end	28,997	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	24,777
Inventories	13,399
Current assets	73,103
Net property & equip.	8,173
Total assets	97,356
Liabilities:	
Current liabilities	40,190
Long-term debt	58,973
Stockholders' equity	(4,519)
Net current assets	32,913

NETGEAR INC**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	04/02/17
Total Revenues	344,973	323,657
Cost & expenses	336,486	300,868
Operating income	8,487	22,789
Interest income	748	405
Other income (expense), net	(1,252)	335
Net before taxes	7,983	23,529
Income taxes	2,393	7,535
Net income	5,590	15,994
Earnings common share		
Primary	\$0.18	\$0.49
Fully Diluted	\$0.17	\$0.47
Common Shares:		
Full Diluted	32,660	34,136
Year-end	31,551	32,454

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	258,795
Inventories	266,345
Current assets	999,533
Net property & equip.	19,779
Total assets	1,213,177
Liabilities:	
Current liabilities	402,156
Stockholders' equity	755,719
Net current assets	597,377

NII HOLDINGS INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	181,013	250,955
Cost & expenses	187,050	317,779
Operating income	(14,461)	(79,849)
Interest income	5,386	9,136
Interest expense	26,606	31,562
Other income (expense), net	(6,330)	(1,775)
Foreign currency	(1,188)	11,375
Income contin. oper.	(43,199)	(92,675)
Net income	(43,320)	(92,713)
Earnings common share		
Primary	\$(0.43)	\$(0.92)
Fully Diluted	\$(0.43)	\$(0.92)
Common Shares:		
Full Diluted	100,385	100,259
Year-end	100,385	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	246,335	246,335
Inventories	5,028	5,028
Current assets	538,038	538,038
Net property & equip.	119,845	119,845
Total assets	1,121,498	1,121,498
Liabilities:		
Current liabilities	366,340	366,340
Long-term debt	639,620	639,620
Stockholders' equity	(38,705)	(38,705)
Net current assets	171,698	171,698

NORTHFIELD BANCORP INC (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	24,298	23,308
Operating income	12,789	12,908
Net before taxes	12,789	12,908
Income taxes	2,344	2,960
Net income	10,445	9,948
Earnings common share		
Primary	\$0.23	\$0.22
Fully Diluted	\$0.22	\$0.21
Common Shares:		
Full Diluted	47,000	46,926
Year-end	49,127	48,844

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	52,574	52,574
Current assets	88,132	88,132
Net property & equip.	25,285	25,285
Total assets	4,069,209	4,069,209
Liabilities:		
Current liabilities	2,905,076	2,905,076
Long-term debt	456,272	456,272
Stockholders' equity	642,818	642,818
Net current assets	(2,816,944)	(2,816,944)

OCLARO INC**Earnings, 9 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Cost & expenses	363,351	361,872
Operating income	58,415	89,081
Other income (expense), net	2,416	583
Foreign currency	4,195	(3,155)
Net before taxes	65,836	72,896
Income taxes	9,803	1,064
Net income	56,033	71,832
Earnings common share		
Primary	\$0.33	\$0.46
Fully Diluted	\$0.33	\$0.44
Common Shares:		
Full Diluted	171,338	163,237
Year-end	170,211	167,281

OFFICE DEPOT, INC.**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Net Sales	2,830,000	2,676,000
Cost & expenses	2,753,000	2,552,000
Operating income	77,000	124,000
Interest income	6,000	6,000
Interest expense	29,000	13,000
Other income (expense), net	1,000	400
Net before taxes	55,000	121,000
Income taxes	22,000	47,000
Income contin. oper.	33,000	74,000

Income discont. oper.	8,000	42,000
Net income	41,000	116,000
Earnings common share		
Primary	\$0.07	\$0.22
Fully Diluted	\$0.07	\$0.22
Common Shares:		
Full Diluted	563,000	532,000
Year-end	557,847	516,640

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	737,000	737,000
Inventories	1,033,000	1,033,000
Current assets	2,928,000	2,928,000
Net property & equip.	713,000	713,000
Total assets	6,390,000	6,390,000
Liabilities:		
Current liabilities	2,106,000	2,106,000
Long-term debt	1,688,000	1,688,000
Stockholders' equity	2,157,000	2,157,000
Net current assets	822,000	822,000

OMEGA FLEX INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	25,397	25,607
Cost & expenses	19,897	19,403
Operating income	5,500	6,204
Other income (expense), net	36	(40)
Net before taxes	5,587	6,188
Income taxes	1,384	2,005
Net income	4,203	4,183
Earnings common share		
Primary	\$0.41	\$0.41
Fully Diluted	\$0.41	\$0.41
Common Shares:		
Full Diluted	10,092	10,092
Year-end	10,092	10,092

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	35,579	35,579
Inventories	7,998	7,998
Current assets	60,352	60,352
Net property & equip.	7,274	7,274
Total assets	74,236	74,236
Liabilities:		
Current liabilities	11,187	11,187
Stockholders' equity	60,028	60,028
Net current assets	49,165	49,165

OMNICELL INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	182,619	148,553
Cost & expenses	181,986	165,105
Operating income	633	(16,552)
Net before taxes	(2,096)	(19,008)
Income taxes	(4,816)	(8,673)
Net income	2,720	(10,335)
Earnings common share		
Primary	\$0.07	\$(0.28)
Fully Diluted	\$0.07	\$(0.28)
Common Shares:		
Full Diluted	39,691	36,840
Year-end	38,860	37,127

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	43,773	43,773
Inventories	101,868	101,868
Current assets	372,231	372,231
Net property & equip.	48,290	48,290
Total assets	1,040,955	1,040,955
Liabilities:		
Current liabilities	221,427	221,427
Long-term debt	190,490	190,490
Stockholders' equity	574,502	574,502
Net current assets	150,804	150,804

OPKO HEALTH INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	254,914	266,382
Cost & expenses	280,254	293,668
Operating income	(42,611)	(45,215)

Interest income	39	249
Interest expense	2,267	1,429
Other income (expense), net	3,289	7,079
Equity earnings	2,456	2,131
Net before taxes	(41,550)	(39,316)
Income taxes	(892)	(6,944)
Net income	(43,114)	(34,503)
Earnings common share		
Primary	\$(0.08)	\$(0.06)
Fully Diluted	\$(0.08)	\$(0.06)
Common Shares:		
Full Diluted	559,474	558,434
Year-end	559,474	559,011

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	99,943	99,943
Inventories	49,815	49,815
Current assets	349,346	349,346
Net property & equip.	148,718	148,718
Total assets	2,578,894	2,578,894
Liabilities:		
Current liabilities	318,077	318,077
Long-term debt	169,064	169,064
Stockholders' equity	1,823,264	1,823,264
Net current assets	31,269	31,269

ORASURE TECHNOLOGIES INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	41,987,000	32,546,000
Cost & expenses	42,485,000	16,675,000
Operating income	(498,000)	15,871,000
Other income (expense), net	412,000	467,000
Net before taxes	(86,000)	16,338,000
Income taxes	2,033,000	3,897,000
Net income	(2,119,000)	12,441,000
Earnings common share		
Primary	\$(0.03)	\$0.22
Fully Diluted	\$(0.03)	\$0.21
Common Shares:		
Full Diluted	60,865,000	58,772,000
Year-end	61,053,000	57,664,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	64,042,000	64,042,000
Inventories	20,907,000	20,907,000
Current assets	196,754,000	196,754,000
Net property & equip.	22,975,000	22,975,000
Total assets	285,923,000	285,923,000
Liabilities:		
Current liabilities	21,186,000	21,186,000
Stockholders' equity	258,718,000	258,718,000
Net current assets	175,568,000	175,568,000

OSI SYSTEMS, INC. (DE)**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	801,960	708,549
Cost & expenses	756,676	678,063
Operating income	45,284	30,486
Other income (expense), net	161	2,088
Net before taxes	31,128	26,858
Income taxes	65,369	7,329
Net income	(34,241)	19,529
Earnings common share		
Primary	\$(1.82)	\$1.03
Fully Diluted	\$(1.82)	\$1.00
Common Shares:		
Full Diluted	18,773	19,585
Year-end	18,065	18,676

OVERSTOCK.COM INC (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	445,331	432,435
Cost & expenses	499,725	434,748
Operating income	(54,394)	(2,313)
Interest income	544	125
Interest expense	874	710
Other income (expense), net	(9)	(3,724)
Net before taxes	(54,733)	(6,622)
Income taxes	(277)	(340)
Net income	(54,456)	(6,282)
Balance for common	(50,909)	(5,903)

Earnings common share		
Primary	\$(1.74)	\$(0.23)
Fully Diluted	\$(1.74)	\$(0.23)
Common Shares:		
Full Diluted	28,566	25,290
Year-end	28,866	24,963

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	259,569	
Inventories	12,471	
Current assets	317,234	
Net property & equip.	126,765	
Total assets	526,274	
Liabilities:		
Current liabilities	223,665	
Long-term debt	39,977	
Stockholders' equity	179,861	
Net current assets	93,569	

PAPA JOHN'S INTERNATIONAL, INC.**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	03/26/17
Total Revenues	427,369	449,266
Cost & expenses	388,513	395,128
Operating income	27,317	43,681
Net before taxes	22,362	41,871
Income taxes	4,982	11,972
Net income	17,380	29,899

Earnings common share

Primary	\$0.50	\$0.78
Fully Diluted	\$0.50	\$0.77
Common Shares:		
Full Diluted	33,552	37,350
Year-end	32,023	36,654

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	31,935	
Inventories	28,285	
Current assets	179,250	
Net property & equip.	229,576	
Total assets	579,817	
Liabilities:		
Current liabilities	156,456	
Long-term debt	568,770	
Stockholders' equity	(265,493)	
Net current assets	22,794	

PATRICK INDUSTRIES INC

Co. Repurchasing Certain Securities On May 18, 2018, Co. announced that its Board of Directors (the "Board") approved an increase in the amount of Co.'s common stock that may be acquired over the next 24 months under Co.'s current stock repurchase program to \$50,000,000, including the amount remaining under the previous authorization. As previously announced in Jan. 2018, the Board authorized repurchases of up to \$50,000,000 over a 24-month period (the "2018 Repurchase Plan"). Year-to-date through May 17, 2018, Co. has repurchased, in the aggregate, 747,995 shares at an average price of \$57.63 per share for a total cost of approximately \$43,100,000 under the 2018 Repurchase Plan. Share repurchases will be made from time to time through open market transactions at prevailing market prices, or in privately negotiated transactions or otherwise.

PATRICK INDUSTRIES INC**Earnings, 3 mos. to (Consol. - \$):**

	04/01/18	03/26/17
Net Sales	551,832,000	345,427,000
Cost & expenses	502,947,000	317,327,000
Operating income	41,758,000	23,915,000
Interest expense	4,378,000	2,014,000
Net before taxes	37,380,000	21,901,000
Net income	30,068,000	17,467,000
Earnings common share		
Primary	\$1.22	\$0.76
Fully Diluted	\$1.20	\$0.75
Common Shares:		
Full Diluted	25,110,000	23,324,000
Year-end	24,775,903	25,146,054

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	71,000	
Inventories	205,902,000	
Current assets	360,697,000	
Net property & equip.	129,022,000	

Total assets	1,029,545,000
Liabilities:	
Current liabilities	179,440,000
Long-term debt	413,146,000
Stockholders' equity	405,778,000
Net current assets	181,257,000

PAYLOCITY HOLDING CORP**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	280,911	223,949
Cost & expenses	259,798	213,219
Operating income	21,113	10,730
Other income (expense), net	465	(4)
Net before taxes	21,578	10,726
Income taxes	(18,573)	164
Net income	40,151	10,562
Earnings common share		
Primary	\$0.77	\$0.21
Fully Diluted	\$0.73	\$0.20
Common Shares:		
Full Diluted	54,717	53,987
Year-end	51,738	51,489

PAYPAL HOLDINGS INC

Acquisition Development On May 18, 2018, Co. announced that it has agreed to buy Swedish financial technology startup iZettle AB for \$2,200,000,000.

PEGASYSYSTEMS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	235,182	256,309
Cost & expenses	227,246	190,402
Operating income	7,936	65,907
Other income (expense), net	363	(279)
Foreign currency	(1,085)	745
Net before taxes	7,978	66,578
Income taxes	(4,222)	13,615
Net income	12,200	52,963
Earnings common share		
Primary	\$0.16	\$0.69
Fully Diluted	\$0.15	\$0.65
Common Shares:		
Full Diluted	83,102	81,875
Year-end	78,546	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	254,837	
Current assets	624,167	
Total assets	1,005,955	
Liabilities:		
Current liabilities	280,132	
Stockholders' equity	662,123	
Net current assets	344,035	

PENN NATIONAL GAMING INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	816,085	776,224
Cost & expenses	583,561	565,701
Deprec., depl. & amort.	60,390	70,236
Operating income	172,134	140,287
Interest income	249	2,646
Interest expense	115,740	114,996
Other income (expense), net	4,483	(20,635)
Net before taxes	61,126	7,302
Income taxes	15,689	2,198
Net income	45,437	5,104
Balance for common	45,437	5,104
Earnings common share		
Primary	\$0.50	\$0.06
Fully Diluted	\$0.48	\$0.06
Common Shares:		
Full Diluted	94,650	91,917
Year-end	91,655	90,959

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	217,997	
Current assets	334,683	
Net property & equip.	2,710,652	
Total assets	5,165,533	
Liabilities:		
Current liabilities	475,319	
Long-term debt	4,640,932	

Stockholders' equity	(33,639)
Net current assets	(140,636)

PEPSICO INC

Acquisition Development On May 25, 2018, Co. announced that it has entered into a definitive agreement to acquire Bare Foods Co. (doing business as Bare Snacks), a U.S.-based maker of baked fruit and vegetable snacks. Terms of the transaction were not disclosed.

PERCEPTRON, INC.**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	61,099	55,596
Cost & expenses	58,006	54,820
Operating income	3,093	776
Other income (expense), net	49	28
Foreign currency	(16)	(226)
Net before taxes	2,989	366
Income taxes	45	795
Net income	2,944	(429)
Earnings common share		
Primary	\$0.31	\$(0.05)
Fully Diluted	\$0.31	\$(0.05)
Common Shares:		
Full Diluted	9,542	9,384
Year-end	9,552	9,420

PETIQ INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	115,066	67,029
Cost & expenses	118,151	62,234
Operating income	(3,085)	4,795
Interest expense	1,765	464
Other income (expense), net	(96)	(3)
Gains or losses	(78)	(49)
Net before taxes	(5,024)	
Income taxes	(1,067)	
Net income	(3,957)	4,279

Earnings common share

Primary	\$(0.14)	\$
Fully Diluted	\$(0.14)	\$
Common Shares:		
Full Diluted	14,575	
Year-end	24,534	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	4,714	
Inventories	79,239	
Current assets	148,519	
Net property & equip.	25,275	
Total assets	402,402	
Liabilities:		
Current liabilities	63,304	
Long-term debt	138,547	
Stockholders' equity	131,817	
Net current assets	85,215	

PHIBRO ANIMAL HEALTH CORP.**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	608,196	569,446
Cost & expenses	535,379	495,031
Operating income	72,817	74,415
Interest expense	10,043	13,198
Foreign currency	958	617
Net before taxes	64,543	63,324
Income taxes	21,779	14,087
Net income	42,764	49,237
Earnings common share		
Primary	\$1.07	\$1.25
Fully Diluted	\$1.06	\$1.23
Common Shares:		
Full Diluted	40,348	39,988
Year-end	40,323	39,626

PILGRIMS PRIDE CORP.**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	03/26/17
Net Sales	2,746,678	2,479,340
Cost & expenses	2,545,085	2,312,616
Operating income	201,593	166,724
Interest income	1,590	368
Other income (expense), net	1,617	2,843

Foreign currency	1,721	(691)
Net before taxes	156,221	150,132
Income taxes	36,997	49,394
Net income	119,224	100,738
Earnings common share		
Primary	\$0.48	\$0.38
Fully Diluted	\$0.48	\$0.38
Common Shares:		
Full Diluted	248,989	248,926
Year-end	248,980	261,752

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	580,811	
Inventories	1,242,352	
Current assets	2,592,561	
Net property & equip.	2,121,630	
Total assets	6,397,635	
Liabilities:		
Current liabilities	1,441,096	
Long-term debt	2,625,698	
Stockholders' equity	2,024,456	
Net current assets	1,151,465	

PINNACLE ENTERTAINMENT INC (NEW)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	628,395	639,974
Cost & expenses	463,019	472,945
Deprec., depl. & amort.	50,039	56,018
Operating income	115,337	111,011
Interest income	200	200
Net before taxes	22,984	16,903
Income taxes	1,190	(305)
Net income	21,794	17,208
Earnings common share		
Primary	\$0.39	\$0.31
Fully Diluted	\$0.35	\$0.28
Common Shares:		
Full Diluted	62,245	60,884
Year-end	50,780	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	152,416	
Inventories	10,409	
Current assets	237,717	
Net property & equip.	2,596,300	
Total assets	3,884,756	
Liabilities:		
Current liabilities	267,678	
Long-term debt	3,881,323	
Stockholders' equity	(310,400)	
Net current assets	(29,961)	

PLEXUS CORP.**Earnings, 6 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Net Sales	1,375,945	1,239,368
Cost & expenses	1,327,073	1,172,894
Operating income	48,872	66,474
Interest income	2,981	2,256
Interest expense	7,272	6,536
Other income (expense), net	(823)	1,251
Net before taxes	43,758	63,445
Income taxes	129,961	5,971
Net income	(86,203)	57,474
Earnings common share		
Primary	\$(2.57)	\$1.71
Fully Diluted	\$(2.57)	\$1.66
Common Shares:		
Full Diluted	33,552	34,631
Year-end	33,293	33,735

POWELL INDUSTRIES, INC.**Earnings, 6 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	191,689	215,021
Cost & expenses	204,295	219,824
Operating income	(12,723)	(4,979)
Interest income	495	131
Interest expense	102	81
Other income (expense), net	507	1,015
Net before taxes	(11,823)	(3,914)
Income taxes	(2,831)	(2,786)
Net income	(8,992)	(1,282)

Earnings common share		
Primary	\$(0.78)	\$(0.10)
Fully Diluted	\$(0.78)	\$(0.10)
Common Shares:		
Full Diluted	11,503	11,441
Year-end	11,463	11,429

PRA GROUP INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	223,183,000	206,558,000
Cost & expenses	164,640,000	148,086,000
Operating income	53,614,000	53,257,000
Other income (expense), net	243,000	
Gains or losses		46,845,000
Foreign currency	1,293,000	2,179,000
Net before taxes	29,369,000	81,024,000
Income taxes	6,137,000	31,409,000
Net income	23,232,000	49,615,000

Earnings common share

Primary	\$0.47	\$1.04
Fully Diluted	\$0.47	\$1.03
Common Shares:		
Full Diluted	45,370,000	46,627,000
Year-end	45,275,000	46,439,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	101,418,000	
Current assets	125,997,000	
Net property & equip.	53,788,000	
Total assets	3,699,581,000	
Liabilities:		
Current liabilities	202,108,000	
Long-term debt	2,150,873,000	
Stockholders' equity	1,127,845,000	
Net current assets	(76,111,000)	

PREMIER INC**Earnings, 9 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,227,300	1,051,575
Cost & expenses	751,329	790,926
Operating income	434,374	226,209
Other income (expense), net	(13,916)	222,757
Gains or losses	(1,725)	(2,243)
Net before taxes	414,494	443,697
Income taxes	257,560	68,080
Net income	156,934	375,617
Balance for common	514,093	389,976
Earnings common share		
Primary	\$9.54	\$7.95
Fully Diluted	\$(0.84)	\$2.22
Common Shares:		
Full Diluted	138,254	141,372
Year-end	132,919	139,114

PRIMO WATER CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	73,659	60,737
Cost & expenses	62,831	57,800
Operating income	4,771	(3,454)
Interest expense	5,286	5,002
Other income (expense), net		(3,220)
Net before taxes	(515)	(11,676)
Income taxes	(1,725)	186
Net income	1,210	(11,862)
Earnings common share		
Primary	\$0.04	\$(0.37)
Fully Diluted	\$0.04	\$(0.37)
Common Shares:		
Full Diluted	34,424	32,364
Year-end	31,003	29,785

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	5,330	
Inventories	5,816	
Current assets	39,498	
Net property & equip.	100,409	
Total assets	387,600	
Liabilities:		
Current liabilities	37,626	
Long-term debt	274,531	
Stockholders' equity	66,453	

Net current assets	1,872
--------------------	-------

PRIMORIS SERVICES CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	504,119,000	561,502,000
Cost & expenses	498,210,000	546,303,000
Operating income	5,909,000	15,199,000
Interest expense	1,998,000	2,262,000
Other income (expense), net	(12,000)	
Foreign currency	257,000	23,000
Net before taxes	4,428,000	13,029,000
Income taxes	212,000	4,517,000
Net income	4,216,000	8,512,000
Earnings common share		
Primary	\$0.01	\$0.15
Fully Diluted	\$0.01	\$0.15
Common Shares:		
Full Diluted	51,747,000	51,851,000
Year-end	51,530,572	51,437,305

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	134,172,000	
Current assets	689,718,000	
Net property & equip.	313,937,000	
Total assets	1,202,447,000	
Liabilities:		
Current liabilities	435,312,000	
Long-term debt	181,972,000	
Stockholders' equity	565,496,000	
Net current assets	254,406,000	

PROGENICS PHARMACEUTICALS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	3,189,000	2,347,000
Cost & expenses	15,607,000	17,600,000
Operating income	(12,418,000)	(15,253,000)
Net income	(13,424,000)	(16,360,000)
Earnings common share		
Primary	\$(0.19)	\$(0.23)
Fully Diluted	\$(0.19)	\$(0.23)
Common Shares:		
Full Diluted	72,517,000	70,196,000
Year-end	72,765,000	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	2017
Cash & equivalents	85,875,000	
Current assets	91,842,000	
Net property & equip.	3,905,000	
Total assets	140,661,000	
Liabilities:		
Current liabilities	14,251,000	
Long-term debt	45,015,000	
Stockholders' equity	60,619,000	
Net current assets	77,591,000	

PROOFPOINT INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	162,461	115,635
Cost & expenses	186,211	128,389
Operating income	(23,750)	(12,754)
Other income (expense), net	343	(129)
Net before taxes	(26,228)	(18,849)
Income taxes	(14,072)	1,434
Net income	(12,156)	(20,283)
Earnings common share		
Primary	\$(0.24)	\$(0.47)
Fully Diluted	\$(0.24)	\$(0.47)
Common Shares:		
Full Diluted	50,504	43,230
Year-end	50,738	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	2017
Cash & equivalents	101,411	
Inventories	603	
Current assets	287,672	
Net property & equip.	78,024	
Total assets	1,057,664	
Liabilities:		
Current liabilities	476,298	
Long-term debt	200,957	

Stockholders' equity	303,694	Long-term debt	6,388,000	Stockholders' equity	1,118,998
Net current assets	(188,626)	Stockholders' equity	5,861,000	Net current assets	355,910
		Net current assets	366,000		

PROVIDENCE SERVICE CORP

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Cost & expenses	389,648,000	386,437,000
Deprec., depl. & amort.	6,798,000	6,269,000
Operating income	9,600,000	6,788,000
Interest expense	326,000	352,000
Gains or losses	(2,321,000)	(2,060,000)
Foreign currency	623,000	62,000
Net before taxes	7,576,000	4,438,000
Income taxes	1,842,000	2,523,000
Income contin. oper.	5,734,000	1,915,000
Income discount. oper.	(8,000)	(5,866,000)
Net income	5,726,000	(3,951,000)
Balance for common	3,762,000	(5,473,000)
Earnings common share		
Primary	\$0.29	\$(0.40)
Fully Diluted	\$0.29	\$(0.40)
Common Shares:		
Full Diluted	13,199,440	13,768,524
Year-end	12,997,069	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	86,229,000
Current assets	318,190,000
Net property & equip.	50,447,000
Total assets	720,243,000
Liabilities:	
Current liabilities	259,796,000
Long-term debt	644,000
Stockholders' equity	323,004,000
Net current assets	58,394,000

QORVO INC

New Accountant On May 18, 2018, Co. dismissed KPMG LLP and engaged Ernst & Young LLP as its new independent public accounting firm.

QUINSTREET, INC.

Earnings, 9 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	292,837	218,253
Cost & expenses	283,229	230,508
Operating income	9,608	(12,255)
Interest expense	118	99
Interest expense		322
Other income (expense), net	869	252
Net before taxes	10,595	(12,226)
Income taxes	86	(1,386)
Net income	10,509	(10,840)
Earnings common share		
Primary	\$0.23	\$(0.24)
Fully Diluted	\$0.21	\$(0.24)
Common Shares:		
Full Diluted	49,201	45,636
Year-end	46,982	45,525

QURATE RETAIL INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	3,230,000	2,327,000
Cost & expenses	2,773,000	1,906,000
Deprec., depl. & amort.	163,000	208,000
Operating income	294,000	213,000
Interest expense	98,000	90,000
Other income (expense), net	89,000	149,000
Net before taxes	285,000	272,000
Income taxes	29,000	84,000
Income contin. oper.	256,000	188,000
Net income	397,000	519,000
Earnings common share		
Common Shares:		
Year-end	472,937	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	1,055,000
Inventories	1,510,000
Current assets	4,303,000
Net property & equip.	1,357,000
Total assets	18,715,000
Liabilities:	
Current liabilities	3,937,000

RA PHARMACEUTICALS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Cost & expenses	16,724	11,481
Operating income	(16,724)	(11,481)
Other income (expense), net	226	121
Net income	(16,498)	(11,360)
Earnings common share		
Primary	\$(0.61)	\$(0.50)
Fully Diluted	\$(0.61)	\$(0.50)
Common Shares:		
Full Diluted	27,242	22,549
Year-end	32,286	22,560

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	109,122
Current assets	110,858
Net property & equip.	5,621
Total assets	118,176
Liabilities:	
Current liabilities	7,215
Stockholders' equity	108,675
Net current assets	103,643

RADISYS CORP.

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	26,190	37,610
Cost & expenses	31,813	45,485
Operating income	(5,821)	(9,135)
Interest expense	1,430	272
Other income (expense), net	1,671	(297)
Net before taxes	(5,580)	(9,704)
Income taxes	865	304
Net income	(6,445)	(10,008)
Earnings common share		
Primary	\$(0.16)	\$(0.26)
Fully Diluted	\$(0.16)	\$(0.26)
Common Shares:		
Full Diluted	39,355	38,715
Year-end	39,425	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	7,402
Inventories	4,599
Current assets	50,401
Net property & equip.	4,131
Total assets	61,641
Liabilities:	
Current liabilities	47,992
Long-term debt	6,364
Stockholders' equity	343
Net current assets	2,409

RAMBUS INC. (DE)

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	46,426	97,351
Cost & expenses	90,039	83,917
Operating income	(43,613)	13,434
Net before taxes	(38,918)	10,382
Income taxes	(3,229)	7,376
Net income	(35,689)	3,006
Earnings common share		
Primary	\$(0.33)	\$0.03
Fully Diluted	\$(0.33)	\$0.03
Common Shares:		
Full Diluted	109,358	115,325
Year-end	107,485	111,729

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	122,361
Inventories	5,596
Current assets	501,762
Net property & equip.	48,392
Total assets	1,539,659
Liabilities:	
Current liabilities	145,852
Long-term debt	137,037

RAPID7 INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	54,515	45,245
Cost & expenses	71,100	55,715
Operating income	(16,585)	(10,470)
Other income (expense), net	78	(115)
Net before taxes	(16,266)	(10,416)
Income taxes	95	129
Net income	(16,361)	(10,545)
Earnings common share		
Primary	\$(0.36)	\$(0.25)
Fully Diluted	\$(0.36)	\$(0.25)
Common Shares:		
Full Diluted	45,210	42,017
Year-end	46,199	42,841

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	99,646
Current assets	188,809
Net property & equip.	9,238
Total assets	320,470
Liabilities:	
Current liabilities	166,191
Stockholders' equity	73,922
Net current assets	22,618

RAVEN INDUSTRIES, INC.

Earnings, 3 mos. to Apr 30(Consol. - \$000):

	2018	2017
Net Sales	111,129	93,535
Cost & expenses	89,598	75,316
Operating income	21,531	18,219
Other income (expense), net	5,679	(230)
Net before taxes	27,210	17,989
Income taxes	5,063	5,641
Net income	22,147	12,348
Earnings common share		
Primary	\$0.62	\$0.34
Fully Diluted	\$0.61	\$0.34
Common Shares:		
Full Diluted	36,381	36,539
Year-end	35,845	36,076

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018
Cash & equivalents	51,317
Inventories	55,162
Current assets	177,774
Net property & equip.	107,037
Total assets	345,102
Liabilities:	
Current liabilities	35,963
Stockholders' equity	293,072
Net current assets	141,811

REALNETWORKS, INC.

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	19,650,000	19,691,000
Cost & expenses	24,604,000	27,940,000
Operating income	(4,954,000)	(8,249,000)
Interest income	87,000	128,000
Other income (expense), net	(41,000)	(974,000)
Net before taxes	(4,908,000)	(9,095,000)
Income taxes	270,000	455,000
Income contin. oper.		(9,550,000)
Net income	(5,178,000)	(9,424,000)
Earnings common share		
Primary	\$(0.14)	\$(0.25)
Fully Diluted	\$(0.14)	\$(0.25)
Common Shares:		
Full Diluted	37,449,000	37,030,000
Year-end	37,564,000	

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018
Cash & equivalents	49,785,000
Current assets	78,437,000
Net property & equip.	3,652,000
Total assets	105,774,000
Liabilities:	

Current liabilities	26,711,000
Stockholders' equity	76,342,000
Net current assets	51,726,000

REATA PHARMACEUTICALS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	32,392	12,732
Cost & expenses	28,035	19,776
Deprec., depl. & amort.	101	130
Operating income	4,082	(7,098)
Interest expense	509	5
Gains or losses	335	81
Net income	4,082	(7,098)
Earnings common share		
Primary	\$0.16	\$(0.32)
Fully Diluted	\$0.15	\$(0.32)
Common Shares:		
Full Diluted	26,634	22,350
Year-end	26,163	22,366

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	105,937
Current assets	134,747
Net property & equip.	829
Total assets	136,813
Liabilities:	
Current liabilities	51,366
Long-term debt	16,977
Stockholders' equity	(142,701)
Net current assets	83,381

RED ROBIN GOURMET BURGERS INC

Earnings, 3 mos. to (Consol. - \$):

	04/22/18	04/16/17
Total Revenues	421,519,000	420,629,000
Cost & expenses	385,307,000	375,127,000
Operating income	7,019,000	17,458,000
Net before taxes	3,612,000	14,474,000
Income taxes	(768,000)	2,907,000
Net income	4,380,000	11,567,000
Earnings common share		
Primary	\$0.34	\$0.90
Fully Diluted	\$0.34	\$0.89
Common Shares:		
Full Diluted	13,065,000	12,953,000
Year-end	12,980,000	12,872,000

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	23,673,000
Inventories	29,388,000
Current assets	80,718,000
Net property & equip.	626,852,000
Total assets	874,645,000
Liabilities:	
Current liabilities	154,278,000
Long-term debt	241,378,000
Stockholders' equity	392,704,000
Net current assets	(73,560,000)

RED ROCK RESORTS INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Cost & expenses	270,034	287,792
Operating income	107,841	92,693
Interest expense	31,111	34,944
Other income (expense), net	16,256	(1,651)
Net before taxes	92,986	56,098
Income taxes	10,856	10,679
Net income	82,130	45,419
Earnings common share		
Primary	\$0.74	\$0.30
Fully Diluted	\$0.65	\$0.30
Common Shares:		
Full Diluted	116,947	65,837
Year-end	116,348	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	179,192
Inventories	11,637
Current assets	286,368
Net property & equip.	2,637,316
Total assets	3,683,887

Liabilities:	
Current liabilities	263,447
Long-term debt	2,581,730
Stockholders' equity	426,618
Net current assets	22,921

REGENXBIO INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	132,391	455
Cost & expenses	30,366	23,377
Operating income	102,025	(22,922)
Interest expense	859	929
Net income	104,239	(21,993)
Balance for common	104,239	(21,993)
Earnings common share		
Primary	\$3.30	\$(0.82)
Fully Diluted	\$3.04	\$(0.82)
Common Shares:		
Full Diluted	34,275	26,673
Year-end	31,900	30,244

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	71,870
Current assets	262,718
Net property & equip.	14,829
Total assets	317,217
Liabilities:	
Current liabilities	14,876
Stockholders' equity	299,340
Net current assets	247,842

REPLIGEN CORP.

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	44,830,000	30,590,000
Cost & expenses	38,854,000	24,914,000
Operating income	5,976,000	5,676,000
Interest expense	1,652,000	1,585,000
Other income (expense), net	71,000	(120,000)
Gains or losses	181,000	96,000
Net before taxes	4,576,000	4,067,000
Income taxes	1,128,000	999,000
Net income	3,448,000	3,068,000
Earnings common share		
Primary	\$0.08	\$0.09
Fully Diluted	\$0.08	\$0.09
Common Shares:		
Full Diluted	44,326,732	34,382,322
Year-end	43,692,303	34,076,544

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	173,876,000
Inventories	40,124,000
Current assets	248,322,000
Net property & equip.	22,674,000
Total assets	743,248,000
Liabilities:	
Current liabilities	20,321,000
Long-term debt	100,276,000
Stockholders' equity	597,183,000
Net current assets	228,001,000

RESTORBIO INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Cost & expenses	10,200	3,357
Operating income	(10,200)	(3,357)
Other income (expense), net	341	
Net income	(9,859)	(3,357)
Earnings common share		
Primary	\$(0.46)	\$(1.20)
Fully Diluted	\$(0.46)	\$(1.20)
Common Shares:		
Full Diluted	21,523	2,790
Year-end	28,046	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	135,705
Current assets	136,845
Net property & equip.	316
Total assets	137,245
Liabilities:	

Current liabilities	6,834
Stockholders' equity	130,383
Net current assets	130,011

RGC RESOURCES, INC.

Earnings, 6 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	43,674,024	40,688,598
Cost & expenses	31,222,426	27,975,659
Deprec., depl. & amort.	3,469,756	3,141,457
Operating income	8,981,842	9,571,482
Interest expense	1,245,831	928,001
Other income (expense), net	335,507	163,883
Net before taxes	8,071,518	8,807,364
Income taxes	2,546,127	3,349,947
Net income	5,525,391	5,457,417
Earnings common share		
Primary	\$0.76	\$0.76
Fully Diluted	\$0.75	\$0.76
Common Shares:		
Full Diluted	7,354,233	7,227,494
Year-end	7,975,392	7,224,429

RIGNET INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

	2018	2017
Total Revenues	53,833	48,072
Cost & expenses	50,316	41,823
Deprec., depl. & amort.	7,987	7,316
Operating income	(4,470)	(1,067)
Interest expense	959	619
Other income (expense), net	506	113
Net before taxes	(4,923)	(1,573)
Income taxes	603	414
Net income	(5,526)	(1,987)
Balance for common	(5,556)	(2,026)
Earnings common share		
Primary	\$(0.31)	\$(0.11)
Fully Diluted	\$(0.31)	\$(0.11)
Common Shares:		
Full Diluted	18,146	17,873
Year-end	19,104	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	21,858
Current assets	85,870
Net property & equip.	60,953
Total assets	245,259
Liabilities:	
Current liabilities	43,945
Long-term debt	51,934
Stockholders' equity	111,722
Net current assets	41,925

RIMINI STREET INC (DE)

Earnings, 3 mos. to Mar 31(Consol. - \$):

	2018	2017
Total Revenues	59,805,000	
Cost & expenses	34,584,000	179,386
Operating income	25,221,000	(179,386)
Interest income		200,175
Interest expense	13,409,000	
Other income (expense), net	(7,789,000)	(25,060)
Net before taxes	4,023,000	
Income taxes	516,000	
Net income	3,507,000	(4,271)
Earnings common share		
Primary	\$0.06	
Fully Diluted	\$0.05	
Common Shares:		
Full Diluted	68,154,000	5,646,918
Year-end	59,440,000	21,562,500

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	22,116,000
Current assets	133,778,000
Net property & equip.	4,130,000
Total assets	145,161,000
Liabilities:	
Current liabilities	251,068,000
Long-term debt	56,391,000
Stockholders' equity	(205,811,000)
Net current assets	(117,290,000)

RPX CORP**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	67,121	75,415
Cost & expenses	66,482	65,858
Operating income	639	9,557
Interest income	327	165
Other income (expense), net	546	210
Net before taxes	1,501	9,024
Income taxes	1,421	3,369
Net income	80	5,655
Earnings common share		
Primary	\$0.12	\$0.12
Fully Diluted	\$0.11	\$0.11
Common Shares:		
Full Diluted	50,267	49,305
Year-end	49,934	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	159,220	159,220
Current assets	272,152	272,152
Net property & equip.	5,025	5,025
Total assets	564,233	564,233
Liabilities:		
Current liabilities	105,982	105,982
Stockholders' equity	443,193	443,193
Net current assets	166,170	166,170

RUSH ENTERPRISES INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	1,240,781	1,044,797
Cost & expenses	1,185,484	1,007,456
Deprec., depl. & amort.	22,908	12,492
Operating income	32,389	24,849
Interest expense	4,306	2,791
Net before taxes	28,083	22,058
Income taxes	7,044	7,579
Net income	21,039	14,479
Earnings common share		
Primary	\$0.53	\$0.37
Fully Diluted	\$0.51	\$0.36
Common Shares:		
Full Diluted	41,092	40,701
Year-end	39,206	39,681

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	131,712	131,712
Inventories	1,044,710	1,044,710
Current assets	1,400,805	1,400,805
Net property & equip.	1,151,646	1,151,646
Total assets	2,899,204	2,899,204
Liabilities:		
Current liabilities	1,205,737	1,205,737
Long-term debt	514,692	514,692
Stockholders' equity	1,031,669	1,031,669
Net current assets	195,068	195,068

RUTH'S HOSPITALITY GROUP INC**Earnings, 3 mos. to** (Consol. – \$000):

	04/01/18	03/26/17
Total Revenues	116,526	105,538
Net Sales	110,364	99,455
Cost & expenses	95,677	85,788
Operating income	16,388	16,245
Interest expense	380	179
Other income (expense), net	12	24
Net before taxes	16,020	16,090
Income taxes	2,384	5,005
Income contin. oper.	13,636	11,085
Net income	13,646	11,048
Earnings common share		
Primary	\$0.46	\$0.36
Fully Diluted	\$0.45	\$0.35
Common Shares:		
Full Diluted	30,384	31,253
Year-end	29,718	30,614

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	2,168	2,168
Inventories	8,368	8,368
Current assets	26,139	26,139
Net property & equip.	112,474	112,474

Total assets	231,811	231,811
Liabilities:		
Current liabilities	73,768	73,768
Long-term debt	43,000	43,000
Stockholders' equity	87,589	87,589
Net current assets	(47,629)	(47,629)

SAFETY INSURANCE GROUP, INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	209,719	204,770
Cost & expenses	198,522	188,122
Operating income	11,197	16,648
Net before taxes	11,197	16,648
Income taxes	2,072	4,629
Net income	9,125	12,019
Earnings common share		
Primary	\$0.60	\$0.80
Fully Diluted	\$0.60	\$0.79
Common Shares:		
Full Diluted	15,191	15,097
Year-end	15,287	15,219

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	24,830	24,830
Current assets	346,106	346,106
Total assets	1,797,337	1,797,337
Liabilities:		
Current liabilities	80,495	80,495
Stockholders' equity	685,645	685,645
Net current assets	265,611	265,611

SANDERSON FARMS INC**Earnings, 6 mos. to Apr 30**(Consol. – \$000):

	2018	2017
Net Sales	1,585,422	1,490,384
Cost & expenses	1,513,123	1,351,385
Operating income	72,299	138,999
Interest income	1,324	496
Interest expense	1,029	860
Other income (expense), net	6	5
Net before taxes	72,600	138,640
Income taxes	(20,554)	47,600
Net income	93,154	91,040
Earnings common share		
Primary	\$4.08	\$4.00
Fully Diluted	\$4.08	\$4.00
Common Shares:		
Full Diluted	22,506	22,387
Year-end	22,836	22,743

SANFILIPPO (JOHN B) & SON INC**Earnings, 9 mos. to** (Consol. – \$000):

	03/29/18	03/30/17
Net Sales	677,090	645,044
Cost & expenses	631,402	596,716
Operating income	45,688	48,328
Interest expense	2,590	2,094
Other income (expense), net	(2,669)	(2,669)
Net before taxes	40,429	43,558
Income taxes	13,610	14,157
Net income	26,819	29,401
Earnings common share		
Primary	\$2.36	\$2.60
Fully Diluted	\$2.34	\$2.58
Common Shares:		
Full Diluted	11,441	11,393
Year-end	11,345	11,281

SB ONE BANCORP**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	14,320	7,903
Operating income	1,523	2,842
Net before taxes	1,523	2,842
Income taxes	215	831
Net income	1,308	2,011
Earnings common share		
Primary	\$0.17	\$0.43
Fully Diluted	\$0.17	\$0.43
Common Shares:		
Full Diluted	7,792	4,727
Year-end	7,930	4,785

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	15,280	15,280
Current assets	28,723	28,723
Net property & equip.	18,672	18,672
Total assets	1,376,484	1,376,484
Liabilities:		
Current liabilities	1,168,356	1,168,356
Long-term debt	57,851	57,851
Stockholders' equity	146,292	146,292
Net current assets	(1,139,633)	(1,139,633)

SCANSOURCE, INC.**Earnings, 9 mos. to Mar 31**(Consol. – \$):

	2018	2017
Net Sales	2,852,408,000	650,895,000
Cost & expenses	2,778,869,000	566,075,000
Operating income	47,880,000	66,128,000
Other income (expense), net	(691,000)	11,280,000
Net before taxes	42,883,000	78,075,000
Income taxes	20,118,000	27,799,000
Net income	22,765,000	50,276,000
Earnings common share		
Primary	\$0.89	\$1.99
Fully Diluted	\$0.89	\$1.97
Common Shares:		
Full Diluted	25,607,000	25,458,000
Year-end	25,572,162	25,314,031

SCPHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	8,699	4,959
Operating income	(8,699)	(4,959)
Interest income	351	37
Interest expense	342	
Other income (expense), net	(42)	10
Net income	(8,732)	(4,912)
Earnings common share		
Primary	\$(0.47)	\$(4.59)
Fully Diluted	\$(0.47)	\$(4.59)
Common Shares:		
Full Diluted	18,535	1,071
Year-end	18,542	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	109,280	109,280
Current assets	111,568	111,568
Net property & equip.	193	193
Total assets	113,652	113,652
Liabilities:		
Current liabilities	5,800	5,800
Long-term debt	9,821	9,821
Stockholders' equity	97,944	97,944
Net current assets	105,768	105,768

SELECTA BIOSCIENCES INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	137	137
Cost & expenses	15,813	14,919
Operating income	(15,813)	(14,782)
Interest expense	350	300
Gains or losses	288	113
Foreign currency	(13)	(165)
Net income	(15,888)	(15,134)
Balance for common	(15,888)	(15,134)
Earnings common share		
Primary	\$(0.71)	\$(0.82)
Fully Diluted	\$(0.71)	\$(0.82)
Common Shares:		
Full Diluted	22,346	18,474
Year-end	22,350	18,552

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	58,304	58,304
Current assets	84,984	84,984
Net property & equip.	2,257	2,257
Total assets	89,937	89,937
Liabilities:		
Current liabilities	11,810	11,810
Long-term debt	21,127	21,127
Stockholders' equity	41,582	41,582
Net current assets	73,174	73,174

SERES THERAPEUTICS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	3,971	3,015
Cost & expenses	32,237	28,905
Operating income	(28,266)	(25,890)
Other income (expense), net	347	416
Net income	(27,919)	(25,474)
Balance for common	(27,919)	(25,474)
Earnings common share		
Primary	\$(0.69)	\$(0.63)
Fully Diluted	\$(0.69)	\$(0.63)
Common Shares:		
Full Diluted	40,628	40,369
Year-end	40,653	40,387

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	47,194	
Current assets	126,454	
Net property & equip.	31,466	
Total assets	159,433	
Liabilities:		
Current liabilities	35,150	
Long-term debt	8,554	
Stockholders' equity	10,033	
Net current assets	91,304	

SERVICOURCE INTERNATIONAL, INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	58,585	56,708
Cost & expenses	65,420	65,972
Operating income	(6,835)	(9,264)
Gains or losses	(1,958)	
Net before taxes	(11,639)	(11,334)
Income taxes	13	290
Net income	(11,652)	(11,624)
Earnings common share		
Primary	\$(0.13)	\$(0.13)
Fully Diluted	\$(0.13)	\$(0.13)
Common Shares:		
Full Diluted	90,358	88,385
Year-end	90,462	88,524

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	51,750	
Current assets	242,552	
Net property & equip.	33,975	
Total assets	290,267	
Liabilities:		
Current liabilities	176,036	
Stockholders' equity	109,216	
Net current assets	66,516	

SESEN BIO INC**New Name** On May 17, 2018, Co. changed its name from Eleven Biotherapeutics Inc. to Sesen Bio Inc.**SHUTTERFLY INC****Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	199,725	191,972
Cost & expenses	233,835	241,732
Operating income	(34,110)	(49,760)
Interest expense	9,633	5,964
Net before taxes	(41,994)	(55,535)
Income taxes	(14,829)	(22,341)
Net income	(27,165)	(33,194)
Earnings common share		
Primary	\$(0.83)	\$(0.98)
Fully Diluted	\$(0.83)	\$(0.98)
Common Shares:		
Full Diluted	32,702	33,712
Year-end	33,122	33,729

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	419,371	
Inventories	10,150	
Current assets	660,121	
Net property & equip.	259,951	
Total assets	1,379,228	
Liabilities:		
Current liabilities	417,144	
Long-term debt	392,279	

Stockholders' equity	555,598	
Net current assets	242,977	

SIENTRA INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Net Sales	14,676	7,489
Cost & expenses	33,603	18,907
Operating income	(18,927)	(11,418)
Interest income	40	22
Interest expense	655	9
Other income (expense), net	119	8
Net before taxes	(11,397)	
Income taxes	25	
Net income	(19,423)	(11,422)
Earnings common share		
Primary	\$(0.99)	\$(0.61)
Fully Diluted	\$(0.99)	\$(0.61)
Common Shares:		
Full Diluted	19,613	18,773
Year-end	19,644	19,012

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	16,059	
Inventories	21,829	
Current assets	52,334	
Net property & equip.	4,934	
Total assets	88,717	
Liabilities:		
Current liabilities	43,109	
Long-term debt	22,735	
Stockholders' equity	9,843	
Net current assets	9,225	

SIGA TECHNOLOGIES INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Cost & expenses	6,282,845	9,470,956
Operating income	(4,534,911)	(4,269,170)
Other income (expense), net	(3,300,879)	(621,790)
Net before taxes	(11,584,608)	(8,499,876)
Income taxes	(2,352)	115,070
Net income	(11,582,256)	(8,614,946)
Earnings common share		
Primary	\$(0.15)	\$(0.11)
Fully Diluted	\$(0.15)	\$(0.11)
Common Shares:		
Full Diluted	79,039,000	78,777,144
Year-end	79,039,000	78,780,059

Consolidated Balance Sheet Items, as of (\$):

	2018	2017
Assets:		
Cash & equivalents	24,784,943	
Inventories	2,983,249	
Current assets	30,932,438	
Net property & equip.	108,850	
Total assets	133,135,253	
Liabilities:		
Current liabilities	4,018,402	
Long-term debt	72,159,240	
Stockholders' equity	(334,616,500)	
Net current assets	26,914,036	

SILGAN HOLDINGS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Net Sales	1,012,280	805,407
Cost & expenses	920,098	748,645
Operating income	92,182	56,762
Other income (expense), net		(2,677)
Net before taxes	61,701	33,667
Income taxes	15,980	10,435
Net income	45,721	23,232
Earnings common share		
Primary	\$0.41	\$0.21
Fully Diluted	\$0.41	\$0.21
Common Shares:		
Full Diluted	111,558	111,216
Year-end	110,569	110,284

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	174,540	
Inventories	743,286	
Current assets	1,568,537	

Net property & equip.	1,502,880
Total assets	4,952,487
Liabilities:	
Current liabilities	1,459,296
Long-term debt	2,174,709
Stockholders' equity	824,791
Net current assets	109,241

SINCLAIR BROADCAST GROUP INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	665,352	626,936
Cost & expenses	460,158	368,753
Operating income	107,314	157,629
Interest expense	69,742	57,318
Other income (expense), net	(9,206)	(1,029)
Net before taxes	28,366	99,282
Income taxes	(15,628)	28,579
Net income	43,994	70,703
Earnings common share		
Primary	\$0.42	\$0.62
Fully Diluted	\$0.42	\$0.61
Common Shares:		
Full Diluted	102,917	93,692
Year-end	102,180	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	810,232	
Current assets	1,714,691	
Net property & equip.	654,432	
Total assets	6,663,411	
Liabilities:		
Current liabilities	591,681	
Long-term debt	3,875,025	
Stockholders' equity	1,607,707	
Net current assets	1,123,010	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	810,232	
Current assets	1,714,691	
Net property & equip.	654,432	
Total assets	6,663,411	
Liabilities:		
Current liabilities	591,681	
Long-term debt	3,875,025	
Stockholders' equity	1,607,707	
Net current assets	1,123,010	

SKYWEST INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	783,400	747,166
Cost & expenses	617,640	600,757
Operating income	88,175	76,295
Interest income	1,705	660
Interest expense	26,234	24,549
Other income (expense), net	3,558	
Net before taxes	67,204	52,406
Income taxes	12,842	17,620
Net income	54,362	34,786
Earnings common share		
Primary	\$1.05	\$0.67
Fully Diluted	\$1.03	\$0.65
Common Shares:		
Full Diluted	53,033	53,202
Year-end	52,046	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	251,447	
Inventories	117,217	
Current assets	952,623	
Net property & equip.	4,375,204	
Total assets	5,600,187	
Liabilities:		
Current liabilities	837,818	
Long-term debt	2,440,771	
Stockholders' equity	1,787,137	
Net current assets	114,805	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	251,447	
Inventories	117,217	
Current assets	952,623	
Net property & equip.	4,375,204	
Total assets	5,600,187	
Liabilities:		
Current liabilities	837,818	
Long-term debt	2,440,771	
Stockholders' equity	1,787,137	
Net current assets	114,805	

Consolidated Balance Sheet Items, as of (\$000):

	2018	2017
Assets:		
Cash & equivalents	251,447	
Inventories	117,217	
Current assets	952,623	
Net property & equip.	4,375,204	
Total assets	5,600,187	
Liabilities:		
Current liabilities	837,818	
Long-term debt	2,440,771	
Stockholders' equity	1,787,137	
Net current assets	114,805	

SMTC CORP.**Earnings, 3 mos. to** (Consol. – \$000):

	04/01/18	04/02/17
Total Revenues	37,120	33,178
Cost & expenses	36,779	33,383
Operating income	341	(205)
Interest expense	307	179
Net before taxes	34	(384)
Income taxes	26	(7)
Net income	8	(377)
Earnings common share		
Primary	\$	\$(0.02)
Fully Diluted	\$	\$(0.02)
Common Shares:		
Full Diluted	17,524	16,661
Year-end	17,092	16,784

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	3,322	
Inventories	19,923	
Current assets	62,127	
Net property & equip.	9,592	
Total assets	72,226	
Liabilities:		
Current liabilities	47,156	
Long-term debt	5,542	
Stockholders' equity	19,528	
Net current assets	14,971	

SOHU.COM INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	454,995	374,103
Cost & expenses	486,485	421,413
Operating income	(31,490)	(47,310)
Interest income	7,808	4,471
Interest expense	3,081	175
Other income (expense), net	12,281	4,099
Foreign currency	(9,340)	(766)
Net before taxes	(23,822)	(39,681)
Income taxes	63,379	10,672
Net income	(87,201)	(50,353)
Balance for common	(92,818)	(68,248)

Earnings common share

Primary	\$(2.39)	\$(1.76)
Fully Diluted	\$(2.39)	\$(1.77)
Common Shares:		
Full Diluted	38,904	38,811
Year-end	38,917	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	1,158,548	
Current assets	2,661,930	
Net property & equip.	545,419	
Total assets	3,444,848	
Liabilities:		
Current liabilities	1,208,504	
Long-term debt	127,224	
Stockholders' equity	664,357	
Net current assets	1,453,426	

SOLAR CAPITAL LTD**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	20,103	18,062
Net income	18,857	16,330
Earnings common share		
Primary	\$0.47	\$0.41
Fully Diluted	\$0.47	\$0.41
Common Shares:		
Full Diluted	42,261	42,249
Year-end	42,261	42,249

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	144,700	
Current assets	170,573	
Total assets	1,643,330	
Liabilities:		
Current liabilities	175,541	
Long-term debt	543,463	
Stockholders' equity	924,326	
Net current assets	(4,968)	

SOLID BIOSCIENCES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	15,973	14,113
Operating income	(15,973)	(14,113)
Interest income	65	62
Other income (expense), net	31	176
Net income	(15,877)	(13,875)
Earnings common share		
Primary	\$(0.54)	\$(0.01)
Fully Diluted	\$(0.54)	\$(0.01)
Common Shares:		
Full Diluted	29,355	3,048
Year-end	35,477	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	164,773	
Current assets	184,378	
Net property & equip.	4,418	
Total assets	189,242	
Liabilities:		
Current liabilities	9,927	
Stockholders' equity	178,950	
Net current assets	174,451	

SPARK THERAPEUTICS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	15,676,000	1,274,000
Cost & expenses	64,588,000	54,148,000
Operating income	(48,912,000)	(52,874,000)
Interest income	2,185,000	585,000
Other income (expense), net	364,000	
Net before taxes	(46,363,000)	
Income taxes	10,000	
Net income	(46,373,000)	(52,289,000)

Earnings common share

Primary	\$(1.25)	\$(1.70)
Fully Diluted	\$(1.25)	\$(1.70)
Common Shares:		
Full Diluted	37,046,235	30,771,867
Year-end	37,222,651	31,077,603

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	127,687,000	
Inventories	5,560,000	
Current assets	620,974,000	
Net property & equip.	62,874,000	
Total assets	687,704,000	
Liabilities:		
Current liabilities	54,639,000	
Long-term debt	832,000	
Stockholders' equity	479,670,000	
Net current assets	566,335,000	

SPARK THERAPEUTICS INC

Interest Sale Completed On May 23, 2018, Co. sold its Rare Pediatric Disease Priority Review Voucher ("PRV") to Jazz Pharmaceuticals Plc.'s wholly-owned subsidiary, Jazz Pharmaceuticals Ireland Ltd., for \$110,000,000.

SPECTRUM PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	30,495	29,101
Net Sales	28,111	25,845
Cost & expenses	48,812	44,121
Operating income	(25,264)	(21,909)
Interest expense	230	2,052
Other income (expense), net	9,681	213
Net before taxes	(15,813)	(23,748)
Income taxes	3	(201)
Net income	(15,816)	(23,547)

Earnings common share

Primary	\$(0.16)	\$(0.30)
Fully Diluted	\$(0.16)	\$(0.30)
Common Shares:		
Full Diluted	100,810	78,523
Year-end	103,935	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	183,513	
Inventories	5,028	
Current assets	277,028	
Net property & equip.	593	
Total assets	444,273	
Liabilities:		
Current liabilities	93,422	
Stockholders' equity	324,294	
Net current assets	183,606	

SPORTSMAN'S WAREHOUSE HOLDINGS INC**Earnings, 3 mos. to (Consol. - \$000):**

	05/05/18	04/29/17
Net Sales	180,059	156,898
Cost & expenses	183,709	160,665
Operating income	(3,650)	(3,767)
Interest expense	3,557	3,150
Net before taxes	(7,207)	(6,917)
Income taxes	(1,379)	(2,410)

Net income	(5,828)	(4,507)
Earnings common share		
Primary	\$(0.14)	\$(0.11)
Fully Diluted	\$(0.14)	\$(0.11)
Common Shares:		
Full Diluted	42,727	42,277
Year-end	42,834	42,500

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	2,379	
Inventories	306,201	
Current assets	318,145	
Net property & equip.	94,809	
Total assets	416,428	
Liabilities:		
Current liabilities	195,605	
Long-term debt	132,142	
Stockholders' equity	47,477	
Net current assets	122,540	

SPS COMMERCE, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	59,092	51,879
Cost & expenses	53,667	47,285
Operating income	4,300	3,379
Other income (expense), net	(154)	(60)
Net before taxes	4,560	3,510
Income taxes	1,306	525
Net income	3,254	2,985
Earnings common share		
Primary	\$0.19	\$0.17
Fully Diluted	\$0.19	\$0.17
Common Shares:		
Full Diluted	17,307	17,393
Year-end	17,110	17,201

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	120,547	
Current assets	228,781	
Net property & equip.	17,304	
Total assets	339,596	
Liabilities:		
Current liabilities	42,096	
Stockholders' equity	288,351	
Net current assets	186,685	

SS&C TECHNOLOGIES HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	421,929	407,699
Cost & expenses	335,082	317,982
Operating income	86,847	89,717
Interest expense	25,354	29,020
Other income (expense), net	438	(2,397)
Net before taxes	61,931	58,300
Income taxes	10,681	10,153
Net income	51,250	48,147
Earnings common share		
Primary	\$0.25	\$0.24
Fully Diluted	\$0.24	\$0.23
Common Shares:		
Full Diluted	217,656	209,704
Year-end	207,803	203,973

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	74,077	
Current assets	386,197	
Net property & equip.	101,994	
Total assets	5,549,584	
Liabilities:		
Current liabilities	374,869	
Long-term debt	1,949,232	
Stockholders' equity	2,815,908	
Net current assets	11,328	

STAMPS.COM INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	133,565,000	105,040,000
Cost & expenses	84,364,000	70,392,000
Operating income	49,201,000	34,648,000
Interest expense	590,000	880,000

Net before taxes	48,660,000	33,798,000
Income taxes	1,616,000	660,000
Net income	47,044,000	33,138,000
Earnings common share		
Primary	\$2.67	\$1.96
Fully Diluted	\$2.54	\$1.82
Common Shares:		
Full Diluted	18,511,000	18,170,000
Year-end	17,883,000	17,076,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	195,848,000	
Current assets	325,612,000	
Net property & equip.	36,598,000	
Total assets	727,396,000	
Liabilities:		
Current liabilities	116,402,000	
Long-term debt	58,158,000	
Stockholders' equity	546,654,000	
Net current assets	209,210,000	

STEEL DYNAMICS INC.**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Net Sales	2,603,875	2,368,216
Cost & expenses	2,273,552	2,026,226
Operating income	323,397	334,566
Interest expense	31,896	33,973
Other income (expense), net	4,463	3,659
Net before taxes	295,964	304,252
Income taxes	70,489	105,586
Net income	225,475	198,666
Earnings common share		
Primary	\$0.96	\$0.83
Fully Diluted	\$0.96	\$0.82
Common Shares:		
Full Diluted	237,723	244,546
Year-end	236,096	242,111

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	985,824	
Inventories	1,600,058	
Current assets	3,652,242	
Net property & equip.	2,657,937	
Total assets	6,972,813	
Liabilities:		
Current liabilities	860,740	
Long-term debt	2,353,703	
Stockholders' equity	3,470,719	
Net current assets	2,791,502	

STERLING CONSTRUCTION INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	222,492	153,416
Cost & expenses	215,813	155,204
Operating income	6,679	(1,788)
Net before taxes	3,721	(1,859)
Income taxes	41	27
Net income	3,680	(1,886)
Earnings common share		
Primary	\$0.09	\$(0.09)
Fully Diluted	\$0.09	\$(0.09)
Common Shares:		
Full Diluted	27,078	25,022
Year-end	27,035	25,051

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	55,462	
Inventories	1,863	
Current assets	257,179	
Net property & equip.	52,142	
Total assets	439,035	
Liabilities:		
Current liabilities	158,462	
Long-term debt	85,106	
Stockholders' equity	144,245	
Net current assets	98,717	

SUN HYDRAULICS CORP.**Earnings, 3 mos. to (Consol. – \$000):**

	03/31/18	04/01/17
Net Sales	97,318	81,353
Cost & expenses	78,016	63,259
Operating income	17,253	15,784
Other income (expense), net	(366)	(66)
Foreign currency	(511)	46
Net before taxes	15,893	15,139
Income taxes	3,982	4,928
Net income	11,911	10,211
Earnings common share		
Primary	\$0.40	\$0.38
Fully Diluted	\$0.40	\$0.38
Common Shares:		
Full Diluted	29,811	26,946
Year-end	31,588	27,037

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	198,528	
Inventories	40,862	
Current assets	290,764	
Net property & equip.	93,922	
Total assets	603,809	
Liabilities:		
Current liabilities	52,260	
Long-term debt	942	
Stockholders' equity	525,076	
Net current assets	238,504	

SUNPOWER CORP**Earnings, 3 mos. to (Consol. – \$000):**

	04/01/18	04/02/17
Total Revenues	391,888	329,095
Cost & expenses	525,930	472,387
Operating income	(134,042)	(143,292)
Interest income	529	938
Interest expense	25,106	20,902
Other income (expense), net	15,794	(74,088)
Equity earnings	2,144	(2,488)
Net before taxes	(142,825)	(237,344)
Income taxes	2,628	2,031
Net income	(147,597)	(236,887)
Earnings common share		
Primary	\$(0.83)	\$(1.58)
Fully Diluted	\$(0.83)	\$(1.58)
Common Shares:		
Full Diluted	140,212	138,902
Year-end	140,848	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	260,672	
Inventories	354,611	
Current assets	1,204,963	
Net property & equip.	1,137,083	
Total assets	3,782,723	
Liabilities:		
Current liabilities	964,731	
Long-term debt	1,248,585	
Stockholders' equity	477,159	
Net current assets	240,232	

SUPERNUS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	90,429	57,576
Cost & expenses	59,035	40,788
Operating income	31,394	16,788
Interest income	1,206	531
Other income (expense), net	(47)	(47)
Net before taxes	31,182	16,223
Income taxes	4,830	5,926
Net income	26,352	10,297
Earnings common share		
Primary	\$0.51	\$0.21
Fully Diluted	\$0.49	\$0.19
Common Shares:		
Full Diluted	53,788	52,764
Year-end	51,634	50,226

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	444,140	
Inventories	19,075	
Current assets	583,246	
Net property & equip.	5,003	

Total assets	825,160
Liabilities:	
Current liabilities	119,088
Long-term debt	318,225
Stockholders' equity	351,869
Net current assets	464,158

SURGERY PARTNERS INC

New Accountant On May 17, 2018, Co. dismissed Ernst & Young LLP as its independent public accounting firm. On May 18, 2018, Co. engaged Deloitte & Touche LLP as its new independent public accounting firm.

SURMODICS INC**Earnings, 6 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	36,071	35,264
Cost & expenses	34,925	29,132
Operating income	(108)	4,945
Gains or losses	440	170
Net before taxes	(207)	5,588
Income taxes	(185)	2,782
Net income	(22)	2,806
Earnings common share		
Primary	\$0.21	\$0.21
Fully Diluted	\$0.21	\$0.21
Common Shares:		
Full Diluted	13,078	13,415
Year-end	13,247	13,277

SYKES ENTERPRISES, INC.**Earnings, 3 mos. to Mar 31(Consol. – \$):**

	2018	2017
Total Revenues	414,371,000	384,014,000
Cost & expenses	381,038,000	339,382,000
Operating income	14,284,000	26,053,000
Interest income	171,000	155,000
Interest expense	1,206,000	1,699,000
Other income (expense), net	(1,293,000)	(366,000)
Gains or losses	1,448,000	1,179,000
Net before taxes	13,404,000	25,322,000
Income taxes	2,456,000	6,610,000
Net income	10,948,000	18,712,000
Earnings common share		
Primary	\$0.26	\$0.45
Fully Diluted	\$0.26	\$0.45
Common Shares:		
Full Diluted	42,232,000	41,905,000
Year-end	42,681,000	

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	172,590,000	
Current assets	558,175,000	
Net property & equip.	153,834,000	
Total assets	1,156,186,000	
Liabilities:		
Current liabilities	195,168,000	
Long-term debt	100,000,000	
Stockholders' equity	806,146,000	
Net current assets	363,007,000	

SYNAPTICS INC**Earnings, 9 mos. to Mar 31(Consol. – \$000):**

	2018	2017
Total Revenues	1,241,800	1,291,700
Cost & expenses	1,286,500	1,235,700
Operating income	(53,200)	46,700
Equity earnings	1,400	
Net before taxes	(68,600)	44,900
Income taxes	52,600	13,900
Net income	(122,600)	31,000
Balance for common	(122,600)	31,000
Earnings common share		
Primary	\$(3.61)	\$0.89
Fully Diluted	\$(3.61)	\$0.87
Common Shares:		
Full Diluted	34,000	35,700
Year-end	34,594	34,304

SYNEOS HEALTH INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

	2018	2017
Total Revenues	1,241,800	1,291,700
Cost & expenses	1,286,500	1,235,700
Operating income	(53,200)	46,700
Equity earnings	1,400	
Net before taxes	(68,600)	44,900
Income taxes	52,600	13,900
Net income	(122,600)	31,000
Balance for common	(122,600)	31,000

Balance for common.....	(4,977)	
Earnings common share		
Primary	\$(0.55)	\$(1.68)
Fully Diluted	\$(0.55)	\$(1.68)
Common Shares:		
Full Diluted	20,146	2,979
Year-end	22,172	2,980

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		27,185
Current assets		127,860
Net property & equip.....		13,704
Total assets		142,661
Liabilities:		
Current liabilities	7,010	
Long-term debt	401	
Stockholders' equity	128,767	
Net current assets	120,850	

SYNOPSIS INC**Earnings, 6 mos. to Apr 30(Consol. - \$000):**

	2018	2017
Total Revenues	1,546,262	1,332,855
Cost & expenses	1,291,255	1,166,475
Operating income	234,732	150,480
Other income (expense), net	8,732	17,737
Net before taxes	239,402	170,381
Income taxes	140,621	30,487
Net income	98,781	139,894
Earnings common share		
Primary	\$0.66	\$0.93
Fully Diluted	\$0.64	\$0.90
Common Shares:		
Full Diluted	153,664	154,754
Year-end	148,961	150,549

SYNTEL INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	245,345	225,869
Cost & expenses	181,077	173,414
Operating income	64,268	52,455
Interest expense	2,433	3,376
Other income (expense), net	561	496
Net before taxes	62,094	49,251
Income taxes	16,455	10,871
Net income	45,639	38,380
Earnings common share		
Primary	\$0.55	\$0.46
Fully Diluted	\$0.55	\$0.46
Common Shares:		
Full Diluted	83,377	83,834
Year-end	82,967	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		41,373
Current assets		261,789
Net property & equip.....		103,255
Total assets		452,444
Liabilities:		
Current liabilities	142,692	
Long-term debt	246,997	
Stockholders' equity	34,067	
Net current assets	119,097	

SYROS PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	370	1,101
Cost & expenses	15,191	12,714
Operating income	(14,821)	(11,613)
Other income (expense), net	358	98
Net income	(14,463)	(11,515)
Balance for common.....	(14,463)	(11,515)
Earnings common share		
Primary	\$(0.48)	\$(0.49)
Fully Diluted	\$(0.48)	\$(0.49)
Common Shares:		
Full Diluted	30,335	23,393
Year-end	32,236	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		121,741
Current assets		123,370
Net property & equip.....		3,565
Total assets		128,100
Liabilities:		
Current liabilities	21,337	
Long-term debt	5	
Stockholders' equity	104,499	
Net current assets	102,033	

T2 BIOSYSTEMS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	2,311	941
Cost & expenses	13,746	14,086
Operating income	(11,435)	(13,145)
Interest expense	1,568	1,637
Other income (expense), net	90	79
Net income	(12,913)	(14,703)
Earnings common share		
Primary	\$(0.36)	\$(0.48)
Fully Diluted	\$(0.36)	\$(0.48)
Common Shares:		
Full Diluted	35,978	30,531
Year-end	36,020	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		29,733
Inventories		2,082
Current assets		33,023
Net property & equip.....		8,710
Total assets		42,119
Liabilities:		
Current liabilities	50,922	
Long-term debt	609	
Stockholders' equity	(10,087)	
Net current assets	(17,899)	

TACTILE SYSTEMS TECHNOLOGY INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	26,848	19,850
Cost & expenses	28,675	22,782
Operating income	(1,827)	(2,932)
Other income (expense), net	91	55
Net before taxes	(1,736)	(2,877)
Income taxes	(1,686)	(1,373)
Net income	(50)	(1,504)
Balance for common.....	(50)	(1,504)
Earnings common share		
Primary	\$(0.09)	\$(0.09)
Fully Diluted	\$(0.09)	\$(0.09)
Common Shares:		
Full Diluted	17,997	16,878
Year-end	18,037	16,909

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		25,313
Inventories		14,656
Current assets		75,169
Net property & equip.....		3,912
Total assets		87,073
Liabilities:		
Current liabilities	12,739	
Stockholders' equity	73,162	
Net current assets	62,430	

TD AMERITRADE HOLDING CORP**Earnings, 6 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	1,796,000,000	964,000,000
Operating income	732,000,000	711,000,000
Other income (expense), net	(2,000,000)	
Gains or losses	(11,000,000)	
Net before taxes	675,000,000	683,000,000
Income taxes	107,000,000	253,000,000
Net income	568,000,000	430,000,000
Earnings common share		
Primary	\$1.00	\$0.81
Fully Diluted	\$1.00	\$0.81
Common Shares:		
Full Diluted	569,000,000	530,000,000
Year-end	567,000,000	528,000,000

TESLA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	3,408,751	2,696,270
Cost & expenses	4,005,725	2,953,819
Operating income	(596,974)	(257,549)
Other income (expense), net	(37,716)	(18,098)
Net before taxes	(779,022)	(371,903)
Income taxes	5,605	25,278
Net income	(784,627)	(397,181)
Earnings common share		
Primary	\$(4.19)	\$(2.04)
Fully Diluted	\$(4.19)	\$(2.04)
Common Shares:		
Full Diluted	169,146	162,129
Year-end	169,750	164,164

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents		2,665,673
Inventories		2,565,826
Current assets		6,383,920
Net property & equip.....		10,519,226
Total assets		27,271,429
Liabilities:		
Current liabilities	8,650,359	
Long-term debt	8,763,726	
Stockholders' equity	4,450,695	
Net current assets	(2,266,439)	

TETRA TECH INC**Earnings, 6 mos. to (Consol. - \$000):**

	04/01/18	04/02/17
Cost & expenses	986,335	918,694
Operating income	91,305	82,811
Interest expense	7,252	6,007
Net before taxes	84,053	76,804
Income taxes	9,254	23,348
Net income	74,799	53,456
Earnings common share		
Primary	\$1.34	\$0.93
Fully Diluted	\$1.32	\$0.92
Common Shares:		
Full Diluted	56,825	58,194
Year-end	55,749	57,203

THERAPEUTICSMD INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	3,773,392	3,985,464
Cost & expenses	28,430,157	25,222,092
Operating income	(24,716,386)	(21,286,327)
Other income (expense), net	314,557	125,968
Net income	(24,401,829)	(21,156,492)
Earnings common share		
Primary	\$(0.11)	\$(0.11)
Fully Diluted	\$(0.11)	\$(0.11)
Common Shares:		
Full Diluted	216,525,316	197,790,040
Year-end	216,584,274	198,593,268

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents		107,349,460
Inventories		1,620,872
Current assets		119,165,195
Net property & equip.....		425,539
Total assets		122,961,942
Liabilities:		
Current liabilities	15,659,642	
Stockholders' equity	107,302,300	
Net current assets	103,505,553	

TIVITY HEALTH INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	149,930,000	140,970,000
Cost & expenses	116,860,000	111,497,000
Operating income	31,947,000	28,686,000
Net before taxes	28,493,000	24,852,000
Income taxes	7,157,000	9,371,000
Income contin. oper		15,481,000
Net income	21,336,000	15,261,000
Earnings common share		
Primary	\$0.54	\$0.39
Fully Diluted	\$0.49	\$0.38

Common Shares:		
Full Diluted	43,589,000	40,541,000
Year-end	39,847,047	39,188,902

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	38,792,000	
Current assets	271,781,000	
Net property & equip.	11,417,000	
Total assets	692,527,000	
Liabilities:		
Current liabilities	386,006,000	
Stockholders' equity	294,575,000	
Net current assets	(114,225,000)	

TIVO CORP**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	189,837	205,764
Cost & expenses	152,324	163,937
Operating income	(9,040)	(5,345)
Interest expense	11,634	10,264
Other income (expense), net	(13,943)	(13,943)
Gains or losses	4,311	521
Net before taxes	(14,797)	(29,094)
Income taxes	4,217	5,567
Income contin. oper.	(19,014)	(23,527)
Net income	(17,717)	(34,661)

Earnings common share

Primary	\$(0.15)	\$(0.29)
Fully Diluted	\$(0.15)	\$(0.29)
Common Shares:		
Full Diluted	122,080	118,813
Year-end	122,924	121,130

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	140,294	
Inventories	13,164	
Current assets	524,843	
Net property & equip.	54,220	
Total assets	3,128,403	
Liabilities:		
Current liabilities	157,219	
Long-term debt	978,280	
Stockholders' equity	1,863,907	
Net current assets	367,624	

TPI COMPOSITES INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Net Sales	253,981	208,615
Cost & expenses	236,886	197,003
Operating income	17,095	11,612
Interest income	41	19
Interest expense	3,338	3,026
Other income (expense), net	818	320
Gains or losses	(4,011)	(1,381)
Net before taxes	10,605	7,544
Income taxes	1,957	2,331
Net income	8,648	5,213

Earnings common share

Primary	\$0.25	\$0.15
Fully Diluted	\$0.24	\$0.15
Common Shares:		
Full Diluted	35,479	33,827
Year-end	34,049	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	138,841	
Inventories	4,205	
Current assets	429,980	
Net property & equip.	126,860	
Total assets	579,864	
Liabilities:		
Current liabilities	249,383	
Long-term debt	82,658	
Stockholders' equity	243,032	
Net current assets	180,597	

TRACON PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	11,189	7,546
Operating income	(8,189)	(6,920)

Interest expense	169	225
Other income (expense), net	(6)	(2)
Net income	(8,364)	(7,147)

Earnings common share

Primary	\$(0.46)	\$(0.44)
Fully Diluted	\$(0.46)	\$(0.44)
Common Shares:		
Full Diluted	18,215	16,206
Year-end	28,442	16,584

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	62,493	
Current assets	63,795	
Net property & equip.	66	
Total assets	63,861	
Liabilities:		
Current liabilities	15,066	
Long-term debt	6,213	
Stockholders' equity	42,489	
Net current assets	48,729	

TRAVELCENTERS OF AMERICA LLC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,584,687	1,391,672
Cost & expenses	1,562,970	1,401,299
Deprec., depl. & amort.	27,548	31,800
Operating income	(5,831)	(41,427)
Interest expense	7,588	7,384
Other income (expense), net	(1,285)	138
Net before taxes	(14,704)	(48,673)
Income taxes	(4,626)	(19,298)
Net income	(10,078)	(29,375)
Balance for common	(9,604)	(27,841)

Earnings common share

Primary	\$(0.25)	\$(0.74)
Fully Diluted	\$(0.25)	\$(0.74)
Common Shares:		
Full Diluted	37,980	37,426
Year-end	40,000	39,518

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	52,139	
Inventories	207,686	
Current assets	437,965	
Net property & equip.	984,396	
Total assets	1,643,365	
Liabilities:		
Current liabilities	364,249	
Long-term debt	684,975	
Stockholders' equity	556,799	
Net current assets	73,716	

TRIMBLE INC**Earnings, 3 mos. to (Consol. - \$000):**

	03/30/18	03/31/17
Total Revenues	742,200	610,600
Cost & expenses	660,600	541,600
Operating income	64,200	54,700
Other income (expense), net	8,300	13,700
Foreign currency	3,700	1,400
Net before taxes	66,700	63,700
Income taxes	8,000	13,900
Net income	58,700	49,800

Earnings common share

Primary	\$0.24	\$0.20
Fully Diluted	\$0.23	\$0.19
Common Shares:		
Full Diluted	253,200	255,900
Year-end	248,700	252,600

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	274,500	
Inventories	289,100	
Current assets	1,124,600	
Net property & equip.	184,300	
Total assets	4,673,700	
Liabilities:		
Current liabilities	1,146,800	
Long-term debt	691,800	
Stockholders' equity	2,499,700	
Net current assets	(22,200)	

TRONC INC

Interest Sale Completed On May 23, 2018, Co.'s indirect wholly-owned subsidiary, ForSaleByOwner.com, LLC, sold substantially all of its assets used in its business of operating a for-sale-by-owner real estate market place, to In-House Realty LLC, a provider of online real estate agency services in buying and selling homes in the United States, for \$2,500,000 in cash, subject to a post-closing working capital adjustment, of which \$700,000 was being held in escrow as security for specified indemnity obligations.

TTEC HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	375,249	338,277
Cost & expenses	332,384	297,287
Operating income	24,941	26,490
Interest income	1,068	426
Interest expense	6,459	2,318
Other income (expense), net	(11,516)	960
Net before taxes	8,034	25,558
Income taxes	2,102	5,391
Net income	5,932	20,167

Earnings common share

Primary	\$0.10	\$0.42
Fully Diluted	\$0.10	\$0.42
Common Shares:		
Full Diluted	46,452	46,315
Year-end	45,979	45,769

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents	81,594	
Current assets	517,664	
Net property & equip.	157,215	
Total assets	1,034,862	
Liabilities:		
Current liabilities	224,927	
Long-term debt	302,500	
Stockholders' equity	345,223	
Net current assets	292,737	

TTM TECHNOLOGIES INC**Earnings, 3 mos. to (Consol. - \$):**

	04/02/18	04/03/17
Net Sales	663,582,000	625,247,000
Cost & expenses	627,720,000	566,765,000
Operating income	30,001,000	52,570,000
Other income (expense), net	(1,107,000)	(1,710,000)
Net before taxes	15,147,000	37,264,000
Income taxes	5,050,000	4,139,000
Net income	10,097,000	33,125,000

Earnings common share

Primary	\$0.10	\$0.33
Fully Diluted	\$0.09	\$0.28
Common Shares:		
Full Diluted	107,517,000	130,922,000
Year-end	103,445,000	101,742,000

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents	352,576,000	
Inventories	82,116,000	
Current assets	1,247,594,000	
Net property & equip.	1,039,751,000	
Total assets	2,786,349,000	
Liabilities:		
Current liabilities	677,528,000	
Long-term debt	977,413,000	
Stockholders' equity	1,054,330,000	
Net current assets	570,066,000	

TWIN DISC INCORPORATED**Earnings, 9 mos. to (Consol. - \$000):**

	03/30/18	03/31/17
Net Sales	166,960	114,591
Cost & expenses	160,398	125,951
Operating income	6,562	(11,360)
Interest expense	227	236
Other income (expense), net	(244)	414
Net before taxes	6,091	(11,182)
Income taxes	2,401	(3,892)
Net income	3,690	(7,290)

Earnings common share

Primary	\$0.31	\$(0.66)
Fully Diluted	\$0.31	\$(0.66)
Common Shares:		

Full Diluted	11,320	11,236
Year-end	11,551	11,519

ULTIMATE SOFTWARE GROUP, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	276,755,000	228,491,000
Cost & expenses	254,666,000	225,422,000
Operating income	22,089,000	3,069,000
Other income (expense), net	385,000	226,000
Net before taxes	22,277,000	3,015,000
Income taxes	1,283,000	(4,225,000)
Net income	20,994,000	7,240,000
Earnings common share		
Primary	\$0.69	\$0.25
Fully Diluted	\$0.67	\$0.24
Common Shares:		
Full Diluted	31,105,000	30,497,000
Year-end	35,259,958	29,688,503

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	143,639,000
Current assets	1,615,082,000
Net property & equip.	259,782,000
Total assets	2,057,522,000
Liabilities:	
Current liabilities	1,499,221,000
Long-term debt	3,981,000
Stockholders' equity	540,647,000
Net current assets	115,861,000

ULTRALIFE CORP**Earnings, 3 mos. to (Consol. - \$000):**

	04/01/18	04/02/17
Total Revenues	23,069	22,035
Cost & expenses	20,713	20,194
Operating income	2,356	1,841
Other income (expense), net	(100)	(25)
Net before taxes	2,223	1,748
Income taxes	55	87
Net income	2,168	1,661
Earnings common share		
Primary	\$0.14	\$0.11
Fully Diluted	\$0.13	\$0.11
Common Shares:		
Full Diluted	16,202	15,656
Year-end	15,872	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	18,239
Inventories	26,961
Current assets	63,751
Net property & equip.	7,359
Total assets	99,077
Liabilities:	
Current liabilities	12,079
Stockholders' equity	83,230
Net current assets	51,672

UNITI GROUP INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	246,915	211,473
Cost & expenses	132,059	130,491
Operating income	135	(20,379)
Net before taxes	135	(20,379)
Income taxes	(1,096)	(379)
Net income	1,231	(20,000)
Balance for common	(870)	(21,788)
Earnings common share		
Primary	\$(0.14)	\$(0.14)
Fully Diluted	\$(0.01)	\$(0.14)
Common Shares:		
Full Diluted	175,499	155,184
Year-end	174,970	155,276

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	56,901
Current assets	94,502
Net property & equip.	3,049,714
Total assets	4,363,513
Liabilities:	
Current liabilities	958,158

Long-term debt	4,503,462
Stockholders' equity	(1,371,485)
Net current assets	(863,656)

US ECOLOGY, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	120,059	110,234
Cost & expenses	106,620	98,075
Operating income	13,439	12,159
Interest income	24	10
Interest expense	2,809	4,130
Other income (expense), net	2,123	137
Foreign currency	(14)	88
Net before taxes	12,763	8,264
Income taxes	3,520	3,079
Net income	9,243	5,185
Earnings common share		
Primary	\$0.42	\$0.24
Fully Diluted	\$0.42	\$0.24
Common Shares:		
Full Diluted	21,957	21,845
Year-end	21,931	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	44,251
Current assets	150,401
Net property & equip.	232,352
Total assets	801,085
Liabilities:	
Current liabilities	58,133
Long-term debt	277,000
Stockholders' equity	330,147
Net current assets	92,268

UTAH MEDICAL PRODUCTS, INC.**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	10,887,000	10,259,000
Cost & expenses	5,916,000	5,534,000
Operating income	4,971,000	4,725,000
Other income (expense), net	37,000	26,000
Net before taxes	5,008,000	4,751,000
Income taxes	916,000	1,215,000
Net income	4,092,000	3,536,000
Earnings common share		
Primary	\$1.10	\$0.95
Fully Diluted	\$1.09	\$0.95
Common Shares:		
Full Diluted	3,748,000	3,728,000
Year-end	3,728,000	3,715,000

Consolidated Balance Sheet Items, as of (\$):

	2018
Assets:	
Cash & equivalents	42,853,000
Inventories	5,558,000
Current assets	53,119,000
Net property & equip.	11,781,000
Total assets	97,188,000
Liabilities:	
Current liabilities	5,120,000
Stockholders' equity	82,686,000
Net current assets	47,999,000

VAREX IMAGING CORP**Earnings, 6 mos. to (Consol. - \$000):**

	03/30/18	03/31/17
Total Revenues	377,400	312,200
Cost & expenses	346,700	270,300
Operating income	30,700	41,900
Other income (expense), net	3,100	300
Net before taxes	22,800	40,700
Income taxes	(1,100)	14,500
Net income	23,900	26,200
Earnings common share		
Primary	\$0.62	\$0.70
Fully Diluted	\$0.62	\$0.69
Common Shares:		
Full Diluted	38,400	37,800
Year-end	37,879	37,538

VEECO INSTRUMENTS INC (DE)**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

Net Sales	158,574	94,499
Cost & expenses	156,477	97,177
Operating income	(11,435)	(5,545)
Interest income	624	793
Interest expense	5,246	4,135
Net before taxes	(16,057)	(8,887)
Income taxes	(230)	(10,527)
Net income	(15,827)	1,640

Earnings common share

Primary	\$(0.34)	\$0.04
Fully Diluted	\$(0.34)	\$0.04
Common Shares:		
Full Diluted	46,963	40,140
Year-end	48,691	40,568

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	245,525
Inventories	130,964
Current assets	583,358
Net property & equip.	83,100
Total assets	1,362,028
Liabilities:	
Current liabilities	208,624
Long-term debt	278,489
Stockholders' equity	827,957
Net current assets	374,734

VERASTEM INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	20,761	13,148
Operating income	(20,761)	(13,148)
Interest income	191	155
Interest expense	480	12
Net income	(21,050)	(13,005)
Earnings common share		
Primary	\$(0.41)	\$(0.35)
Fully Diluted	\$(0.41)	\$(0.35)
Common Shares:		
Full Diluted	50,835	36,992
Year-end	50,968	

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	64,215
Current assets	66,030
Net property & equip.	1,003
Total assets	68,411
Liabilities:	
Current liabilities	14,845
Long-term debt	14,913
Stockholders' equity	38,552
Net current assets	51,185

VERITONE INC

New Accountant On May 18, 2018, Co. dismissed Marcum LLP and engaged Grant Thornton LLP as its new independent public accounting firm.

VERMILLION INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	649	726
Cost & expenses	3,484	3,382
Operating income	(2,835)	(2,656)
Other income (expense), net	(3)	(5)
Net income	(2,850)	(2,673)

Earnings common share

Primary	\$(0.05)	\$(0.05)
Fully Diluted	\$(0.05)	\$(0.05)
Common Shares:		
Full Diluted	60,037	54,123
Year-end	60,039	56,089

Consolidated Balance Sheet Items, as of (\$000):

	2018
Assets:	
Cash & equivalents	3,103
Inventories	102
Current assets	4,428
Net property & equip.	1,019
Total assets	5,447
Liabilities:	
Current liabilities	2,774
Long-term debt	1,434
Stockholders' equity	1,239
Net current assets	1,654

VERSARTIS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	8,517	29,660
Operating income	(8,517)	(29,660)
Interest income	193	199
Other income (expense), net	(657)	(261)
Net income	(8,981)	(29,722)

Earnings common share

Primary	\$(0.25)	\$(0.85)
Fully Diluted	\$(0.25)	\$(0.85)

Common Shares:

Full Diluted	36,019	35,004
Year-end	36,070	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents		74,686
Current assets		75,155
Net property & equip.		739
Total assets		87,109
Liabilities:		
Current liabilities		3,535
Long-term debt		6,944
Stockholders' equity		76,630
Net current assets		71,620

VIAMI SOLUTIONS INC**Earnings, 9 mos. to (Consol. – \$000):**

	03/31/18	04/01/17
Total Revenues	616,400	613,300
Cost & expenses	591,300	601,300
Operating income	14,100	1,600
Gains or losses	(100)	186,600
Net before taxes	(15,000)	169,000
Income taxes	2,200	15,800
Net income	(17,200)	153,200

Earnings common share

Primary	\$(0.08)	\$0.66
Fully Diluted	\$(0.08)	\$0.65

Common Shares:

Full Diluted	227,300	235,900
Year-end	226,000	227,000

VIEWRAY INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Total Revenues	26,190,000	1,227,000
Cost & expenses	37,482,000	12,179,000
Operating income	(11,292,000)	(10,952,000)
Interest income	2,000	1,000
Interest expense	1,866,000	1,737,000
Other income (expense), net	8,342,000	(15,273,000)
Net income	(4,814,000)	(27,961,000)
Balance for common	(7,542,000)	(27,961,000)

Earnings common share

Primary	\$(0.11)	\$(0.54)
Fully Diluted	\$(0.11)	\$(0.54)

Common Shares:

Full Diluted	68,943,918	51,821,422
Year-end	72,022,089	56,086,583

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents		78,916,000
Inventories		40,442,000
Current assets		154,013,000
Net property & equip.		12,955,000
Total assets		168,625,000
Liabilities:		
Current liabilities		40,630,000
Long-term debt		44,551,000
Stockholders' equity		57,664,000
Net current assets		113,383,000

VIRTU FINANCIAL INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Total Revenues	815,053,000	147,287,000
Cost & expenses	324,327,000	116,595,000
Operating income	468,536,000	23,882,000
Net before taxes	468,536,000	23,882,000
Income taxes	58,514,000	2,808,000
Net income	410,022,000	21,074,000

Earnings common share

Primary	\$1.89	\$0.10
---------	--------	--------

Fully Diluted	\$1.86	\$0.10
---------------	--------	--------

Common Shares:

Full Diluted	92,406,318	40,398,381
Year-end	188,189,636	139,359,201

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents		1,869,958,000
Current assets		3,303,997,000
Net property & equip.		128,675,000
Total assets		7,757,931,000
Liabilities:		
Current liabilities		5,177,992,000
Long-term debt		1,121,464,000
Stockholders' equity		999,945,000
Net current assets		(1,873,995,000)

VIRTU INVESTMENT PARTNERS INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	129,028	79,776
Cost & expenses	100,360	68,832
Operating income	22,617	10,047
Other income (expense), net	1,319	646
Gains or losses	2,697	4,741
Net before taxes	30,350	18,178
Income taxes	6,523	4,433
Net income	23,827	13,745
Balance for common	21,216	10,943

Earnings common share

Primary	\$2.95	\$1.67
Fully Diluted	\$2.77	\$1.62

Common Shares:

Full Diluted	8,411	6,773
Year-end	7,217	6,989

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents		136,499
Current assets		1,991,090
Net property & equip.		11,396
Total assets		2,538,209
Liabilities:		
Current liabilities		62,164
Long-term debt		1,705,579
Stockholders' equity		608,787
Net current assets		1,928,926

VITAL THERAPIES INC**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Cost & expenses	14,492	12,687
Operating income	(14,492)	(12,687)
Interest income	170	97
Other income (expense), net	(66)	(12)
Net income	(14,388)	(12,602)

Earnings common share

Primary	\$(0.34)	\$(0.39)
Fully Diluted	\$(0.34)	\$(0.39)

Common Shares:

Full Diluted	42,369	32,645
Year-end	42,369	42,207

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents		43,647
Current assets		44,835
Net property & equip.		2,072
Total assets		47,008
Liabilities:		
Current liabilities		9,666
Stockholders' equity		37,295
Net current assets		35,169

VIVUS, INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	11,900	27,012
Cost & expenses	14,192	19,778
Operating income	(2,292)	7,234
Net before taxes	(10,641)	(1,068)
Income taxes	12	(12)
Net income	(10,653)	(1,056)

Earnings common share

Primary	\$(0.10)	\$(0.01)
Fully Diluted	\$(0.10)	\$(0.01)

Common Shares:

Full Diluted	106,014	105,479
Year-end	106,041	105,629

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents		76,805
Inventories		21,006
Current assets		247,869
Net property & equip.		510
Total assets		249,303
Liabilities:		
Current liabilities		28,589
Long-term debt		235,671
Stockholders' equity		(19,543)
Net current assets		219,280

WEB.COM GROUP, INC.**Earnings, 3 mos. to Mar 31**(Consol. – \$000):

	2018	2017
Total Revenues	186,741	185,118
Cost & expenses	153,695	146,142
Deprec., depl. & amort.	17,514	18,433
Operating income	15,532	20,543
Net before taxes	6,772	12,652
Income taxes	2,196	6,134
Net income	4,576	6,518

Earnings common share

Primary	\$0.10	\$0.13
Fully Diluted	\$0.09	\$0.13

Common Shares:

Full Diluted	49,066	50,800
Year-end	49,437	

Consolidated Balance Sheet Items, as of (\$000):

Assets:	2018	
Cash & equivalents		9,660
Current assets		123,743
Net property & equip.		56,280
Total assets		1,495,671
Liabilities:		
Current liabilities		322,532
Long-term debt		625,403
Stockholders' equity		285,814
Net current assets		(198,789)

WEYCO GROUP, INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Net Sales	69,526,000	69,120,000
Cost & expenses	65,959,000	65,661,000
Operating income	3,567,000	3,459,000
Other income (expense), net	(43,000)	(135,000)
Net before taxes	3,757,000	3,496,000
Income taxes	941,000	1,381,000
Net income	2,816,000	2,115,000

Earnings common share

Primary	\$0.29	\$0.21
Fully Diluted	\$0.29	\$0.21

Common Shares:

Full Diluted	10,361,000	10,498,000
Year-end	10,280,518	10,403,947

Consolidated Balance Sheet Items, as of (\$):

Assets:	2018	
Cash & equivalents		30,082,000
Inventories		51,087,000
Current assets		140,679,000
Net property & equip.		30,758,000
Total assets		257,550,000
Liabilities:		
Current liabilities		16,290,000
Stockholders' equity		202,535,000
Net current assets		124,389,000

WILLDAN GROUP INC**Earnings, 3 mos. to Mar 31**(Consol. – \$):

	2018	2017
Cost & expenses	51,557,000	65,478,000
Deprec., depl. & amort.	1,064,000	909,000
Operating income	1,974,000	1,964,000
Interest expense	23,000	33,000
Other income (expense), net	10,000	37,000
Net before taxes	1,961,000	1,968,000
Income taxes	(242,000)	(673,000)
Net income	2,203,000	2,641,000

Earnings common share		
Primary	\$0.25	\$0.32
Fully Diluted	\$0.24	\$0.30
Common Shares:		
Full Diluted	9,185,000	8,854,000
Year-end	8,861,000	8,559,000
Consolidated Balance Sheet Items, as of (\$):		
Assets:		2018
Cash & equivalents	5,353,000	
Current assets	73,497,000	
Net property & equip.	5,189,000	
Total assets	127,982,000	
Liabilities:		
Current liabilities	41,729,000	
Long-term debt	2,723,000	
Stockholders' equity	75,367,000	
Net current assets	31,768,000	

WINDSTREAM HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	1,454,300	1,365,700
Cost & expenses	1,003,500	983,100
Deprec., depl. & amort.	381,800	338,500
Operating income	69,000	44,100
Interest expense	223,100	211,800
Other income (expense), net	(2,300)	(600)
Net before taxes	(156,400)	(168,300)
Income taxes	(35,000)	(57,000)
Net income	(121,400)	(111,300)
Balance for common	(121,400)	(111,900)
Earnings common share		
Primary	\$(3.25)	\$(4.45)
Fully Diluted	\$(3.25)	\$(4.45)
Common Shares:		
Full Diluted	37,400	25,220
Year-end	40,920	38,080

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	60,500	
Inventories	90,300	
Current assets	943,500	
Net property & equip.	5,263,600	
Total assets	10,981,300	
Liabilities:		
Current liabilities	1,288,000	
Long-term debt	10,522,100	
Stockholders' equity	(1,337,200)	
Net current assets	(344,500)	

WOODSTOCK HOLDINGS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	1,763,471	1,635,881
Cost & expenses	1,816,621	1,668,487
Net income	(53,150)	(32,606)
Earnings common share		
Primary	\$(0.04)	\$(0.03)
Fully Diluted	\$(0.04)	\$(0.03)
Common Shares:		
Full Diluted	2,031,588	1,953,853
Year-end	2,141,862	1,953,858

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	406,164	
Current assets	744,511	
Net property & equip.	870,262	
Total assets	1,856,744	
Liabilities:		
Current liabilities	330,809	
Long-term debt	768,149	
Stockholders' equity	691,118	
Net current assets	413,702	

XENCOR, INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Cost & expenses	30,649	19,859
Operating income	(30,649)	(16,359)
Interest income	1,158	1,057
Interest expense	4	3
Other income (expense), net	2	
Net before taxes	(15,305)	

Income taxes		170
Net income	(29,493)	(15,475)
Earnings common share		
Primary	\$(0.62)	\$(0.33)
Fully Diluted	\$(0.62)	\$(0.33)
Common Shares:		
Full Diluted	47,754	46,599
Year-end	55,617	

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	251,572	
Current assets	470,919	
Net property & equip.	8,921	
Total assets	612,272	
Liabilities:		
Current liabilities	73,431	
Stockholders' equity	537,664	
Net current assets	397,488	

ZAGG INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Net Sales	112,066,000	92,946,000
Cost & expenses	101,375,000	96,574,000
Operating income	7,919,000	(6,649,000)
Interest expense	500,000	490,000
Other income (expense), net	495,000	(20,000)
Net before taxes	7,914,000	(7,159,000)
Income taxes	885,000	(1,021,000)
Net income	7,029,000	(6,138,000)
Earnings common share		
Primary	\$0.25	\$(0.22)
Fully Diluted	\$0.24	\$(0.22)
Common Shares:		
Full Diluted	28,693,000	28,059,000
Year-end	28,351,000	27,979,000

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	17,745,000	
Inventories	78,891,000	
Current assets	175,059,000	
Net property & equip.	12,794,000	
Total assets	264,455,000	
Liabilities:		
Current liabilities	104,991,000	
Long-term debt	22,038,000	
Stockholders' equity	137,426,000	
Net current assets	70,068,000	

ZEBRA TECHNOLOGIES CORP.**Earnings, 3 mos. to (Consol. - \$000):**

	03/31/18	04/01/17
Net Sales	977,000	865,000
Cost & expenses	810,000	775,000
Operating income	144,000	40,000
Foreign currency		(1,000)
Net before taxes	133,000	(2,000)
Income taxes	24,000	(10,000)
Net income	109,000	8,000
Earnings common share		
Primary	\$2.04	\$0.16
Fully Diluted	\$2.01	\$0.16
Common Shares:		
Full Diluted	53,986	52,947
Year-end	53,397	52,754

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	64,000	
Inventories	448,000	
Current assets	1,053,000	
Net property & equip.	262,000	
Total assets	4,249,000	
Liabilities:		
Current liabilities	932,000	
Long-term debt	2,090,000	
Stockholders' equity	981,000	
Net current assets	121,000	

ZILLOW GROUP INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	299,879	245,775
Cost & expenses	311,243	244,611

Operating income	(11,364)	1,164
Other income (expense), net	2,446	953
Net before taxes	(15,991)	
Income taxes	2,600	
Net income	(18,591)	(4,606)
Earnings common share		
Primary	\$(0.10)	\$(0.03)
Fully Diluted	\$(0.10)	\$(0.03)
Common Shares:		
Full Diluted	191,464	183,158
Year-end	192,944	183,830

Consolidated Balance Sheet Items, as of (\$000):

Assets:		2018
Cash & equivalents	397,393	
Current assets	922,247	
Net property & equip.	114,828	
Total assets	3,344,137	
Liabilities:		
Current liabilities	120,697	
Long-term debt	389,624	
Stockholders' equity	2,768,441	
Net current assets	801,550	

ZIX CORP**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Total Revenues	16,654,000	15,893,000
Cost & expenses	14,045,000	13,231,000
Operating income	2,609,000	2,662,000
Other income (expense), net	119,000	79,000
Net before taxes	2,728,000	2,741,000
Income taxes	836,000	966,000
Net income	1,892,000	1,775,000
Earnings common share		
Primary	\$0.04	\$0.03
Fully Diluted	\$0.04	\$0.03
Common Shares:		
Full Diluted	53,481,104	53,666,649
Year-end	54,251,627	54,398,490

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	29,269,000	
Current assets	33,051,000	
Net property & equip.	3,843,000	
Total assets	81,117,000	
Liabilities:		
Current liabilities	31,609,000	
Stockholders' equity	46,966,000	
Net current assets	1,442,000	

ZYNERBA PHARMACEUTICALS INC**Earnings, 3 mos. to Mar 31(Consol. - \$):**

	2018	2017
Cost & expenses	12,396,136	7,703,248
Operating income	(12,396,136)	(7,703,248)
Foreign currency	(85,382)	367,342
Net income	(12,306,334)	(7,259,021)
Earnings common share		
Primary	\$(0.91)	\$(0.60)
Fully Diluted	\$(0.91)	\$(0.60)
Common Shares:		
Full Diluted	13,467,694	12,067,453
Year-end	13,561,373	13,214,825

Consolidated Balance Sheet Items, as of (\$):

Assets:		2018
Cash & equivalents	52,131,598	
Current assets	57,965,316	
Net property & equip.	155,334	
Total assets	59,901,632	
Liabilities:		
Current liabilities	8,909,354	
Stockholders' equity	50,330,278	
Net current assets	49,055,962	

ZYNCA INC**Earnings, 3 mos. to Mar 31(Consol. - \$000):**

	2018	2017
Total Revenues	208,232	194,284
Cost & expenses	203,975	203,264
Operating income	4,257	(8,980)
Interest income	1,810	937
Other income (expense), net	3,401	1,436
Net before taxes	9,468	(6,607)

Income taxes	3,859	2,867
Net income	5,609	(9,474)
Earnings common share		
Primary	\$0.01	\$(0.01)
Fully Diluted	\$0.01	\$(0.01)
Common Shares:		
Full Diluted	893,774	875,712
Year-end	863,612
Consolidated Balance Sheet Items, as of (\$000):		
Assets:		2018
Cash & equivalents	361,581	
Current assets	764,292	
Net property & equip.	264,580	
Total assets	1,919,011	
Liabilities:		
Current liabilities	232,871	
Stockholders' equity	1,643,865	
Net current assets	531,421	

*

MERGENT OTC INDUSTRIAL News Reports 0027-0865 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC INDUSTRIAL Manual and provide periodic updates. Send address changes to MERGENT OTC INDUSTRIAL, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2018 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.